Genetics and tumor genomics in familial colorectal cancer by Middeldorp, J.W.
Genetics and Tumor Genomics in 
Familial Colorectal Cancer
Genetics and Tumor Genomics in Familial Colorectal Cancer
©2010 Anneke Middeldorp
Printing: Ipskamp Drukkers
Layout cover: Ipskamp Drukkers
The studies described in this thesis were performed at the Department of Pathology and the 
Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
The research described in this thesis was financially supported by the Dutch Cancer Society 
(UL2005-3247) and the NutsOhra Foundation (SNO-T-07-092).
The printing of this thesis was financially supported by the Dutch Cancer Society, Stichting 
Nationaal Fonds tegen Kanker - voor onderzoek naar reguliere en alternatieve therapieën, 
and the J.E. Jurriaanse Stichting.




de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties







Promotores: Prof. dr. H. Morreau
  Prof. dr. P. Devilee
Copromotores: Dr. T. van Wezel
  Dr. J. Wijnen
Overige leden: Dr. F.J. Hes  
  Prof. dr. N.C. Hoogerbrugge (Radboud University Medical Center)
  Prof. dr. G.A. Meijer (VU Medical Center)
   
Contents




A procedure for the detection of linkage with high density SNP arrays in a large 
pedigree with colorectal cancer
BMC Cancer (2007) 7:6
Chapter 3
Comprehensive Genetic Analysis of Seven Large Families with Mismatch Repair 
Proficient Colorectal Cancer 
Genes, Chromosomes and Cancer (2010) 49:539-548
Chapter 4
Enrichment of Low Penetrance Susceptibility Loci in a Dutch Familial 
Colorectal Cancer Cohort
Cancer, Epidemiology, Biomarkers & Prevention (2009) 18(11):3062-3067 
Chapter 5
High frequency of copy-neutral LOH in MUTYH-associated polyposis 
carcinomas
Journal of Pathology (2008) 216(1):25-31
Chapter 6




Genome-Wide Allelic State Analysis on Flow-Sorted Tumor Fractions Provides an 
Accurate Measure of Chromosomal Aberrations
Cancer Research (2008) 68(24):10333-10340
Chapter 8






















Aims and outline of this thesis
The aim of the work described in this thesis was to identify novel genes that predispose to 
colorectal cancer (CRC). Colorectal cancer is one of the most common malignancies in the 
Western world. The lifetime risk in the Netherlands for developing CRC is about 6%, with a 
5-year survival of about 55%. The risk of CRC can be increased both by genetic and environ-
mental factors. In twin studies it was estimated that in up to 30% of all CRC cases inherited 
predisposition plays a role. However, only 6% of all cases is explained by the known syn-
dromes, like Lynch syndrome, Familial Adenomatous Polyposis (FAP) and MUTYH-associat-
ed polyposis (MAP). In the remaining familial cases the underlying genetics remain elusive. In 
the cases that show a strong familial history of CRC, a high penetrance genetic factor can be 
expected to be responsible for the increased CRC risk. In other cases with a less strong family 
history but with an early onset of the disease, the increased cancer risk might be explained 
by common genetic variants, each conferring a small CRC risk. It is of great importance to 
identify both the low and high risk factors, because this knowledge can aid in obtaining further 
insight in the etiology of the disease. Moreover, identifying high risk factors will aid in identify-
ing individuals at significant increased risk for CRC. These individuals can then be offered a 
regular screening of their colon to detect precursor lesions, and thereby prevent the disease 
from developing into a malignant lesion.
Chapter 1 provides a general introduction in the genetic and environmental factors that influ-
ence the risk of CRC. Moreover, genetic loci that have been identified to possibly harbor a 
high risk gene are discussed as well as low level risk loci that have been identified. Colorectal 
tumorigenesis is briefly discussed and the genetic en genomic instability seen in colorectal 
tumors is described, both for sporadic and familial tumors. Finally, new fields in CRC research, 
prevention, and treatment are reviewed.
Different approaches were used to identify novel genetic factors predisposing to CRC. These 
approaches can be broadly divided into germ-line genetic approaches and somatic genomic 
approaches. Chapter 2 and 3 describe the germ-line approach to identify genetic loci har-
boring high or moderate penetrance risk factors. Linkage analysis was used in large families 
affected with CRC. The linkage scan was performed using 10K SNP arrays. With this high 
number of markers and large pedigrees the computational burden of the linkage analysis was 
high. The procedure we developed to handle this complexity is described in Chapter 2. The 
results of the linkage analysis in seven large CRC families are described in Chapter 3.
In the search for low risk factors we replicated the association of six loci, identified in large ge-
nome-wide association studies, in a Dutch clinical-based cohort of 995 familial CRC patients. 
We studied the possible association of these loci with several clinico-pathological parameters. 
The results of this study are described in Chapter 4.
The third approach we used was to study the genomic profile of the tumors familial CRC pa-
tients develop. With profiling the tumors from patients with familial CRC we aimed on one side 
at stratifying the different families based on the genomic profile of their tumors and moreover, 
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we aimed at identifying a locus that is frequently affected in these tumors indicating that there 
might be a gene important for the development of the disease located in that region. To prop-
erly interpret the profile of the tumors from patients with an unknown cause of their increased 
CRC predisposition, we first generated the profile for known CRC syndromes. The results 
of the profiling of tumors from patients with MUTYH-associated polyposis are described in 
Chapter 5. We also studied the profile of tumors from Lynch syndrome patients in the context 
of another PhD thesis. For the familial cases with unknown cause we studied the profile of 
30 tumors originating from 15 families (2 tumors per family were studied). The results of this 
study are described in Chapter 6. And in Chapter 7, an improved method for tumor profiling 
is described, with which the allelic state of the chromosomes can be determined.
In Chapter 8, all results described in this thesis are discussed and perspectives for future 





Colorectal cancer (CRC) is one of the most common cancers in the Western world.[1] In the 
Netherlands, each year around 11,000 patients are diagnosed with colorectal cancer.[2] The 
lifetime risk in the Netherlands for developing colorectal cancer is approximately 6%, with a 
five-year survival of about 55%.1 The age distribution is wide; however, over half of the pa-
tients are diagnosed with colorectal cancer above 70 years of age. 
The risk of CRC is influenced by both genetic and environmental factors. Although most 
colorectal cancer arises on a sporadic basis, in 10-30% of the cases inherited predisposition 
plays a role, as was estimated in twin studies.[3] First-degree relatives of CRC patients are 
at increased risk of developing colorectal cancer, with a relative risk of about 2.2. This risk is 
strongly correlated with the number of affected family members and an early onset of disease.
[4] With two or more affected family members, the relative risk increases to about 4.0.[5,6] 
Individuals with a first-degree relative affected with colorectal adenomas are also at increased 
risk of CRC, with a relative risk of about 2.0.[6] The risk increases when the age at diagno-
sis of colorectal adenomas of the first-degree relative decreases.[7,8] About 6% of the CRC 
cases can be explained by several colorectal cancer syndromes, including Lynch syndrome, 
familial adenomatous polyposis (FAP), and MUTYH-associated polyposis (MAP). However, 
for the other familial cases, the underlying genetics remain elusive. High or moderate risk fac-
tors could play a role in families affected with colorectal cancer. Moreover, co-inheritance of 
several low risk factors could explain the excess risk in such cases. 
Tumorigenesis
The development of colorectal cancer is a multistep process that involves somatic genetic and 
epigenetic changes. Several genes acquire a mutation that provides the cell with a growth 
advantage. The transcription of genes and microRNAs is dysregulated in cancers; tumor sup-
pressor genes are shut down and oncogenes are activated. 
Colorectal cancer generally develops from normal epithelium through different adenoma 
stages with increasing dysplasia into carcinoma.[9] A genetic model for the development of 
sporadic CRC was first postulated by Fearon and Vogelstein in 1990 (Figure 1).[10] They 
described the genetic changes of colorectal tumors along their development from adenoma 
to carcinoma and they assumed that – although the accumulation of mutations seems most 
important - the genetic changes occur in a specific order in most CRCs. Later, more genes 
and genetic aberrations were added to this model.[11,12]
Recent advances have provided more insight in the biology of the colonic crypts and their 
relation to tumorigenesis (reviewed by [13]). Colonic crypts are finger-like invaginations of the 
colonic epithelial layer in the underlying connective tissue of the lamina propria. At the base 
of each crypt stem cells are located that are capable of regenerating all intestinal cell types. 









up the whole crypt. Subsequently, crypt fission can lead to spreading of the mutation in neigh-
boring epithelium. Such aberrant crypt foci (ACF), consisting of a cluster of a small number of 
abnormal crypts, are thought to be an early step in the formation of adenomatous polyps.[13]
Colorectal cancer development is often initiated by mutations in APC, which leads to an in-
creased proliferation of the cell. APC mutations and/or loss of heterozygosity at the APC 
locus are found in over 80% of all colorectal cancers.[14-16] Mutations in CTNNB1, encoding 
β-catenin, have also been found to occur in CRC.[17] KRAS mutations are seen with progres-
sion of the adenoma. Later, in the progression from adenoma to carcinoma, additional muta-
tions are acquired in for example SMAD2 and SMAD4, and p53, often accompanied by loss 
of heterozygosity (LOH) of 17p and 18q.[11,18] 
Recent studies show that the majority of mutations in a tumor occur in genes other than these 
commonly mutated genes, leading to a unique mutational signature for each tumor.[19,20] 
However, the role of these other mutations in tumorigenesis still needs to be elucidated. 
The carcinogenesis model described above applies mainly to sporadic CRC. In hereditary 
syndromes, the carcinogenesis model is different depending on the germ-line defect.
Figure 1. Genetic model of colorectal tumorigenesis as proposed by Fearon and Vogelstein 
[10]
Signaling Pathways
Several signaling pathways are involved in colorectal tumorigenesis. These pathways be-
come dysregulated via mutational activation or inactivation of one of its proteins or via other 
ways of (in)activation like methylation. 
Wnt signaling pathway 
Activation of the Wnt signaling cascade is considered to be the initiating event in colorectal 
cancer. In the Wnt signaling cascade, β-catenin functions as a transcription factor upon bind-
ing to nuclear proteins of the Tcf family and regulates genes involved in cellular activation. APC 
is a key regulator of β-catenin because it regulates the levels of cytoplasmic β-catenin. APC 
forms a complex with GSK3β, axin, and β-catenin, that modulates the cytoplasmic β-catenin 
levels by degradation. Mutational inactivation of APC is observed in over 80% of the CRCs 
and leads to accumulation of β-catenin in the cytoplasm.[14-16] This accumulation leads to 
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dysregulation of the transcriptional targets of β-catenin/Tcf.[21] Fifty percent of the tumors that 
lack mutations in APC, display mutations in the β-catenin gene CTNNB1.[22] Examples of 
genes that are regulated by β-catenin/Tcf include cell cycle regulator c-MYC, G1/S-regulating 
cyclin D1, and MMP-7 (matrilysin), a matrix-degrading metalloproteinase.[23-25] Germ-line 
mutations in the APC gene give rise to an inherited cancer predisposing syndrome, familial 
adenomatous polyposis (discussed below). 
TGF-β signaling pathway 
The transforming growth factor β (TGF-β) signaling pathway regulates the proliferation and 
differentiation of cells, embryonic development, wound healing, and angiogenesis.[26] TGF- β 
can bind three high-affinity cell-surface receptors (type I, II, and III). The intra-cellular domains 
of receptor type I and II contain serine-threonine protein kinases that initiate phosphorylation 
of SMAD transcription factors. Receptor type III binds TGF-β and transfers it to the signaling 
receptors type II. Upon binding of TGF-β, receptor type II forms a complex with receptor type 
I and phosphorylates the receptor, thereby stimulating the kinase-activity of the receptor.[27] 
The activated receptor type I phosphorylates SMAD2 and SMAD3 which then bind to SMAD4. 
This SMAD-complex then translocates to the nucleus, where it acts as a transcription factor. 
In epithelial cells, TGF-β inhibits cellular proliferation, which explains its tumor suppressor 
function. 
Mutation inactivation of the TGF-β pathway is frequent in colorectal tumors. About 30% of the 
sporadic CRCs have a mutation in the SMAD4 gene.[28] Moreover, the TGF-β receptor type 
II (TGFRB2) is frequently mutated in tumors with DNA mismatch repair deficiency (discussed 
below) and about 15% of DNA mismatch repair proficient colorectal carcinomas display mu-
tational inactivation of TGFBR2.[29,30] Germ-line mutations in SMAD4 are found in patients 
with Juvenile Polyposis (discussed below).[31]
Bone morphogenetic proteins (BMPs) also act in the TGF-β signaling pathway. Similar to 
TGF-β, BMPs bind to serine-threonine kinase receptors type 1 and 2 (BMPR1 and BMPR2). 
BMPR2 then phosphorylates and activates receptor type I. The activated BMPR1 subse-
quently phosphorylates SMAD1, SMAD5, and SMAD8, which associate with SMAD4 and 
translocate to the nucleus (reviewed by [32]). In addition to SMAD4 mutations, germ-line 
mutations in BMPR1A are also found in Juvenile Polyposis patients.[33]
p53 signaling pathway
The p53 pathway is an important pathway that is involved in cell-cycle arrest upon cellular 
stress. It thereby acts as a tumor suppressor.[34] When cellular stresses occur, including DNA 
damage or hypoxia, p53 is stabilized and binds to the DNA to act as a transcription regula-
tor. Genes regulated by p53 regulates are involved in important cellular processes like DNA 
repair, cell-cycle arrest, senescence, and apoptosis. Genes that are transcriptionally activated 
by p53 include p21, MDM2, GADD45, and Bax.[35] The pathway is often inactivated in CRC 








allele of the p53 gene through physical loss of chromosome arm 17p.[36,37] Inactivation of 
p53 coincides with the transition of an adenoma to the carcinoma stage.[38]
MAPK signaling pathway 
Mitogen-activated protein kinases (MAPK) cascade is an important signaling pathway in-
volved in cellular proliferation. Three major subfamilies of MAP kinases include the extra-cel-
lular-signal-regulated kinases, stress-activated protein kinases, and MAPK14. The subfamily 
of extracellular-signal-regulated kinases (ERK MAPK), including Ras, Raf, MEK, and ERK, is 
important for intestinal epithelial differentiation.[39] Upon binding of extracellular signal pro-
teins the Ras/Raf/MEK/ERK cascade transmits the signal to the nucleus where it regulates 
the transcription of genes involved in proliferation and differentiation. The cascade includes 
several proto-oncogenes and is dysregulated in about 30% of all cancers. Activating muta-
tions in KRAS are found in approximately 38% of colorectal cancer.[40] BRAF mutations are 
observed in about 10% of colorectal cancers and are particularly observed in tumors with 
MLH1 promoter hypermethylation.[41,42] Mutations in KRAS and BRAF appear to be mutu-
ally exclusive.[42,43] 
Activation of the epidermal growth factor receptor (EGFR) stimulates the MAPK signaling 
pathway and is a target for cancer treatment. Oncogenic activation of the Ras/Raf/MEK/ERK 
cascade in colorectal cancer is strongly correlated with impaired response to anti-EGFR treat-
ments like panitumumab and cetuximab.[44]
PI3K signaling pathway
Phosphatidylinositol 3-kinase (PI3K) is an enzyme that phosphorylates inositol phospholipids 
(IPs). The phosphorylated IPs (PIPs) subsequently activate the downstream AKT pathway. 
Activation of AKT leads to increased cell survival, growth and cellular proliferation (reviewed 
by [45]). Protein targets of AKT include mTor, Bad, Caspase 9, Tuberin, and GSK3β.[46] About 
32% of colorectal tumors carry an activating mutation in PIK3CA, encoding the catalytic sub-
unit.[47] PTEN functions as an inhibitor of the PI3K pathway because it dephosphorylates the 
inositol phospholipids. The PI3K pathway is interlinked with the MAPK pathway and is also 
stimulated upon EGFR activation. Consequently, inactivating PTEN mutations or activating 
PI3K mutations have been associated with reduced response to anti-EGFR treatment.[48,49]
Genetic instability
In addition to acquiring mutations in genes, colorectal tumors become genetically instable. 





Microsatellites are short repetitive sequences within the DNA. An accumulation of mutations 
in microsatellites, that make them shorter or longer, is called microsatellite instability (MSI or 
MIN). This microsatellite instability is caused by a defective DNA mismatch repair system, 
which fails to repair errors during DNA replication. MSI-H (MSI-high) is typically seen in tumors 
from patients with Lynch syndrome, which carry mutations in DNA mismatch repair genes 
MLH1, MSH2, MSH6, or PMS2. However, MSI is also observed in sporadic colorectal cancers 
due to hypermethylation of the promoter region of MLH1.[50-52] This is observed in about 
15% of all colorectal cancers.[53,54] BRAF mutations are common in sporadic MSI-H tumors, 
whereas no BRAF mutations are observed in MSI-H Lynch tumors.[42]
Mutation rates are at least 100-fold increased in MMR deficient cells as compared to MMR 
proficient cells.[55,56] Via this pathway several genes that contain repeat sequences are 
targeted. Frequently targeted genes include growth factor receptors TGFB-RII and IGFRII, 
pro-apoptotic gene BAX, and Caspase 5.[30,57-59] MSI tumors are generally diploid or near-
diploid and gross chromosomal gains and losses are absent.[60-62] However, some studies 
reported the presence of copy number aberrations in a minor fraction of MSI-H tumors, includ-
ing gains of chromosomes 4, 8, 12, 13, and 20 and losses of chromosomes 1, 9, 11, and 15. 
[63,64]
Chromosomal instability
Chromosomal instability (CIN) is seen in the majority of CRCs and is characterized by nu-
merous chromosomal gains and losses and copy neutral loss of heterozygosity (cnLOH). 
Many studies analyzed the genomic profile of tumors for gains and losses of chromosomes or 
chromosome arms using array comparative genomic hybridization. With recent advances in 
technology, genome-wide LOH studies have become feasible using SNP arrays. These SNP 
arrays not only provide genome-wide LOH information, but can also detect LOH in the ab-
sence of copy number aberrations (copy neutral LOH) which for example can arise via mitotic 
recombination or a physical loss followed by reduplication. CIN tumors are mostly aneuploid, 
reflecting their chromosomal instability.
Based on a comprehensive meta-analysis of tumor genome profiling studies, a model of ge-
netic colorectal tumor progression has been established.[65] Losses of chromosomes 17p 
and 18 and gains of chromosomes 8q, 13q, and 20 occur early during tumor development. 
Losses of chromosomes 4p and 8p, and gains of 7p and 17q are correlated with the transition 
from primary tumor to liver metastasis. Loss of chromosome 14q and gains of chromosomes 
1q, 11, 12p, and 19 are considered to be late events in tumor progression.[65]
Table 2 provides an overview of genomic profiling studies that have been performed since 
this meta-analysis was published. Most studies used metaphase-based CGH or array CGH 
to study genomic aberrations and only a minority of the studies used SNP arrays, which also 
provide information on LOH. Moreover, in most studies sporadic colorectal tumors were ana-








from Lynch patients - were studied to a much lesser extent.
Although the molecular basis for CIN is still unknown, several genes have been associated 
with the CIN pathway. Mitotic checkpoint genes hBUB1 and hBUBR1 have been described 
to contribute to chromosomal instability.[66,67] Tumor suppressor gene p53, involved in G1 
arrest and apoptosis, is mutated in about 50% of sporadic colorectal cancers.[36] Inactivation 
of p53 has been associated with the development of aneuploidy in cancers, because of loss of 
the arrest at the G1 checkpoint.[68] Mutations in the adenomatous polyposis coli gene APC, a 
member of the Wnt signal transduction pathway, occur early in tumorigenesis and have been 
linked to chromosomal instability.[69] Other genes that are frequently targeted by point muta-
tions in CIN tumors are oncogene KRAS, whose activation leads to growth promotion, and 
SMAD4, a component of the TGF-β pathway. 
CpG Island Methylator Phenotype
A third type of genetic instability observed in colorectal cancers is the occurrence of aberrant 
methylation of CpG islands, leading to the CpG island methylator phenotypes (CIMP).[70] 
CpG islands are short DNA sequences that are rich in CpG dinucleotides. Such islands are 
found in the 5’ region of about half of all human genes.[71]. Hypermethylation of the cytosines 
in these CpG islands leads to transcriptional inactivation of such genes. Simultaneous hy-
permethylation of CpG islands of several genes has been termed the CIMP phenotype. Two 
subclasses can be distinguished: CIMP1 or CIMP-high with intense methylation of multiple 
genes and CIMP2 or CIMP-low with methylation of a limited number of genes. CIMP1 tumors 
are generally MSI-H and have a high frequency of BRAF mutations, whereas CIMP2 tumors 
are generally MSS and have a high frequency of KRAS mutations.[72] The cause of CIMP is 
currently unknown.
Hereditary Colorectal Cancer Syndromes
Several high penetrance colorectal cancer syndromes have been identified in the past two de-
cades. The genes responsible for these syndromes have been identified using linkage analy-
sis, deletion mapping, positional cloning, and by exploring tumor characteristics (Figure 2). 
The different CRC syndromes are briefly described below. An overview of all CRC syndromes 
as well as of polyposis syndromes is provided in Table 1. For several polyposis syndromes, 
including for example Cowden syndrome and hereditary mixed polyposis syndrome, a firm 
association with CRC has not yet been identified.
Lynch syndrome
Lynch syndrome, formerly called hereditary non-polyposis colorectal cancer or HNPCC, is the 
most prevalent CRC syndrome. It is estimated that Lynch syndrome accounts for at least 3% 
of all colorectal cancers.[73,74] Familial clustering of colorectal cancer, stomach, and uterine 
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cancer was already described by Warthin et al. in 1913.[75] Later, Lynch et al. described two 
additional families with clustering of colorectal cancer and uterine cancer.[76] In the early nine-
ties, the genes predisposing to Lynch syndrome were identified. The syndrome is caused by 
germ-line mutations the DNA mismatch repair genes MLH1, MSH2, MSH6, and PMS2.[77-82] 
In addition, germ-line epigenetic inactivation of MLH1, by hypermethylation of the promoter of 
MLH1, leads to Lynch syndrome.[83] Recently, it was shown that a deletion of the last exons 
of TACSTD1, upstream of MSH2, also predisposes individuals to Lynch syndrome, because 
this deletion leads to epigenetic inactivation of MSH2 in TACSTD1-expressing tissues.[84]
Lynch syndrome is characterized by the development of colorectal carcinomas at a mean 
age of 42 years for men and 47 years for women. The mean age at diagnosis of endometrial 
carcinomas in Lynch syndrome patients is approximately 47
years.[85] The colorectal cancers predominantly develop at the right side of the colon.[86] 
Other manifestations include cancers of the stomach, small bowel, ovaries, and the urinary 
tract.[87,88] The lifetime risk for developing CRC for carriers of amutation in one of the mis-
match repair genes is approximately 66% for men and approximately 43% for women. The 
cumulative risk of endometrial cancer or CRC in women is approximately 73%.[85]
Autosomal dominant inheritable CRC without polyps Genes MIM No
Lynch syndrome MLH1, MSH2, MSH6, 
PMS2 120435
   
Autosomal dominant inheritable CRC with adenomatous polyps   
Familial adenomatous polyposis (FAP) APC 175100
Attenuated FAP (AFAP) APC 175100
   
Autosomal dominant inheritable CRC with hamartomatous/mixed/
hyperplastic polyps   
Peutz-Jeghers syndrome (PJS) STK11 (LKB1) 175200
Juvenile polyposis syndrome (JPS) SMAD4, BMPR1A 174900
Hereditary hemorrhagic telangiectasia syndrome (HHT) * ENG, ACVRL1 187300
Hyperplastic polyposis syndrome (HPT) * MUTYH, MBD4 unassigned
Hereditary mixed polyposis syndrome (HMPS) *  601228
Cowden disease (CD) * PTEN 158350
Birt-Hogg-Dube syndrome (BHT) * FLCN 135150
   
Autosomal recessive inheritable CRC with adenomatous, serrated 
adenomas and hyperplastic polyps   
MUTYH-associated polyposis (MAP) MUTYH 608456
Table 1. Overview of colorectal cancer syndromes and polyposis syndromes








Mutations in a DNA mismatch repair gene lead to a failure to repair errors during DNA rep-
lication, especially concerning mismatches and insertion/deletion loops. As a consequence, 
the hallmark of tumors from Lynch patients is an accumulation of errors in short repetitive 
sequences, so-called microsatellite instability (MSI).[54,89-91]
In 1990, clinical guidelines were established to identify Lynch syndrome families for research 
purposes. These so-called Amsterdam Criteria were based on family characteristics, age at 
diagnosis and the type of cancer.[92] However, because these criteria did not account for 
extracolonic cancers, new criteria (Amsterdam Criteria II) were established in 1999.[93] The 
Amsterdam Criteria have a high specificity, but a lower sensitivity to detect Lynch syndrome 
families. About 40% of the tumors from families that fulfill the Amsterdam Criteria II do not 
show an MSI phenotype.[94] Therefore, in 1997 the Bethesda guidelines were developed to 
identify tumors that should be tested for microsatellite instability, as a marker of patients that 
should be screened for germ-line mutations in one of the DNA mismatch repair genes.[95] 
These guidelines also select smaller families. In 2004, the Bethesda guidelines were revised 
to further improve the identification of Lynch syndrome patients.[96] Other criteria, which do 
not take family history into account, but select patients only on basis of early onset of colorec-
tal adenomas and carcinomas, or recurrent disease, have been tested as well. These criteria 
prove a sensitive strategy to identify Lynch syndrome patients.[97] Additionally, immunohis-
tochemical screening of all CRC patients for MLH1, MSH2, MSH6, and PMS2 has also been 
proposed and has so far only been implemented in Denmark. Using this approach, Lynch 
patients in small families and patients diagnosed at older age or with de novo mutations can 
also be identified.[98,99]
When a MMR gene mutation is identified in a family, colonoscopic surveillance is offered to the 
family. This surveillance facilitates early detection of precursor lesions, thereby preventing it 
from developing into a malignant lesion. In the Netherlands, large scale surveillance of Lynch 
syndrome families was introduced in the late 1980s.[100] It has been shown that the mortal-
ity because of CRC has decreased since the introduction of colonoscopic surveillance.[101]
Recently, two genetic factors have been found to modify the colorectal cancer risk in Lynch 
Syndrome families. It has been shown that two common low penetrance risk alleles (dis-
cussed below), located on 8q23.3 and 11q23.1, are associated with increased colorectal can-
cers risks. The latter association (11q23.1) was found in female Lynch syndrome patients only.
[102]
Bi-allelic MMR mutations
Heterozygous mutations in the mismatch repair genes give rise to Lynch syndrome; however, 
rare cases of bi-allelic MMR mutations have also been described. Patients with homozygous 
or compound heterozygous mutations in MLH1, MSH2, PMS2, and MSH6 develop juvenile 




The Muir-Torre syndrome (MTS) is characterized by a combination of cutaneous lesions (mul-
tiple keratoacanthomas and sebaceous gland tumors) and colorectal, endometrial, urologi-
cal, and upper gastrointestinal tumors.[110] Most MTS patients carry a germ-line mutation in 
MSH2 or MLH1. Therefore, the syndrome is considered to be a clinical variant of the Lynch 
syndrome. In MTS families, mutations in MSH2 are more frequent than mutations in MLH1, 
as compared to Lynch syndrome families.[111] Recently it was shown that sebaceous gland 
tumors can also occur in MUTYH-associated polyposis.[112]
Turcot’s syndrome
Turcot’s syndrome (TS) is a rare disorder that is clinically characterized by primary tumors 
of the central nervous system and colorectal polyposis. The phenotypic spectrum is broad, 
including various types of central nervous tumors and single adenomas are observed as well 
as adenomatous polyposis. In patients affected with this syndrome, germ-line mutations were 
identified in the APC gene or in one of the mismatch repair genes. The disease phenotype 
for patients with an APC mutation differs from that of patients with a mutation in one if the 
mismatch repair genes.[113] 
Familial adenomatous polyposis 
Familial adenomatous polyposis (FAP) is an autosomal dominantly inherited disease which 
hallmark is the development of a hundred to thousands of adenomatous polyps. FAP ac-
counts for approximately 1% of all colorectal cancers.[114] The polyps develop already during 
adolescence, but symptoms usually present in the third decade of life.[115-117] The risk of 
developing carcinomas is nearly 100% if patients are not treated.[115] Extracolonic manifes-
tations include epidermoid cysts, facial osteomas, thyroid carcinoma, duodenal carcinoma, 
and malignancies of the biliary tract.[115,116] Moreover, approximately 10% of FAP patients 
develop desmoid tumors, also referred to as aggressive fibromatoses.[118,119]
Germ-line mutations in the adenomatous polyposis coli (APC) gene were identified to be re-
sponsible for FAP.[120-124] APC is involved in the Wnt signaling pathway and its mutational 
inactivation leads to activation of the Wnt signaling through reduced degradation of β-catenin. 
The majority of the APC mutations in FAP patients concern nonsense mutations or frameshift 
mutations that lead to a truncated protein. Mutations at codons 1061 and 1309 account for 
about a third of all germ-line mutations. The tumors from FAP patients carry an additional so-
matic mutation in APC. The nature of this second-hit appears to be dependent on the type and 
location of the germ-line mutation.[125] The ‘just-right’ signaling model has been put forward 
as an explanation for this phenomenon. This model proposes that selection of APC genotypes 
occurs to retain some downregulation of β-catenin signaling rather than a constitutive activa-









Attenuated FAP is a phenotypic variant of classical FAP, in which patients develop less adeno-
matous polyps and have a later onset of colorectal cancer. The number of polyps that patients 
develop can be very variable; within one family some affected members have few polyps while 
other family members have several hundred polyps at young age.[127-129] Attenuated FAP 
seems to be associated with mutations in the 3’ and 5’ end and exon 9 of APC.[129-132] 
MUTYH-associated polyposis
MUTYH-associated polyposis (MAP) is the only colorectal cancer syndrome described with a 
recessive mode of inheritance. It is caused by bi-allelic mutations in the base excision repair 
gene MUTYH.[133-135] MAP patients develop multiple polyps and cancer in their colon. How-
ever, the number of polyps is generally lower as compared to FAP patients.[134,136,137] The 
MUTYH protein plays a role in the repair of oxidative DNA damage: upon oxidative DNA dam-
age, MUTYH removes incorrectly incorporated adenines opposite to an 8-oxo-guanine. As a 
consequence of MUTYH deficiency, somatic G:C>T:A transversions are seen in MAP patients 
in critical genes such as APC and KRAS. In APC, these transversions occur primarily in GAA 
DNA sequences.[133,134] In KRAS, a specific GGT>TGT mutation (c.34 G>T, p.Gly12Cys) is 
found in about 64% of MAP carcinomas.[138]
The penetrance of colorectal cancer development in MAP patients is nearly 100% at the age 
of 60 years.[139] 
The clinical relevance of heterozygous mutations in MUTYH is still under debate. Recent as-
sociation studies in large series using different approaches found some evidence for a modest 
and late onset increase in CRC risk for heterozygous mutation carriers (odds ratios 1.5-1.7).
[139-141] This risk is comparable to the risk of CRC that first-degree relatives of individuals 
with CRC have. Most studies, however, fail to find significant associations between hetero-
zygous MUTYH mutations and CRC risk. Similarly, two meta-analyses do not find evidence 
for such association.[142,143] However, these meta-analyses analyzed only the two hotspot 
mutations Y179C and G396D.
It has also been hypothesized that MUTYH mutations act as phenotypical modifiers in MMR 
mutation carriers, especially concerning MSH6 mutation carriers. Enrichment of MUTYH mu-
tations in carriers of missense mutations in MSH6 has been described, but could not be con-
firmed in a second study. Furthermore, a strikingly mild phenotype was observed in a patient 
with a bi-allelic mutation in MUTYH and a MSH6 mutation.[144-146]
Juvenile polyposis
Juvenile polyposis syndrome (JPS) is characterized by the development of multiple juvenile 
hamartomatous polyps in the gastrointestinal tract and an increased risk of cancer. It is a rare 
autosomal inherited disease with a penetrance of up to 70%.[147] About 1 in 100,000 indi-
viduals are affected with JPS and the mean age at diagnosis is 16 years.[148] JPS is caused 
by germ-line mutations in SMAD4 and BMPR1A.[31,33] Mutations in these genes explain, 
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however, only about 40% of JPS patients. SMAD4 and BMPR1A are both members of the 
transforming growth factor-β (TGF-β) superfamily. The BMP receptor type 1A activates the 
transcription factor SMAD4 to downregulate cellular growth and division.
Figure 2. Genetic risk factors for colorectal cancer
This graph shows the known CRC risk factors. Rare variants with a low CRC risk are very difficult to find 
(lower left white area) and common variants that confer a high CRC risk are believed not to exist (upper 
right white area).
The MMR genes include MLH1, MSH2, MSH6, and PMS2. For the risk variant identified in genome-wide 
association studies their respective chromosomal locations are depicted in the graph: 8q23, rs16892766; 
8q24, rs6983267; 10p14, rs10795668; 11q23, rs3802842; 14q22, rs4444235; 15q13, rs4779584; 16q22, 
rs9929218; 18q21, novel 1; 19q13, rs10411210; 20p14, rs961253.
Peutz-Jeghers syndrome
The Peutz-Jeghers syndrome (PJS) is an autosomal dominant inherited disease that pre-
disposes to hamartomatous polyposis, affecting mostly the small bowel. It affects approxi-
mately 1 in 200,000 individuals and has a high penetrance. In around 50% of the patients, the 
syndrome is caused by germ-line mutations in STK11 (also named LKB1), encoding serine/
threonine protein kinase 11.[149] STK11 forms a complex with Ste adaptor protein STRAD 
and MO25.[150,151] This complex is involved in the regulation of cellular responses tot en-
ergy stress and cell polarity.[152] In addition to (benign) hamartomatous polyps, PJS patients 
develop mucocutaneous pigmentation and have an increased risk of developing malignancies 
in the gastrointestinal tract.[153] 








provided a conclusive answer to the question how STK11 exerts its tumor suppressor func-
tion.[128] STK11 has been described to have a regulatory role in control of cell-cycle arrest, 
p53-mediated apoptosis, the Wnt signaling cascade, the ras-pathway, TGF-β signaling, and 
energy metabolism (reviewed by [154]).
Familial Colorectal Cancer of unknown cause
As briefly mentioned above, heritable factors may play a role in up to 30% of all CRC.[3] Fam-
ily history is a strong risk factor for the development of colorectal cancer. About 6% of all CRC 
is explained by the colorectal cancer syndromes described above. However, for the other 
familial cases the underlying genetics remain elusive. Among these familial cases are large 
families with a clear positive family history of CRC. Such Amsterdam Criteria positive families 
without a mismatch repair defect have been termed ‘Familial Colorectal Cancer Type X’ or 
mismatch repair proficient CRC.[155] It has been estimated that about forty percent of the 
families fulfilling the Amsterdam Criteria is not affected with the Lynch syndrome, suggesting 
that other yet to be identified genetic factors predispose these families to CRC.[94] Moreover, 
it can be calculated from a Finnish study that only about 12% of the excess CRC risk associ-
ated with a family history of mismatch repair proficient CRC is explained by the known genes.
[4,156] 
In mismatch repair proficient CRC families, the cancer incidence is generally lower than in 
Lynch families.[4,155] Segregation analysis performed by Lubbe and colleagues suggested 
that aggregation of CRC in mismatch repair proficient families follows a recessive inheritance 
model.[4] Jenkins et al. also reported a role for recessively inherited factors in familial CRC.
[157] The results of the study of Lindor et al. on the other hand, supported a dominant model 
of inheritance.[155] These differences in the suggested model of inheritance might be ex-
plained by differences in patient ascertainment. Lindor et al. included Amsterdam Criteria pos-
itive families, whereas Lubbe et al. included CRC patients diagnosed below 70 years of age. 
Finally, Jenkins et al. included only CRC patients with an age at diagnosis below 24 years.
High penetrance risk loci
Generally, linkage analysis is adopted to identify rare alleles that confer a high risk of familial 
colorectal cancer. Several loci have been identified using this approach; however, none of 
these have yet led to the identification of the genes responsible for the increased CRC risk in 
FCC families. 
Wiesner and colleagues reported genetic linkage of CRC to chromosome 9q22.2-31.2 in a 
set of 74 affected sibling pairs.[158] Two other studies provided support for the presence of a 
CRC susceptibility locus in this region.[159,160] Kemp and colleagues described linkage to 
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colorectal cancer susceptibility of a region located on chromosome 3q21-q24.[161] In a later 
extension of this study including 34 additional families, linkage to this region was confirmed. 
However, mutation screening of 30 genes failed to identify pathogenic variants.[162] Further 
support for this region harboring a CRC susceptibility locus was provided by a Swedish link-
age study of Picelli et al.[163] A linkage scan in 18 Swedish colorectal cancer families re-
vealed linkage on chromosome 11, 14 and 22.[164] And finally, linkage to chromosome 7q31 
has been identified using an affected sibling approach.[165] 
Recently, a 111 kb copy number variable region on 3q26 was proposed to contain a regulatory 
element for PPMIL which could cause CRC susceptibility in APC mutation-negative polyposis 
families.[166] This region was identified using copy number analysis in polyps of these pa-
tients and subsequent gene expression analysis in the candidate region.
Low Penetrance Risk Alleles
Two approaches are generally used to identify low penetrance colorectal cancer risk variants. 
The first method is the candidate gene analysis. In candidate gene approaches, the following 
groups of genes are most frequently studied: genes involved in carcinogen metabolism, genes 
involved in methylation, genes encoding DNA repair proteins, microenvironmental modifiers, 
and oncogenes and tumor suppressor genes.[167,168] Two large meta-analyses of studies 
using the candidate gene approach, identified several polymorphisms that are associated 
with an increased or decreased colorectal cancer risk (Figure 2). The C677T polymorphism 
in MTHFR (methylene tetrahydrofolate reductase) is associated with a decreased CRC risk 
for homozygous carriers of the variant allele. HRAS1 is a proto-oncogene that contains a 
variable number of tandem repeats region (VNTR). Rare alleles of this VNTR are associated 
with a moderately increased colorectal cancer risk. For the NAT2 gene, only a phenotypic 
association was identified, i.e. a fast acetylatorship has been associated with an increased 
CRC risk. However, genotypic associations could not be identified. GSTT1, a detoxification 
enzyme, is associated with a small increase in colorectal cancer risk for the null genotype 
(homozygous deletion). ALDH2, a mitochondrial enzyme responsible for oxidation of acetal-
dehyde, is associated with in increased risk both in heterozygous and homozygous carriers of 
the variant allele. And finally, the variant I1307K in APC is associated with an increased CRC 
risk.[167,168] Other low risk variants that have been associated with CRC include CHEK2 
1100delC, AKAP9 M463I, PTGS1 G213G, IL8 c.-352T>A, MTHFR A429E.[169-171]
The second approach to identify low risk variants is genome-wide association studies, which 
have become feasible with the availability of high density single nucleotide polymorphism 
(SNP) arrays. Recent genome-wide association studies have successfully identified sever-
al loci that are associated with an increased risk of developing colorectal cancer. Risk loci 
were identified on chromosomes 8q24.21 (rs6983267), 18q21.1 (rs4939827, rs12953717 and 








8q23.3 (rs16892766), 20p12.3 (rs961253), 14q22.2 (rs4444235), 16q22.1 (rs9929218), and 
19q13.1 (rs10411210).[172-181] The next step is to study the mechanisms that underlie CRC 
susceptibility associated with the different loci. Some of the loci are in high linkage disequi-
librium with genes that are strong candidates for the causal relation with colorectal cancer. 
However, for other loci no genes are in the direct vicinity, which makes the interpretation of 
these risk factors much more difficult. For rs6983267 (8q24.21), it has now been shown that it 
is located in a transcriptional enhancer and that it affects the DNA-binding affinity of Wnt-reg-
ulated transcription factor TCF7L2 (or TCF4). The enhancer element interacts with the MYC 
promoter; however, no correlation was observed between the rs6983267 genotype and MYC 
expression.[182,183] Additionally, a role in tumor evolution was suggested for rs6983267; 
tumor studies showed that the risk allele was favored in about 66% of the tumors with allelic 
imbalance at the locus of rs6983267.[184] For the locus on 18q21.1, the causal SNP has been 
identified by resequencing the genomic region. This SNP - named Novel 1 - also maps to a 
transcription factor binding site and has been associated with reduced expression of SMAD7. 
No relation with copy number changes on chromosome 18q21.1 was identified for Novel 1 in 
tumors.[185] 
Environmental Factors
Several environmental factors can influence the risk of the development of colorectal cancer. 
First, diet is an important factor that influences the CRC risk. Intake of vegetables and fruits 
is found to reduce the risk of CRC. The effect of raw vegetables, green vegetables, and cru-
ciferous vegetables has been particularly consistent in different studies.[186] The degree of 
risk reduction however, varies in the different studies. Fiber intake has also been suggested 
to decrease colorectal cancer risk, however existing data are inconsistent.[186] Consumption 
of red meat and processed meat has, on the other hand, been associated with an increased 
risk of colorectal cancer.[186,187] Moreover, alcohol consumption has been associated with 
an increased colorectal cancer risk.[186,188] Secondly, physical activity and body mass can 
influence CRC risk. Physical activity is known to reduce the risk of colon cancer, whereas obe-
sity increases the risk of colon cancer. However, both factors do not seem to influence the risk 
of rectal cancer.[186,188,189] Thirdly, non-steroidal anti-inflammatory drugs (NSAIDs) and 
hormone replacement therapy (HRT) are described to lower the risk of colorectal cancer.[186] 
Fourthly, smoking of cigarettes, cigars, and pipes increases the risk of developing colorectal 
cancer.[186,188] And finally, recent studies in mice suggest that commensal colonic bacteria 
can promote colorectal tumorigenesis via inflammation.[190]
The influence of environmental factors differs per individual, based on their individual lifestyle. 
However, environmental factors can in part be shared by individuals from the same family. For 
example, dietary habits are part of a shared environment or ‘inherited environment’ within a 
family. In a study that analyzed cancer risk in monozygotic and dizygotic pairs of twins it was 
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estimated that shared environmental factors contribute up to 5% to the total colorectal cancer 
risk.[3]
New fields in CRC research, prevention, and treatment
Recent studies that identified colon cancer tumor-initiating cells, provide support for the can-
cer stem cell hypothesis.[191-193] The stem cell model proposes that tumorigenesis is initi-
ated by dysregulation of the process of self-renewal of colonic stem cells and that as a conse-
quence tumors contain a subcomponent that retains stem cell properties.[194] These cancer 
stem cells have been suggested to exhibit a greater plasticity that the stem cells populating 
the normal crypts. The stem cell properties (“stemness”) of certain subpopulations of cancer 
cells can therefore also be seen as an extreme plasticity of tumors to adapt to and survive 
variable and constantly changing environmental conditions.[195] The concept of cancer stem 
cells has several consequences for cancer prevention and treatment. Cancer stem cells are 
more resistant to cytotoxic chemotherapy, because an intrinsic property of stem cells is that 
they promote survival and are resistant to apoptosis. Additionally, stem cells express multi-
drug resistant genes, including multifunctional efflux transporters that have an important role 
in drug distribution.[196] This indicates that novel treatments should be developed that can 
eradicate the cancer stem cells. Moreover, it has been proposed that stem cells are capable 
of metastasizing and can remain quiet until the appropriate signals activate them to develop 
into a macroscopic metastasis.[194]
Current topic in cancer prevention is the possible installation of population-based screening 
for colorectal cancer. The fecal occult blood test (FOBT) provides a non-invasive and sensitive 
method (sensitivity: ~65%) for detecting invasive colorectal cancer.[197] The Health Council 
of the Netherlands has advised to implement biennial immunochemical FOBT in men and 
women of 55-75 years of age as a nationwide screening program.[198] Another potential 
non-invasive screening method is a DNA test in stool, in which a panel of genetic markers is 
tested.[199]
New strategies in the diagnosis and treatment of colorectal cancer have been developed 
in recent years. For rectum cancer a more standardized way of treatment by the so-called 
total mesorectal excision (TME) in combination with preoperative radiotherapy has led to a 
reduction of local recurrence.[200] Furthermore, transanal endoscopic microsurgery (TEM) 
was introduced. Initially it was solely used as an approach to curatively remove large sessile 
adenomas of the rectum.[201] However, trials are now underway to also use the TEM tech-
nique in combination with neoadjuvant (preoperative) radio-chemotherapy to treat early rectal 
cancer. Biomarkers and imaging modules are being further developed to predict and monitor 
therapy response. 
Surgeons more and more use endoscopic techniques to remove colorectal cancer with 








Whereas 15 years ago a patient with liver metastases would soon die of this condition, nowa-
days partial liver resections are being performed, sometimes in combination with isolated 
liver perfusions and/or radiofrequency ablation (RFA).[202,203] These developments have 
thereby increased the lifespan of such CRC patients.[204] Furthermore, the use of new che-
motherapeutic regimens such as the addition of oxaliplatin and irinotecan has led to improved 
patient outcomes.[205-207] The introduction of orally given 5-fluorouracil (5-FU) derivatives 
is of major benefit for patients in terms of tolerability.[208] As a second line of therapy the use 
of targeted drugs i.e. inhibitors of cancer transduction pathways have shown its effects in cer-
tain groups of CRC patients.[209] Biomarkers are identified that predict treatment response. 
An example for the latter is that the presence of a somatic KRAS mutation predicts a lack of 
response upon treatment with epidermal growth factor receptor (EGFR) inhibitors.[210] There 
is a peculiar subgroup of CRC patients with peritoneal carcinomatosis patterns that benefit 
from cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy 
(HIPEC). This therapy had shown to increase the overall survival of such patients.[211] More 
recently, it has been discussed whether HIPEC should be offered as a prophylactic treatment 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin (2005), 55: 74-
108.
2. Kiemeney LA, Lemmers FA, Verhoeven RH et al. [The risk of cancer in the Netherlands]. Ned 
Tijdschr Geneeskd (2008), 152: 2233-2241.
3. Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation 
of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med (2000), 
343: 78-85.
4. Lubbe SJ, Webb EL, Chandler IP et al. Implications of familial colorectal cancer risk profiles and 
microsatellite instability status. J Clin Oncol (2009), 27: 2238-2244.
5. Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individu-
als with a family history: a meta-analysis. Eur J Cancer (2006), 42: 216-227.
6. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. 
Am J Gastroenterol (2001), 96: 2992-3003.
7. Ahsan H, Neugut AI, Garbowski GC et al. Family history of colorectal adenomatous polyps and 
increased risk for colorectal cancer. Ann Intern Med (1998), 128: 900-905.
8. Winawer SJ, Zauber AG, Gerdes H et al. Risk of colorectal cancer in the families of patients with 
adenomatous polyps. National Polyp Study Workgroup. N Engl J Med (1996), 334: 82-87.
9. Kumar V, Abbas AK, Fausto N, Aster J: Pathologic Basis of Disease, 8 edn. 2010.
10. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell (1990), 61: 759-767.
11. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet (1993), 9: 138-141.
12. Houlston RS. What we could do now: molecular pathology of colorectal cancer. Mol Pathol (2001), 
54: 206-214.
13. Humphries A, Wright NA. Colonic crypt organization and tumorigenesis. Nat Rev Cancer (2008), 8: 
415-424.
14. Powell SM, Zilz N, Beazer-Barclay Y et al. APC mutations occur early during colorectal tumorigen-
esis. Nature (1992), 359: 235-237.
15. Miyoshi Y, Nagase H, Ando H et al. Somatic mutations of the APC gene in colorectal tumors: muta-
tion cluster region in the APC gene. Hum Mol Genet (1992), 1: 229-233.
16. Miyaki M, Konishi M, Kikuchi-Yanoshita R et al. Characteristics of somatic mutation of the adeno-
matous polyposis coli gene in colorectal tumors. Cancer Res (1994), 54: 3011-3020.
17. Morin PJ, Sparks AB, Korinek V et al. Activation of beta-catenin-Tcf signaling in colon cancer by 
mutations in beta-catenin or APC. Science (1997), 275: 1787-1790.
18. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor develop-
ment. N Engl J Med (1988), 319: 525-532.
19. Sjoblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and 
colorectal cancers. Science (2006), 314: 268-274.
20. Wood LD, Parsons DW, Jones S et al. The genomic landscapes of human breast and colorectal 
cancers. Science (2007), 318: 1108-1113.
21. Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 
(2000), 18: 1967-1979.
22. Sparks AB, Morin PJ, Vogelstein B et al. Mutational analysis of the APC/beta-catenin/Tcf pathway 
in colorectal cancer. Cancer Res (1998), 58: 1130-1134.
23. Crawford HC, Fingleton BM, Rudolph-Owen LA et al. The metalloproteinase matrilysin is a target of 
beta-catenin transactivation in intestinal tumors. Oncogene (1999), 18: 2883-2891.
24. He TC, Sparks AB, Rago C et al. Identification of c-MYC as a target of the APC pathway. Science 
(1998), 281: 1509-1512.
25. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. 








26. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. 
N Engl J Med (2000), 342: 1350-1358.
27. Wrana JL, Attisano L, Wieser R et al. Mechanism of activation of the TGF-beta receptor. Nature 
(1994), 370: 341-347.
28. Thiagalingam S, Lengauer C, Leach FS et al. Evaluation of candidate tumour suppressor genes on 
chromosome 18 in colorectal cancers. Nat Genet (1996), 13: 343-346.
29. Grady WM, Myeroff LL, Swinler SE et al. Mutational inactivation of transforming growth factor beta 
receptor type II in microsatellite stable colon cancers. Cancer Res (1999), 59: 320-324.
30. Markowitz S, Wang J, Myeroff L et al. Inactivation of the type II TGF-beta receptor in colon cancer 
cells with microsatellite instability. Science (1995), 268: 1336-1338.
31. Howe JR, Roth S, Ringold JC et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Sci-
ence (1998), 280: 1086-1088.
32. Hardwick JC, Kodach LL, Offerhaus GJ et al. Bone morphogenetic protein signalling in colorectal 
cancer. Nat Rev Cancer (2008), 8: 806-812.
33. Howe JR, Bair JL, Sayed MG et al. Germline mutations of the gene encoding bone morphogenetic 
protein receptor 1A in juvenile polyposis. Nat Genet (2001), 28: 184-187.
34. Baker SJ, Markowitz S, Fearon ER et al. Suppression of human colorectal carcinoma cell growth 
by wild-type p53. Science (1990), 249: 912-915.
35. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell (1997), 88: 323-331.
36. Baker SJ, Fearon ER, Nigro JM et al. Chromosome 17 deletions and p53 gene mutations in 
colorectal carcinomas. Science (1989), 244: 217-221.
37. Petitjean A, Achatz MI, Borresen-Dale AL et al. TP53 mutations in human cancers: functional selec-
tion and impact on cancer prognosis and outcomes. Oncogene (2007), 26: 2157-2165.
38. Baker SJ, Preisinger AC, Jessup JM et al. p53 gene mutations occur in combination with 17p allelic 
deletions as late events in colorectal tumorigenesis. Cancer Res (1990), 50: 7717-7722.
39. Taupin D, Podolsky DK. Mitogen-activated protein kinase activation regulates intestinal epithelial 
differentiation. Gastroenterology (1999), 116: 1072-1080.
40. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal 
cancer: the multicenter “RASCAL” study. J Natl Cancer Inst (1998), 90: 675-684.
41. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature (2002), 
417: 949-954.
42. Deng G, Bell I, Crawley S et al. BRAF mutation is frequently present in sporadic colorectal cancer 
with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 
(2004), 10: 191-195.
43. Rajagopalan H, Bardelli A, Lengauer C et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-
repair status. Nature (2002), 418: 934.
44. Siena S, Sartore-Bianchi A, Di NF et al. Biomarkers predicting clinical outcome of epidermal growth 
factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009), 101: 
1308-1324.
45. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev 
Cancer (2002), 2: 489-501.
46. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol (2006), 18: 77-82.
47. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human 
cancers. Science (2004), 304: 554.
48. Frattini M, Saletti P, Romagnani E et al. PTEN loss of expression predicts cetuximab efficacy in 
metastatic colorectal cancer patients. Br J Cancer (2007), 97: 1139-1145.
49. Sartore-Bianchi A, Martini M, Molinari F et al. PIK3CA mutations in colorectal cancer are associ-
ated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009), 69: 
1851-1857.
50. Kane MF, Loda M, Gaida GM et al. Methylation of the hMLH1 promoter correlates with lack of ex-
32
Chapter 1
pression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. 
Cancer Res (1997), 57: 808-811.
51. Veigl ML, Kasturi L, Olechnowicz J et al. Biallelic inactivation of hMLH1 by epigenetic gene silenc-
ing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A (1998), 95: 8698-
8702.
52. Herman JG, Umar A, Polyak K et al. Incidence and functional consequences of hMLH1 promoter 
hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998), 95: 6870-6875.
53. Kim H, Jen J, Vogelstein B et al. Clinical and pathological characteristics of sporadic colorectal 
carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol (1994), 145: 148-
156.
54. Aaltonen LA, Peltomaki P, Leach FS et al. Clues to the pathogenesis of familial colorectal cancer. 
Science (1993), 260: 812-816.
55. Bhattacharyya NP, Skandalis A, Ganesh A et al. Mutator phenotypes in human colorectal carci-
noma cell lines. Proc Natl Acad Sci U S A (1994), 91: 6319-6323.
56. Eshleman JR, Lang EZ, Bowerfind GK et al. Increased mutation rate at the hprt locus accompanies 
microsatellite instability in colon cancer. Oncogene (1995), 10: 33-37.
57. Souza RF, Appel R, Yin J et al. Microsatellite instability in the insulin-like growth factor II receptor 
gene in gastrointestinal tumours. Nat Genet (1996), 14: 255-257.
58. Rampino N, Yamamoto H, Ionov Y et al. Somatic frameshift mutations in the BAX gene in colon 
cancers of the microsatellite mutator phenotype. Science (1997), 275: 967-969.
59. Schwartz S Jr, Yamamoto H, Navarro M et al. Frameshift mutations at mononucleotide repeats in 
caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite 
mutator phenotype. Cancer Res (1999), 59: 2995-3002.
60. Kouri M, Laasonen A, Mecklin JP et al. Diploid predominance in hereditary nonpolyposis colorectal 
carcinoma evaluated by flow cytometry. Cancer (1990), 65: 1825-1829.
61. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature (1997), 386: 
623-627.
62. van Puijenbroek M, Middeldorp A, Tops CM et al. Genome-wide copy neutral LOH is infrequent in 
familial and sporadic microsatellite unstable carcinomas. Fam Cancer (2008), 7: 319-330.
63. Trautmann K, Terdiman JP, French AJ et al. Chromosomal instability in microsatellite-unstable and 
stable colon cancer. Clin Cancer Res (2006), 12: 6379-6385.
64. Li LS, Kim NG, Kim SH et al. Chromosomal imbalances in the colorectal carcinomas with microsat-
ellite instability. Am J Pathol (2003), 163: 1429-1436.
65. Diep CB, Kleivi K, Ribeiro FR et al. The order of genetic events associated with colorectal cancer 
progression inferred from meta-analysis of copy number changes. Genes Chromosomes Cancer 
(2006), 45: 31-41.
66. Cahill DP, Lengauer C, Yu J et al. Mutations of mitotic checkpoint genes in human cancers. Nature 
(1998), 392: 300-303.
67. Perez dC, I, de Carcer G, Malumbres M. A census of mitotic cancer genes: new insights into tumor 
cell biology and cancer therapy. Carcinogenesis (2007), 28: 899-912.
68. Shackney SE, Shankey TV. Common patterns of genetic evolution in human solid tumors. Cytom-
etry (1997), 29: 1-27.
69. Fodde R, Kuipers J, Rosenberg C et al. Mutations in the APC tumour suppressor gene cause 
chromosomal instability. Nat Cell Biol (2001), 3: 433-438.
70. Toyota M, Ahuja N, Ohe-Toyota M et al. CpG island methylator phenotype in colorectal cancer. 
Proc Natl Acad Sci U S A (1999), 96: 8681-8686.
71. Bird AP. CpG-rich islands and the function of DNA methylation. Nature (1986), 321: 209-213.
72. Shen L, Toyota M, Kondo Y et al. Integrated genetic and epigenetic analysis identifies three differ-
ent subclasses of colon cancer. Proc Natl Acad Sci U S A (2007), 104: 18654-18659.








and the feasibility of molecular screening for the disease. N Engl J Med (1998), 338: 1481-1487.
74. Salovaara R, Loukola A, Kristo P et al. Population-based molecular detection of hereditary nonpol-
yposis colorectal cancer. J Clin Oncol (2000), 18: 2193-2200.
75. Warthin AS. Heredity with reference to carcinoma. Arch Intern Med (1913), 9: 546-555.
76. Lynch HT, Shaw MW, Magnuson CW et al. Hereditary factors in cancer. Study of two large mid-
western kindreds. Arch Intern Med (1966), 117: 206-212.
77. Fishel R, Lescoe MK, Rao MR et al. The human mutator gene homolog MSH2 and its association 
with hereditary nonpolyposis colon cancer. Cell (1993), 75: 1027-1038.
78. Lindblom A, Tannergard P, Werelius B et al. Genetic mapping of a second locus predisposing to 
hereditary non-polyposis colon cancer. Nat Genet (1993), 5: 279-282.
79. Peltomaki P, Aaltonen LA, Sistonen P et al. Genetic mapping of a locus predisposing to human 
colorectal cancer. Science (1993), 260: 810-812.
80. Bronner CE, Baker SM, Morrison PT et al. Mutation in the DNA mismatch repair gene homologue 
hMLH1 is associated with hereditary non-polyposis colon cancer. Nature (1994), 368: 258-261.
81. Nicolaides NC, Papadopoulos N, Liu B et al. Mutations of two PMS homologues in hereditary non-
polyposis colon cancer. Nature (1994), 371: 75-80.
82. Miyaki M, Konishi M, Tanaka K et al. Germline mutation of MSH6 as the cause of hereditary non-
polyposis colorectal cancer. Nat Genet (1997), 17: 271-272.
83. Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. 
Nat Genet (2004), 36: 497-501.
84. Ligtenberg MJ, Kuiper RP, Chan TL et al. Heritable somatic methylation and inactivation of MSH2 
in families with Lynch syndrome due to deletion of the 3’ exons of TACSTD1. Nat Genet (2009), 41: 
112-117.
85. Stoffel E, Mukherjee B, Raymond VM et al. Calculation of risk of colorectal and endometrial cancer 
among patients with Lynch syndrome. Gastroenterology (2009), 137: 1621-1627.
86. Mecklin JP, Jarvinen HJ. Clinical features of colorectal carcinoma in cancer family syndrome. Dis 
Colon Rectum (1986), 29: 160-164.
87. Vasen HF, Offerhaus GJ, Hartog Jager FC et al. The tumour spectrum in hereditary non-polyposis 
colorectal cancer: a study of 24 kindreds in the Netherlands. Int J Cancer (1990), 46: 31-34.
88. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 
(1993), 71: 677-685.
89. Ionov Y, Peinado MA, Malkhosyan S et al. Ubiquitous somatic mutations in simple repeated se-
quences reveal a new mechanism for colonic carcinogenesis. Nature (1993), 363: 558-561.
90. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 
(1993), 260: 816-819.
91. Peltomaki P, Lothe RA, Aaltonen LA et al. Microsatellite instability is associated with tumors that 
characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res (1993), 53: 
5853-5855.
92. Vasen HF, Mecklin JP, Khan PM et al. The International Collaborative Group on Hereditary Non-
Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum (1991), 34: 424-425.
93. Vasen HF, Watson P, Mecklin JP et al. New clinical criteria for hereditary nonpolyposis colorectal 
cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. 
Gastroenterology (1999), 116: 1453-1456.
94. de Jong AE, van Puijenbroek M, Hendriks Y et al. Microsatellite instability, immunohistochemistry, 
and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer 
Res (2004), 10: 972-980.
95. Rodriguez-Bigas MA, Boland CR, Hamilton SR et al. A National Cancer Institute Workshop on He-
reditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J 
Natl Cancer Inst (1997), 89: 1758-1762.
96. Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis 
34
Chapter 1
colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004), 96: 
261-268.
97. Kievit W, de Bruin JH, Adang EM et al. Cost effectiveness of a new strategy to identify HNPCC 
patients. Gut (2005), 54: 97-102.
98. Hampel H, Frankel WL, Martin E et al. Feasibility of screening for Lynch syndrome among patients 
with colorectal cancer. J Clin Oncol (2008), 26: 5783-5788.
99. Jensen LH, Lindebjerg J, Byriel L et al. Strategy in clinical practice for classification of unselected 
colorectal tumours based on mismatch repair deficiency. Colorectal Dis (2008), 10: 490-497.
100. Vasen HF, Hartog Jager FC, Menko FH et al. Screening for hereditary non-polyposis colorectal 
cancer: a study of 22 kindreds in The Netherlands. Am J Med (1989), 86: 278-281.
101. de Jong AE, Hendriks YM, Kleibeuker JH et al. Decrease in mortality in Lynch syndrome families 
because of surveillance. Gastroenterology (2006), 130: 665-671.
102. Wijnen JT, Brohet RM, van Eijk R et al. Chromosome 8q23.3 and 11q23.1 variants modify colorec-
tal cancer risk in Lynch syndrome. Gastroenterology (2009), 136: 131-137.
103. Ricciardone MD, Ozcelik T, Cevher B et al. Human MLH1 deficiency predisposes to hematological 
malignancy and neurofibromatosis type 1. Cancer Res (1999), 59: 290-293.
104. Wang Q, Lasset C, Desseigne F et al. Neurofibromatosis and early onset of cancers in hMLH1-
deficient children. Cancer Res (1999), 59: 294-297.
105. De Rosa M, Fasano C, Panariello L et al. Evidence for a recessive inheritance of Turcot’s syn-
drome caused by compound heterozygous mutations within the PMS2 gene. Oncogene (2000), 19: 
1719-1723.
106. Whiteside D, McLeod R, Graham G et al. A homozygous germ-line mutation in the human MSH2 
gene predisposes to hematological malignancy and multiple cafe-au-lait spots. Cancer Res (2002), 
62: 359-362.
107. De Vos M, Hayward BE, Picton S et al. Novel PMS2 pseudogenes can conceal recessive muta-
tions causing a distinctive childhood cancer syndrome. Am J Hum Genet (2004), 74: 954-964.
108. Menko FH, Kaspers GL, Meijer GA et al. A homozygous MSH6 mutation in a child with cafe-au-lait 
spots, oligodendroglioma and rectal cancer. Fam Cancer (2004), 3: 123-127.
109. Ostergaard JR, Sunde L, Okkels H. Neurofibromatosis von Recklinghausen type I phenotype 
and early onset of cancers in siblings compound heterozygous for mutations in MSH6. Am J Med 
Genet A (2005), 139A: 96-105.
110. Ponti G, Ponz dL. Muir-Torre syndrome. Lancet Oncol (2005), 6: 980-987.
111. Suspiro A, Fidalgo P, Cravo M et al. The Muir-Torre syndrome: a rare variant of hereditary nonpol-
yposis colorectal cancer associated with hMSH2 mutation. Am J Gastroenterol (1998), 93: 1572-
1574.
112. Vogt S, Jones N, Christian D et al. Expanded extracolonic tumor spectrum in MUTYH-associated 
polyposis. Gastroenterology (2009), 137: 1976-1985.
113. Hamilton SR, Liu B, Parsons RE et al. The molecular basis of Turcot’s syndrome. N Engl J Med 
(1995), 332: 839-847.
114. Jarvinen HJ. Epidemiology of familial adenomatous polyposis in Finland: impact of family screen-
ing on the colorectal cancer rate and survival. Gut (1992), 33: 357-360.
115. Bulow S. Clinical features in familial polyposis coli. Results of the Danish Polyposis Register. Dis 
Colon Rectum (1986), 29: 102-107.
116. Aaltonen LA. Hereditary intestinal cancer. Semin Cancer Biol (2000), 10: 289-298.
117. Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. Oncogene (2004), 23: 
6445-6470.
118. Bertario L, Russo A, Sala P et al. Genotype and phenotype factors as determinants of desmoid 
tumors in patients with familial adenomatous polyposis. Int J Cancer (2001), 95: 102-107.









120. Bodmer WF, Bailey CJ, Bodmer J et al. Localization of the gene for familial adenomatous polyposis 
on chromosome 5. Nature (1987), 328: 614-616.
121. Groden J, Thliveris A, Samowitz W et al. Identification and characterization of the familial adeno-
matous polyposis coli gene. Cell (1991), 66: 589-600.
122. Kinzler KW, Nilbert MC, Su LK et al. Identification of FAP locus genes from chromosome 5q21. Sci-
ence (1991), 253: 661-665.
123. Leppert M, Dobbs M, Scambler P et al. The gene for familial polyposis coli maps to the long arm of 
chromosome 5. Science (1987), 238: 1411-1413.
124. Nishisho I, Nakamura Y, Miyoshi Y et al. Mutations of chromosome 5q21 genes in FAP and 
colorectal cancer patients. Science (1991), 253: 665-669.
125. Lamlum H, Ilyas M, Rowan A et al. The type of somatic mutation at APC in familial adenomatous 
polyposis is determined by the site of the germline mutation: a new facet to Knudson’s ‘two-hit’ 
hypothesis. Nat Med (1999), 5: 1071-1075.
126. Albuquerque C, Breukel C, van der Luijt R et al. The ‘just-right’ signaling model: APC somatic mu-
tations are selected based on a specific level of activation of the beta-catenin signaling cascade. 
Hum Mol Genet (2002), 11: 1549-1560.
127. Brensinger JD, Laken SJ, Luce MC et al. Variable phenotype of familial adenomatous polyposis in 
pedigrees with 3’ mutation in the APC gene. Gut (1998), 43: 548-552.
128. Hezel AF, Bardeesy N. LKB1; linking cell structure and tumor suppression. Oncogene (2008), 27: 
6908-6919.
129. Soravia C, Berk T, Madlensky L et al. Genotype-phenotype correlations in attenuated adenomatous 
polyposis coli. Am J Hum Genet (1998), 62: 1290-1301.
130. Spirio L, Otterud B, Stauffer D et al. Linkage of a variant or attenuated form of adenomatous pol-
yposis coli to the adenomatous polyposis coli (APC) locus. Am J Hum Genet (1992), 51: 92-100.
131. Spirio L, Olschwang S, Groden J et al. Alleles of the APC gene: an attenuated form of familial 
polyposis. Cell (1993), 75: 951-957.
132. van der Luijt RB, Meera KP, Vasen HF et al. Germline mutations in the 3’ part of APC exon 15 do 
not result in truncated proteins and are associated with attenuated adenomatous polyposis coli. 
Hum Genet (1996), 98: 727-734.
133. Al Tassan N, Chmiel NH, Maynard J et al. Inherited variants of MYH associated with somatic G:C--
>T:A mutations in colorectal tumors. Nat Genet (2002), 30: 227-232.
134. Jones S, Emmerson P, Maynard J et al. Biallelic germline mutations in MYH predispose to multiple 
colorectal adenoma and somatic G:C-->T:A mutations. Hum Mol Genet (2002), 11: 2961-2967.
135. Sampson JR, Dolwani S, Jones S et al. Autosomal recessive colorectal adenomatous polyposis 
due to inherited mutations of MYH. Lancet (2003), 362: 39-41.
136. Nielsen M, Franken PF, Reinards TH et al. Multiplicity in polyp count and extracolonic manifesta-
tions in 40 Dutch patients with MYH associated polyposis coli (MAP). J Med Genet (2005), 42: e54.
137. Sieber OM, Lipton L, Crabtree M et al. Multiple colorectal adenomas, classic adenomatous polypo-
sis, and germ-line mutations in MYH. N Engl J Med (2003), 348: 791-799.
138. Lipton L, Halford SE, Johnson V et al. Carcinogenesis in MYH-associated polyposis follows a 
distinct genetic pathway. Cancer Res (2003), 63: 7595-7599.
139. Farrington SM, Tenesa A, Barnetson R et al. Germline susceptibility to colorectal cancer due to 
base-excision repair gene defects. Am J Hum Genet (2005), 77: 112-119.
140. Cleary SP, Cotterchio M, Jenkins MA et al. Germline MutY human homologue mutations and 
colorectal cancer: a multisite case-control study. Gastroenterology (2009), 136: 1251-1260.
141. Jones N, Vogt S, Nielsen M et al. Increased colorectal cancer incidence in obligate carriers of 
heterozygous mutations in MUTYH. Gastroenterology (2009), 137: 489-94, 494.
142. Lubbe SJ, Di Bernardo MC, Chandler IP et al. Clinical implications of the colorectal cancer risk as-
sociated with MUTYH mutation. J Clin Oncol (2009), 27: 3975-3980.
143. Webb EL, Rudd MF, Houlston RS. Colorectal cancer risk in monoallelic carriers of MYH variants. 
36
Chapter 1
Am J Hum Genet (2006), 79: 768-771.
144. Steinke V, Rahner N, Morak M et al. No association between MUTYH and MSH6 germline muta-
tions in 64 HNPCC patients. Eur J Hum Genet (2008), 16: 587-592.
145. Niessen RC, Sijmons RH, Ou J et al. MUTYH and the mismatch repair system: partners in crime? 
Hum Genet (2006), 119: 206-211.
146. van Puijenbroek M, Nielsen M, Reinards TH et al. The natural history of a combined defect in 
MSH6 and MUTYH in a HNPCC family. Fam Cancer (2007), 6: 43-51.
147. Jarvinen H, Franssila KO. Familial juvenile polyposis coli; increased risk of colorectal cancer. Gut 
(1984), 25: 792-800.
148. Sayed MG, Ahmed AF, Ringold JR et al. Germline SMAD4 or BMPR1A mutations and phenotype 
of juvenile polyposis. Ann Surg Oncol (2002), 9: 901-906.
149. Hemminki A, Markie D, Tomlinson I et al. A serine/threonine kinase gene defective in Peutz-Jeghe-
rs syndrome. Nature (1998), 391: 184-187.
150. Baas AF, Boudeau J, Sapkota GP et al. Activation of the tumour suppressor kinase LKB1 by the 
STE20-like pseudokinase STRAD. EMBO J (2003), 22: 3062-3072.
151. Boudeau J, Baas AF, Deak M et al. MO25alpha/beta interact with STRADalpha/beta enhancing 
their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J (2003), 22: 5102-5114.
152. Baas AF, Kuipers J, van der Wel NN et al. Complete polarization of single intestinal epithelial cells 
upon activation of LKB1 by STRAD. Cell (2004), 116: 457-466.
153. Giardiello FM, Welsh SB, Hamilton SR et al. Increased risk of cancer in the Peutz-Jeghers syn-
drome. N Engl J Med (1987), 316: 1511-1514.
154. Baas AF, Smit L, Clevers H. LKB1 tumor suppressor protein: PARtaker in cell polarity. Trends Cell 
Biol (2004), 14: 312-319.
155. Lindor NM, Rabe K, Petersen GM et al. Lower cancer incidence in Amsterdam-I criteria families 
without mismatch repair deficiency: familial colorectal cancer type X. JAMA (2005), 293: 1979-
1985.
156. Aaltonen L, Johns L, Jarvinen H et al. Explaining the familial colorectal cancer risk associated with 
mismatch repair (MMR)-deficient and MMR-stable tumors. Clin Cancer Res (2007), 13: 356-361.
157. Jenkins MA, Baglietto L, Dite GS et al. After hMSH2 and hMLH1--what next? Analysis of three-
generational, population-based, early-onset colorectal cancer families. Int J Cancer (2002), 102: 
166-171.
158. Wiesner GL, Daley D, Lewis S et al. A subset of familial colorectal neoplasia kindreds linked to 
chromosome 9q22.2-31.2. Proc Natl Acad Sci U S A (2003), 100: 12961-12965.
159. Kemp ZE, Carvajal-Carmona LG, Barclay E et al. Evidence of linkage to chromosome 9q22.33 in 
colorectal cancer kindreds from the United kingdom. Cancer Res (2006), 66: 5003-5006.
160. Skoglund J, Djureinovic T, Zhou XL et al. Linkage analysis in a large Swedish family supports the 
presence of a susceptibility locus for adenoma and colorectal cancer on chromosome 9q22.32-
31.1. J Med Genet (2006), 43: e7.
161. Kemp Z, Carvajal-Carmona L, Spain S et al. Evidence for a colorectal cancer susceptibility locus 
on chromosome 3q21-q24 from a high-density SNP genome-wide linkage scan. Hum Mol Genet 
(2006), 15: 2903-2910.
162. Papaemmanuil E, Carvajal-Carmona L, Sellick GS et al. Deciphering the genetics of hereditary 
non-syndromic colorectal cancer. Eur J Hum Genet (2008), 16: 1477-1486.
163. Picelli S, Vandrovcova J, Jones S et al. Genome-wide linkage scan for colorectal cancer suscepti-
bility genes supports linkage to chromosome 3q. BMC Cancer (2008), 8: 87.
164. Djureinovic T, Skoglund J, Vandrovcova J et al. A genome wide linkage analysis in Swedish fami-
lies with hereditary non-familial adenomatous polyposis/non-hereditary non-polyposis colorectal 
cancer. Gut (2006), 55: 362-366.
165. Neklason DW, Kerber RA, Nilson DB et al. Common familial colorectal cancer linked to chromo-








166. Thean LF, Loi C, Ho KS et al. Genome-wide scan identifies a copy number variable region at 3q26 
that regulates PPM1L in APC mutation-negative familial colorectal cancer patients. Genes Chromo-
somes Cancer (2010), 49: 99-106.
167. de Jong MM, Nolte IM, te Meerman GJ et al. Low-penetrance genes and their involvement in 
colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev (2002), 11: 1332-1352.
168. Houlston RS, Tomlinson IP. Polymorphisms and colorectal tumor risk. Gastroenterology (2001), 
121: 282-301.
169. Wasielewski M, Vasen H, Wijnen J et al. CHEK2 1100delC is a susceptibility allele for HNPCC-
related colorectal cancer. Clin Cancer Res (2008), 14: 4989-4994.
170. Webb EL, Rudd MF, Sellick GS et al. Search for low penetrance alleles for colorectal cancer 
through a scan of 1,467 non-synonymous SNPs in 2,575 cases and 2,707 controls with validation 
by kin-cohort analysis of 14,704 first-degree relatives. Hum Mol Genet (2006).
171. Kury S, Buecher B, Robiou-du-Pont S et al. Low-penetrance alleles predisposing to sporadic 
colorectal cancers: a French case-controlled genetic association study. BMC Cancer (2008), 8: 
326.
172. Broderick P, Carvajal-Carmona L, Pittman AM et al. A genome-wide association study shows that 
common alleles of SMAD7 influence colorectal cancer risk. Nat Genet (2007), 39: 1315-1317.
173. Gruber SB, Moreno V, Rozek LS et al. Genetic Variation in 8q24 Associated with Risk of Colorectal 
Cancer. Cancer Biol Ther (2007), 6: 1143-1147.
174. Houlston RS, Webb E, Broderick P et al. Meta-analysis of genome-wide association data identifies 
four new susceptibility loci for colorectal cancer. Nat Genet (2008), 40: 1426-1435.
175. Jaeger E, Webb E, Howarth K et al. Common genetic variants at the CRAC1 (HMPS) locus on 
chromosome 15q13.3 influence colorectal cancer risk. Nat Genet (2008), 40: 26-28.
176. Pittman AM, Webb E, Carvajal-Carmona L et al. Refinement of the basis and impact of common 
11q23.1 variation to the risk of developing colorectal cancer. Hum Mol Genet (2008), 17: 3720-
3727.
177. Poynter JN, Figueiredo JC, Conti DV et al. Variants on 9p24 and 8q24 are associated with risk of 
colorectal cancer: results from the Colon Cancer Family Registry. Cancer Res (2007), 67: 11128-
11132.
178. Tenesa A, Farrington SM, Prendergast JG et al. Genome-wide association scan identifies a 
colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat 
Genet (2008), 40: 631-637.
179. Tomlinson I, Webb E, Carvajal-Carmona L et al. A genome-wide association scan of tag SNPs 
identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet (2007), 39: 984-988.
180. Tomlinson IP, Webb E, Carvajal-Carmona L et al. A genome-wide association study identifies 
colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008), 40: 
623-630.
181. Zanke BW, Greenwood CM, Rangrej J et al. Genome-wide association scan identifies a colorectal 
cancer susceptibility locus on chromosome 8q24. Nat Genet (2007), 39: 989-994.
182. Pomerantz MM, Ahmadiyeh N, Jia L et al. The 8q24 cancer risk variant rs6983267 shows long-
range interaction with MYC in colorectal cancer. Nat Genet (2009), 41: 882-884.
183. Tuupanen S, Turunen M, Lehtonen R et al. The common colorectal cancer predisposition SNP 
rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet (2009), 
41: 885-890.
184. Tuupanen S, Niittymaki I, Nousiainen K et al. Allelic imbalance at rs6983267 suggests selection of 
the risk allele in somatic colorectal tumor evolution. Cancer Res (2008), 68: 14-17.
185. Pittman AM, Naranjo S, Webb E et al. The colorectal cancer risk at 18q21 is caused by a novel 
variant altering SMAD7 expression. Genome Res (2009), 19: 987-993.
186. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst (1999), 91: 916-932.
187. Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospec-
38
Chapter 1
tive studies. Int J Cancer (2006), 119: 2657-2664.
188. Huxley RR, Ansary-Moghaddam A, Clifton P et al. The impact of dietary and lifestyle risk factors 
on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer 
(2009), 125: 171-180.
189. Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 
31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev (2007), 16: 2533-2547.
190. Wu S, Rhee KJ, Albesiano E et al. A human colonic commensal promotes colon tumorigenesis via 
activation of T helper type 17 T cell responses. Nat Med (2009), 15: 1016-1022.
191. Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human colorectal cancer stem 
cells. Proc Natl Acad Sci U S A (2007), 104: 10158-10163.
192. O’Brien CA, Pollett A, Gallinger S et al. A human colon cancer cell capable of initiating tumour 
growth in immunodeficient mice. Nature (2007), 445: 106-110.
193. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-
initiating cells. Nature (2007), 445: 111-115.
194. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea--a paradigm shift. Cancer Res (2006), 
66: 1883-1890.
195. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med (2009), 15: 
1010-1012.
196. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neopla-
sia (2009), 14: 3-9.
197. Morikawa T, Kato J, Yamaji Y et al. A comparison of the immunochemical fecal occult blood test 
and total colonoscopy in the asymptomatic population. Gastroenterology (2005), 129: 422-428.
198. Health Council of the Netherlands. A national colorectal cancer screening programme. publication 
no. 2009/13E. 2009. The Hague. 
199. Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analy-
sis. Nat Rev Cancer (2005), 5: 199-209.
200. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total meso-
rectal excision for resectable rectal cancer. N Engl J Med (2001), 345: 638-646.
201. Buess G, Mentges B, Manncke K et al. Technique and results of transanal endoscopic microsur-
gery in early rectal cancer. Am J Surg (1992), 163: 63-69.
202. Rothbarth J, Tollenaar RA, Schellens JH et al. Isolated hepatic perfusion for the treatment of 
colorectal metastases confined to the liver: recent trends and perspectives. Eur J Cancer (2004), 
40: 1812-1824.
203. McGahan JP, Brock JM, Tesluk H et al. Hepatic ablation with use of radio-frequency electrocautery 
in the animal model. J Vasc Interv Radiol (1992), 3: 291-297.
204. Stang A, Fischbach R, Teichmann W et al. A systematic review on the clinical benefit and role of 
radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer (2009), 45: 1748-
1756.
205. de GA, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line 
treatment in advanced colorectal cancer. J Clin Oncol (2000), 18: 2938-2947.
206. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care 
versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. 
Lancet (1998), 352: 1413-1418.
207. Rougier P, Van CE, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous 
infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998), 352: 
1407-1412.
208. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil 
plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a 
randomized phase III study. J Clin Oncol (2001), 19: 2282-2292.








Cancer Control (2010), 17: 7-15.
210. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in 
advanced colorectal cancer. N Engl J Med (2008), 359: 1757-1765.
211. Verwaal VJ, Bruin S, Boot H et al. 8-year follow-up of randomized trial: cytoreduction and hyper-
thermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal 
carcinomatosis of colorectal cancer. Ann Surg Oncol (2008), 15: 2426-2432.
212. Verwaal VJ. Long-term results of cytoreduction and HIPEC followed by systemic chemotherapy. 
Cancer J (2009), 15: 212-215.
213. Sheffer M, Bacolod MD, Zuk O et al. Association of survival and disease progression with chromo-
somal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A (2009), 106: 
7131-7136.
214. Darbary HK, Dutt SS, Sait SJ et al. Uniparentalism in sporadic colorectal cancer is independent of 
imprint status, and coordinate for chromosomes 14 and 18. Cancer Genet Cytogenet (2009), 189: 
77-86.
215. Postma C, Koopman M, Buffart TE et al. DNA copy number profiles of primary tumors as predictors 
of response to chemotherapy in advanced colorectal cancer. Ann Oncol (2009), 20: 1048-1056.
216. Coss A, Tosetto M, Fox EJ et al. Increased topoisomerase IIalpha expression in colorectal cancer 
is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis. 
Cancer Lett (2009), 276: 228-238.
217. Nakao M, Kawauchi S, Furuya T et al. Identification of DNA copy number aberrations associated 
with metastases of colorectal cancer using array CGH profiles. Cancer Genet Cytogenet (2009), 
188: 70-76.
218.  Melcher R, Zopf W, Hartmann E et al. Spectral karyotyping and SNP microarray analysis define 
uniparental disomy (UPD) as a novel mutational mechanism in MSI- and CSI-colorectal cancers. 
Cell Oncol (2008), 30: 507.
219. Al Mulla F, Hagan S, Al Ali W et al. Raf kinase inhibitor protein: mechanism of loss of expression 
and association with genomic instability. J Clin Pathol (2008), 61: 524-529.
220. Camps J, Grade M, Nguyen QT et al. Chromosomal breakpoints in primary colon cancer cluster at 
sites of structural variants in the genome. Cancer Res (2008), 68: 1284-1295.
221. Lips EH, van Eijk R, de Graaf EJ et al. Progression and tumor heterogeneity analysis in early rectal 
cancer. Clin Cancer Res (2008), 14: 772-781.
222. Derks S, Postma C, Carvalho B et al. Integrated analysis of chromosomal, microsatellite and epi-
genetic instability in colorectal cancer identifies specific associations between promoter methyla-
tion of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations. 
Carcinogenesis (2008), 29: 434-439.
223. Blaker H, Mechtersheimer G, Sutter C et al. Recurrent deletions at 6q in early age of onset non-
HNPCC- and Non-FAP-Associated Intestinal Carcinomas. Evidence for a Novel Cancer Suscepti-
bility Locus at 6q14-q22. Genes Chromosomes Cancer (2008), 47: 159-164.
224. Martin ES, Tonon G, Sinha R et al. Common and distinct genomic events in sporadic colorectal 
cancer and diverse cancer types. Cancer Res (2007), 67: 10736-10743.
225. Fijneman RJ, Carvalho B, Postma C et al. Loss of 1p36, gain of 8q24, and loss of 9q34 are associ-
ated with stroma percentage of colorectal cancer. Cancer Lett (2007), 258: 223-229.
226. Jones AM, Thirlwell C, Howarth KM et al. Analysis of copy number changes suggests chromosomal 
instability in a minority of large colorectal adenomas. J Pathol (2007), 213: 249-256.
227. Xiao XY, Zhou XY, Yan G et al. Chromosomal alteration in Chinese sporadic colorectal carcinomas 
detected by comparative genomic hybridization. Diagn Mol Pathol (2007), 16: 96-103.
228. Lips EH, de Graaf EJ, Tollenaar RA et al. Single nucleotide polymorphism array analysis of chro-
mosomal instability patterns discriminates rectal adenomas from carcinomas. J Pathol (2007), 212: 
269-277.
229. Fensterer H, Radlwimmer B, Strater J et al. Matrix-comparative genomic hybridization from multi-
40
Chapter 1
center formalin-fixed paraffin-embedded colorectal cancer tissue blocks. BMC Cancer (2007), 7: 
58.
230. De Angelis PM, Stokke T, Beigi M et al. Chromosomal 20q gain in the DNA diploid component of 
aneuploid colorectal carcinomas. Int J Cancer (2007), 120: 2734-2738.
231. Grade M, Hormann P, Becker S et al. Gene expression profiling reveals a massive, aneuploidy-
dependent transcriptional deregulation and distinct differences between lymph node-negative and 
lymph node-positive colon carcinomas. Cancer Res (2007), 67: 41-56.
232. Bartos JD, Gaile DP, McQuaid DE et al. aCGH local copy number aberrations associated with 
overall copy number genomic instability in colorectal cancer: coordinate involvement of the regions 
including BCR and ABL. Mutat Res (2007), 615: 1-11.
233. Ghadimi BM, Grade M, Monkemeyer C et al. Distinct chromosomal profiles in metastasizing and 
non-metastasizing colorectal carcinomas. Cell Oncol (2006), 28: 273-281.
234. Derks S, Postma C, Moerkerk PT et al. Promoter methylation precedes chromosomal alterations in 
colorectal cancer development. Cell Oncol (2006), 28: 247-257.
235. Liu XP, Kawauchi S, Oga A et al. Chromosomal aberrations detected by comparative genomic hy-
bridization predict outcome in patients with colorectal carcinoma. Oncol Rep (2007), 17: 261-267.
236. Kim MY, Yim SH, Kwon MS et al. Recurrent genomic alterations with impact on survival in colorec-
tal cancer identified by genome-wide array comparative genomic hybridization. Gastroenterology 
(2006), 131: 1913-1924.
237. Habermann JK, Paulsen U, Roblick UJ et al. Stage-specific alterations of the genome, transcrip-
tome, and proteome during colorectal carcinogenesis. Genes Chromosomes Cancer (2007), 46: 
10-26.
238. Unotoro J, Kamiyama H, Ishido Y et al. Analysis of the relationship between sex and chromosomal 
aberrations in colorectal cancer by comparative genomic hybridization. J Int Med Res (2006), 34: 
397-405.
239. Yaginuma Y, Unotoro J, Kamiyama H et al. Genomic copy-number aberrations related to lymph-
node metastasis of colon cancer. J Int Med Res (2006), 34: 390-396.
240. Rodriguez J, Frigola J, Vendrell E et al. Chromosomal instability correlates with genome-wide DNA 
demethylation in human primary colorectal cancers. Cancer Res (2006), 66: 8462-9468.
241. Swede H, Bartos JD, Chen N et al. Genomic profiles of colorectal cancers differ based on patient 
smoking status. Cancer Genet Cytogenet (2006), 168: 98-104.
242. Alrawi SJ, Carroll RE, Hill HC et al. Genomic instability of human aberrant crypt foci measured by 
inter-(simple sequence repeat) PCR and array-CGH. Mutat Res (2006), 601: 30-38.
243. Andersen CL, Wiuf C, Kruhoffer M et al. Frequent occurrence of uniparental disomy in colorectal 
cancer. Carcinogenesis (2007), 28: 38-48.
244. Al Mulla F, Behbehani AI, Bitar MS et al. Genetic profiling of stage I and II colorectal cancer may 
predict metastatic relapse. Mod Pathol (2006), 19: 648-658.
245. Cardoso J, Molenaar L, de Menezes RX et al. Chromosomal instability in MYH- and APC-mutant 
adenomatous polyps. Cancer Res (2006), 66: 2514-2519.
246. Tsafrir D, Bacolod M, Selvanayagam Z et al. Relationship of gene expression and chromosomal 
abnormalities in colorectal cancer. Cancer Res (2006), 66: 2129-2137.
247. Mehigan BJ, Ashman JN, Baker RP et al. Mismatch repair, p53 and chromosomal aberrations in 
primary colorectal carcinomas. Acta Oncol (2006), 45: 61-66.
248. Grade M, Ghadimi BM, Varma S et al. Aneuploidy-dependent massive deregulation of the cellular 
transcriptome and apparent divergence of the Wnt/beta-catenin signaling pathway in human rectal 
carcinomas. Cancer Res (2006), 66: 267-282.
A procedure for the detection of linkage 
with high density SNP arrays in a large 
pedigree with colorectal cancer





Page 1 of 8
(page number not for citation purposes)
BMC Cancer
Open AccessResearch article
A procedure for the detection of linkage with high density SNP 
arrays in a large pedigree with colorectal cancer
Anneke Middeldorp1, Shantie Jagmohan-Changur2, Quinta Helmer3, 
Heleen M van der Klift4, Carli MJ Tops4, Hans FA Vasen5, Peter Devilee2, 
Hans Morreau1, Jeanine J Houwing-Duistermaat3, Juul T Wijnen2,4 and 
Tom van Wezel*1
Address: 1Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands, 2Department of Human Genetics, Leiden 
University Medical Center, Leiden, The Netherlands, 3Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, 
Leiden, The Netherlands, 4Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands and 5The Netherlands 
Foundation for the Detection of Hereditary Tumours, Leiden, The Netherlands
Email: Anneke Middeldorp - j.w.middeldorp@lumc.nl; Shantie Jagmohan-Changur - s.c.jagmohan@lumc.nl; 
Quinta Helmer - q.helmer@lumc.nl; Heleen M van der Klift - h.m.van_der_klift@lumc.nl; Carli MJ Tops - c.m.j.tops@lumc.nl; 
Hans FA Vasen - hfavasen@stoet.nl; Peter Devilee - p.devilee@lumc.nl; Hans Morreau - j.morreau@lumc.nl; Jeanine J Houwing-
Duistermaat - j.j.houwing@lumc.nl; Juul T Wijnen - j.wijnen@lumc.nl; Tom van Wezel* - t.van_wezel@lumc.nl
* Corresponding author    
Abstract
Background: The apparent dominant model of colorectal cancer (CRC) inheritance in several large families, without
mutations in known CRC susceptibility genes, suggests the presence of so far unidentified genes with strong or moderate
effect on the development of CRC. Linkage analysis could lead to identification of susceptibility genes in such families. In
comparison to classical linkage analysis with multi-allelic markers, single nucleotide polymorphism (SNP) arrays have
increased information content and can be processed with higher throughput. Therefore, SNP arrays can be excellent tools
for linkage analysis. However, the vast number of SNPs on the SNP arrays, combined with large informative pedigrees (e.g.
>35–40 bits), presents us with a computational complexity that is challenging for existing statistical packages or even
exceeds their capacity. We therefore setup a procedure for linkage analysis in large pedigrees and validated the method by
genotyping using SNP arrays of a colorectal cancer family with a known MLH1 germ line mutation.
Methods: Quality control of the genotype data was performed in Alohomora, Mega2 and SimWalk2, with removal of
uninformative SNPs, Mendelian inconsistencies and Mendelian consistent errors, respectively. Linkage disequilibrium was
measured by SNPLINK and Merlin. Parametric linkage analysis using two flanking markers was performed using MENDEL.
For multipoint parametric linkage analysis and haplotype analysis, SimWalk2 was used.
Results: On chromosome 3, in the MLH1-region, a LOD score of 1.9 was found by parametric linkage analysis using two
flanking markers. On chromosome 11 a small region with LOD 1.1 was also detected. Upon linkage disequilibrium removal,
multipoint linkage analysis yielded a LOD score of 2.1 in the MLH1 region, whereas the LOD score dropped to negative
values in the region on chromosome 11. Subsequent haplotype analysis in the MLH1 region perfectly matched the mutation
status of the family members.
Conclusion: We developed a workflow for linkage analysis in large families using high-density SNP arrays and validated
this workflow in a family with colorectal cancer. Linkage disequilibrium has to be removed when using SNP arrays, because
it can falsely inflate the LOD score. Haplotype analysis is adequate and can predict the carrier status of the family members.
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Background
Colorectal cancer (CRC) is the one of the most common
malignancies in the Western world. Already in 1913,
familial aggregation of CRC was described by Warthin [1]
and later Lynch et al. described an additional family with
clustering of colorectal and endometrial cancer [2]. Clini-
cal definition of Lynch syndrome, or HNPCC, in 1991
[3,4] was instrumental for linkage analysis, and ultimately
for the identification of the underlying gene defects in
HNPCC families. The first HNPCC loci were mapped to
chromosomes 2 and 3 using microsatellite markers [5,6].
This eventually led to the identification of germ line muta-
tions in MSH2 [7] and MLH1 [8], respectively. Later,
PMS2 [9], MSH6 [10,11] and recently MutYH [12] were
identified as CRC susceptibility genes. However, the so far
identified CRC susceptibility genes can only explain up to
5% of all cases [13], while in ~35% of all colorectal cancer
cases familial clustering is seen [14]. Furthermore, it is
shown that first degree relatives of patients with colorectal
cancer have a relative risk of 2.3 to develop the disease
[15]. This indicates that still some genes with strong or
moderate effect on CRC development remain to be iden-
tified. In order to identify these genes, linkage analysis in
families could point to the loci where unknown suscepti-
bility genes may reside. Indeed, different linkage analysis
studies revealed potentially interesting regions on chro-
mosomes 3q, 9q, 11q, 14q, 15q and 22q [16-20].
Families with a clustering of colorectal cancer but without
germ line mutations in CRC genes have been under sur-
veillance in Leiden since the 1980s. Due to the long
period of follow-up, with three to four affected genera-
tions, these Dutch HNPCC-like families have become
informative for linkage analysis.
Traditionally, linkage analysis is performed with multi-
allelic microsatellite markers. Recently, however, the
more advanced single nucleotide polymorphism (SNP)
arrays were brought into use for linkage analysis. It was
shown that the information content of a dense SNP map
is significantly and uniformly higher than that of a
genome wide microsatellite marker map [21]. Several
studies conducting linkage analysis on genotype data
from SNP arrays appeared in recent years [22-24]. In these
studies non-parametric as well as parametric linkage anal-
ysis was performed in sib pairs or in small to moderate
size pedigrees. However, to date, no studies have been
published on linkage analysis using SNPs in large pedi-
grees (e.g. >35–40 bits).
Studying large families with thousands of SNPs results in
a computational complex analysis that is challenging for
existing statistical packages and that may even exceed their
capacity. Current linkage analysis programs can handle
either large pedigrees or large numbers of markers,
depending on the underlying algorithm. In order to per-
form linkage analysis in large pedigrees using SNP arrays,
we explored the possibilities of currently available linkage
analysis software. Most currently available programs are
based on the Lander-Green or the Elston-Stewart algo-
rithm or both. The computation time of the former algo-
rithm increases exponentially with the number of bits (2n
- f, where 'n' is the number of non-founders and 'f' the
number of founders) in a pedigree, whereas the latter
scales exponentially with the number of markers. To per-
form multipoint linkage analysis in a large family with
SNP arrays in one run would probably take several
months computation time, if at all possible.
Several programs are suitable for linkage analysis with bi-
allelic markers. Genehunter and Merlin can handle a rela-
tive large numbers of markers, however the analysis is
restricted to pedigrees of up to ~30-bits [25,26]. Both pro-
grams are based on the Lander-Green Hidden Markov
Model algorithm and can perform non-parametric as well
as parametric linkage analysis. In Genehunter, the Elston-
Stewart algorithm is also implemented, allowing the per-
formance of simultaneous analysis of several markers as
well as analysis of pedigrees of moderate size. A third pro-
gram based on the Lander-Green Hidden Markov Model
algorithm is Allegro 2. This program can handle large ped-
igrees (up to ~40 bits), although the computational costs
increase substantially when not all genotype information
of the family is available [27,28]. Allegro calculates para-
metric LOD scores as well as NPL scores and allele-sharing
LOD scores. Another program, SNPLINK [28,29] can per-
form automated linkage analysis with LD removal using
either Allegro or Merlin. However, for all the above men-
tioned programs the different branches of large families
(i.e. >35–40 bits) need to be analyzed separately. This will
lead to substantial loss of information and potential
undetected linkage.
MENDEL [30] is a program that is suitable for linkage
analysis with SNPs in large pedigrees. It allows adjusting
the maximum number of meioses, though the computa-
tion time will increase in that case. Both parametric and
non-parametric linkage analysis can be performed in
MENDEL. The program will either use the Lander-Green
or the Elston-Stewart algorithm, depending on whichever
is more efficient for the pedigree. SimWalk2 is a program
that can perform multipoint parametric linkage analysis,
haplotype analysis and a few other analyses in large pedi-
grees using bi-allelic markers. It uses Markov chain Monte
Carlo methods to compute the likelihood [31]. Simwalk2
uses the MENDEL program for computing location scores.
With the aim to detect linkage in CRC families exceeding
40 bits we established a procedure using freely available
software packages and validated this in a large colorectal
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cancer family, with a known causal MLH1 germ line muta-
tion on chromosome 3.
Methods
Patients
A large colorectal cancer family (Figure 1) with a recently
identified mutation in the MLH1 gene (c.1046dupT,
p.Pro350fs) was studied. Nine family members are
affected with colorectal cancer. Another two family mem-
bers are affected with polyps and three cases with skin can-
cer (non-specified) and one case with endometrium
cancer (non-specified) are seen as well. Peripheral blood
lymphocytes were collected from the family members.
DNA was extracted using standard procedures. A total of
thirteen family members were genotyped on Affymetrix
GeneChip Human Mapping 10K 2.0 SNP arrays. The
arrays were processed according to the instructions of the
manufacturer. The mean SNP call rate was 96.3% (89.0%-
98.5%).
The study was approved by the Medical Ethical Commit-
tee of the LUMC (protocol P01-019).
Workflow
We processed the data according to the following work-
flow: 1) First, the genotype data were generated by Gene-
Chip DNA Analysis Software (GDAS) from Affymetrix. 2)
These genotype data were combined with the pedigree
and the marker information in Alohomora. 3) In this pro-
gram the uninformative SNPs were removed as well. 4) To
be able to perform linkage analysis in the desired pro-
gram, the output files (in Merlin-format) of Alohomora
were by Mega2 converted to the proper format. 5) Mega2
also removed the Mendelian inconsistent errors. 6) The
files were then ready to perform parametric linkage analy-
sis using 2 flanking markers in MENDEL; affected-only
analysis as well as parametric linkage analysis using liabil-
ity classes was performed. 7) Based on the second analy-
sis, regions of interest were defined that were further
tested for Mendelian consistent errors and 8) possible
linkage disequilibrium was removed in SNPLINK. 9)
Multipoint parametric linkage analysis using the liability
classes was then performed in Simwalk2 for the ROIs and
10) finally, the haplotypes were inferred in Simwalk2.
Data formatting and quality control
Genotype data of the individual family members were
generated using GeneChip DNA Analysis Software
(GDAS) from Affymetrix. In the Alohomora program [32]
the pedigree information, allele frequencies and map
position of the SNPs were combined with the genotype
data generated by GDAS. The uninformative SNPs in this
pedigree, that show either only A alleles and No Calls or
only B alleles and No Calls, were removed from further
analysis by Alohomora. The data files were exported in
Merlin format. Subsequently, in Mega2 [33] these Alo-
homora files were converted into the appropriate format
for the programs used for linkage analysis, i.e. either the
Mendel 5 format or the SimWalk2 format. Mendelian
inconsistent errors were removed from analysis with
Mega2 by setting all genotypes of these SNPs to unknown.
Mendelian consistent errors
Mendelian consistent errors were identified by mistyping
analysis. Since this analysis is computationally complex
and therefore time consuming (2 1/4 hours for 35 SNPs),
only the regions of interest were analyzed for Mendelian
consistent errors. All chromosomal regions with LOD
scores exceeding 1 and lacking negative LOD scores were
defined as regions of interest (ROI). SimWalk2 [31] was
used to check all ROI for Mendelian consistent errors by
performing mistyping analysis. An error model with a uni-
form error rate for all mistypings was used. The overall
rate of mistyping was set at 0.004 [34,35]. The threshold
for the posterior probability of mistyping was set at 0.5
[36].
Linkage disequilibrium estimation
In the ROI the pair-wise correlation coefficient r2, as a
measure of linkage disequilibrium (LD) between adjacent
SNPs, was estimated using SNPLINK [29] and Merlin [26].
Since we are only interested in estimates of r2, we split the
large family into nuclear families. In addition to the fam-
ily under study, genotypes from 12 Dutch nuclear families
from other studies (unpublished results) were used to cal-
culate LD. The program SNPLINK provides a list of SNPs
to be removed. We used as cut off value for LD removal an
r2 ≥ 0.4. The information content was computed before
and after removal of the SNPs using Merlin.
Linkage analysis
To determine the power to detect linkage in the MLH1
family, we performed a simulation study using Simlink
[37] under the assumption of a dominant trait with a
piecewise linear penetrance. Subsequently, we performed
an affected-only linkage analysis and modeled a domi-
nant trait with an allele frequency of 0.001. For parametric
linkage analysis, the proper assignment of affected status
to family members is crucial since, due to the surveillance
of the families, adenomas will be detected and removed
before they can develop into a carcinoma. Additionally,
the risk of cancer increases with age. And the risk of devel-
oping an adenoma is different from the risk of developing
a carcinoma. To adjust for these phenomena, we defined
10 liability classes: four classes were defined with different
penetrances for colorectal cancer; four classes for polyp
carriers and two more liability classes for spouses, that
carry a population risk of developing polyps or colorectal
cancer and one for the family members of which the dis-
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Haplotype analysis in a HNPCC family segregating the MLH1 Pro350fs mutationFigure 1
Haplotype analysis in a HNPCC family segregating the MLH1 Pro350fs mutation. The haplotypes were constructed 
in SimWalk2 and subsequently visualized with HaploPainter [39]. CRC:55, colorectal cancer diagnosed at age 55; Endo, 
endometrial cancer; Skin, skin cancer; P, polyps; Pro350fs, carrier of the Pro350fs mutation in MLH1; wt, non-carrier; black 
dot, DNA of this family member has been typed on a 10K SNP array.
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on the incidences of CRC and adenomas in the members
of HNPCC families in the Netherlands, that do not carry
the disease causing mutation [38].
In MENDEL [30], an affected-only parametric linkage
analysis was performed using two flanking markers (com-
putation time: ~20 sec per chromosome). In this analysis
only family members with colorectal cancer were defined
as affected and all other persons were set to unknown.
Parametric linkage analysis with liability classes was per-
formed thereafter, using two flanking markers (computa-
tion time: ~20 sec per chromosome). Cancers other than
colorectal cancer were not considered to be part of the
syndrome. In the ROIs appearing from this linkage analy-
sis, possible Mendelian consistent errors were removed as
well as the possible presence of linkage disequilibrium.
Subsequently, multipoint parametric linkage analysis was
performed in SimWalk2 [31], using the ten liability
classes. In this multipoint analysis no more than 30 SNPs
were analyzed, limited by the computational complexity
(analysis time: 1 3/4 hours for 30 SNPs).
Haplotype analysis
Haplotype analysis was performed in the ROI, using
SimWalk2. All SNPs in the region of interest (~18) were
included in this analysis (computation time: 1 1/3 hours
for 18 SNPs). The results of the haplotyping were visual-
ized in HaploPainter [39]. The haplotype segregation in
the family could then be compared to the segregation of
the mutation in MLH1 in this family.
Results and discussion
Linkage analysis using bi-allelic genotype data from SNP
arrays and large families is a computational challenge
using commonly used, freely available analysis software.
For the different steps of the linkage analysis; e.g. data for-
matting, detection of Mendelian inconsistencies, mistyp-
ing analysis, LD removal and single to multipoint linkage
analysis, we have chosen the following programs that can
handle large pedigrees and many SNPs where required;
Alohomora [32], Mega2 [33], MENDEL [30], SNPLINK
[29] and SimWalk2 [31].
In advance of the linkage analysis we performed a simula-
tion study to calculate the power using Simlink. The mean
LOD score in 1000 simulations in this family was 2.0.
The Alohomora program [32] was used first to combine
the genotype data generated with the SNP arrays, and the
pedigree and SNP information and secondly, to convert
these data into the appropriate format for further analysis.
In addition, 1256 of the 10053 SNPs were uninformative
and were therefore removed from analysis by Alohomora.
Since errors in genotyping can easily mask linkage, the
data were checked for different types of errors. First, we
have estimated the genotyping error rate in five duplicate
experiments. The mean genotyping error rate between the
duplicates was only 0.0051.
Mega2 was then used for several data validation checks,
including errors in the pedigree data or Mendelian incon-
sistent errors. Mega2 was used since it supports 28 differ-
ent programs, including the programs MENDEL and
SimWalk2, which we have used for linkage analysis and
haplotype analysis. The genotypes of 18 SNPs (0.21%)
were removed from analysis, because of Mendelian incon-
sistencies. However, with bi-allelic markers not all errors
appear as Mendelian inconsistent errors [40]. The data
were therefore also checked for Mendelian consistent
errors. Because of the computational complexity of these
multipoint analyses, this error check was performed only
in the regions of interest. The mistyping analysis option in
SimWalk2 was used, since this program can handle such a
complex analysis in a large pedigree. No Mendelian con-
sistent errors were identified in the ROI.
Affected-only parametric linkage analysis and parametric
linkage analysis using liability classes was performed in
MENDEL, using two flanking markers. This analysis
showed a maximum LOD score of 1.8 in the affected-only
analysis and 1.9 using liability classes for a 1.7 Mb region
around the MLH1 gene on chromosome 3 (Figure 2). A
second region with a LOD 1.1 was found, both in the
affected-only analysis and using liability classes, near the
centromere on chromosome 11.
Current linkage analysis programs assume LD between
markers and a disease locus and importantly, linkage
equilibrium between markers. The presence of linkage
disequilibrium between two markers can falsely inflate
the LOD score and missing genotypes can increase this
effect. Therefore, the r2 as a measure of LD was computed
in Merlin and SNPLINK. Using the threshold r2 ≥ 0.4, 5 of
the 27 SNPs in the region on chromosome 3 were
removed from the analysis. From the region of interest on
chromosome 11, 14 of the 30 SNPs with an r2 ≥ 0.4 were
removed from the analysis. After LD removal, multipoint
linkage analysis in the region on chromosome 3 yielded a
LOD score of 2.1, whereas on chromosome 11 negative
LOD scores were seen by multipoint linkage analysis after
LD was removed. This indicates that the strong LD in the
region on chromosome 11 was responsible for the peak in
the LOD in that region. On both chromosomes, the
removal of SNPs with high LD had no significant effect on
the information content (not shown).
We inferred the haplotypes of the family members, using
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known affected MLH1-mutation carriers share the same
haplotype, as well as the affected obligate carriers. There-
fore, this haplotype perfectly co-segregates with the clini-
cal phenotype of the family members (Figure 1). Case 23,
who had developed polyps at age 60, does not share this
haplotype. Subsequent mutation analysis showed that
this individual indeed did not carry the disease causing
mutation in MLH1. Therefore, this case showed to be a
phenocopy. Another family member, case 39, has to date
not developed clinical symptoms of HNPCC, although he
did inherit the disease causing allele according to the hap-
lotype analysis. Indeed, sequence analysis showed that
this person carries the mutation.
Conclusion
In conclusion, we show that we can perform linkage anal-
ysis with high-density 10K SNP arrays in large families for
which not all members could be genotyped. We devel-
oped a workflow with different publicly available soft-
ware to perform the analyses: removal of Mendelian
consistent and Mendelian inconsistent errors, two and
multipoint parametric linkage analysis, removal of link-
age disequilibrium and haplotype analysis. The procedure
was validated in a large CRC family carrying a known
germ line mutation in MLH1. Linkage was found with the
MLH1 gene and subsequent haplotype analysis corre-
sponds to the mutation status of the family members. This
procedure can now be used for linkage analysis of large




SNP; single nucleotide polymorphism
LD; linkage disequilibrium
LOD; log of odds
HNPCC; hereditary nonpolyposis colorectal cancer
GDAS; GeneChip DNA Analysis Software
ROI; regions of interest
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Parametric linkage analysis on chromosome 3, using two flanking markersFigur  2
Parametric linkage analysis on chromosome 3, using two flanking markers. The maximum LOD score is 1.9. The 
gray line represents the raw results of the linkage analysis. The black line is the moving average with a period of ten.
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Approximately 40% of colorectal cancer (CRC) families with a diagnosis of hereditary nonpolyposis CRC on the basis of
clinical criteria are not a consequence of mismatch repair (MMR) deficiency. Such families provide supporting evidence for
the existence of a hitherto unidentified highly penetrant gene mutation. To gain further understanding of MMR-competent
familial colorectal cancer (FCC), we studied seven large families with an unexplained predisposition for CRC to identify
genetic regions that could harbor CRC risk factors. First, we conducted a genome-wide linkage scan using 10K single-nucleo-
tide polymorphism (SNP) arrays to search for disease loci. Second, we studied the genomic profiles of the tumors of affected
family members to identify commonly altered genomic regions likely to harbor tumor suppressor genes. Finally, we studied
the possible role of recently identified low-risk variants in the familial aggregation of CRC in these families. Linkage analysis
did not reveal clear regions of linkage to CRC. However, our results provide support linkage to 3q, a region that has previ-
ously been linked to CRC susceptibility. Tumor profiling did not reveal any genomic regions commonly targeted in the
tumors studied here. Overall, the genomic profiles of the tumors show some resemblance to sporadic CRC, but additional
aberrations were also present. Furthermore, the FCC families did not appear to have an enrichment of low-risk CRC suscep-
tibility loci. These data suggest that factors other than a highly penetrant risk factor, such as low or moderate-penetrance
risk factors, may explain the increased cancer risk in a subset of familial CRCs. VC 2010 Wiley-Liss, Inc.
INTRODUCTION
Colorectal cancer (CRC) is one of the most
common malignancies in Western populations
(Parkin et al., 2005). As estimated in twin studies,
hereditary factors may play a role in up to 35% of
CRC cases (Lichtenstein et al., 2000). In the
early 1990s, the first gene conferring a high risk
of developing CRC was described for familial ad-
enomatous polyposis (Bodmer et al., 1987; Lep-
pert et al., 1987; Groden et al., 1991; Kinzler
et al., 1991). The gene defects of several Mende-
lian disorders have been identified since then,
including Lynch syndrome, MUTYH-associated
polyposis, Juvenile Polyposis, and Peutz–Jeghers
syndrome. However, these syndromes account for
only 6% of CRC cases. In the other familial
CRC cases, the underlying genetic factors are
currently unknown (Jenkins et al., 2002; Aaltonen
et al., 2007).
The Amsterdam criteria I (AC-I), based on
family history and age at diagnosis of CRC, are
used to identify patients with a presumptive diag-
nosis of Lynch syndrome (Vasen et al., 1999).
However, 40% of patients fulfilling the AC-I do
not have tumors with microsatellite instability,
which is characteristic of a mismatch repair
(MMR) deficiency. These data provide strong
evidence that other genetic factors may play a
role in the development of CRC in these families
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(Wijnen et al., 1998; Vasen et al., 1999; de Jong
et al., 2004; Mangold et al., 2005).
Several linkage studies of dominantly inherited
microsatellite stable (MSS) CRC families have
been performed, and various genomic regions,
including 3q21-q24, 7q31, 9q22.2-31.2, 11q23.2,
11q13.4, 14q24.2, and 22q12.1, have been linked
to CRC predisposition (Wiesner et al., 2003;
Djureinovic et al., 2006; Skoglund et al., 2006;
Kemp et al., 2006a, b; Neklason et al., 2008;
Papaemmanuil et al., 2008; Picelli et al., 2008).
To date, none of these studies has, however led
to the identification of a novel CRC susceptibility
gene.
In addition to highly penetrant mutations, fam-
ilial clustering could be caused by polygenic sus-
ceptibility. Evidence for several low-risk variants
for CRC has recently been provided by genome-
wide association (GWA) studies (Broderick et al.,
2007; Tomlinson et al., 2007; Zanke et al., 2007;
Houlston et al., 2008; Jaeger et al., 2008; Tenesa
et al., 2008; Tomlinson et al., 2008). We previ-
ously have demonstrated that familial CRC cases
display a modest enrichment of these low-risk
variants (Middeldorp et al., 2009).
Profiles of genomic aberrations in tumors of
patients with familial CRC provide a means of
obtaining insight into the biological basis of
CRC. Distinct characteristic profiles have already
been described for breast cancers from patients
with germ line mutations in BRCA1 and to a
lesser extent BRCA2 (Wessels et al., 2002; Jons-
son et al., 2005; Joosse et al., 2008). Similarly, the
genomic profiles of Lynch syndrome carcinomas,
familial adenomatous polyposis adenomas,
MUTYH-associated polyposis carcinomas, and
sporadic CRC are clearly distinct (Cardoso et al.,
2006; Diep et al., 2006; Lips et al., 2007; Middel-
dorp et al., 2008; van Puijenbroek et al., 2008).
Hence, tumor profiles of CRC from families with
an unexplained CRC predisposition offer the
prospect of identifying regions commonly
affected by aberrations that are shared by the
affected individuals within the families.
To further our understanding of MMR-compe-
tent familial CRC, we analyzed seven large
Dutch families with a history of CRC. We per-
formed a genome-wide linkage scan and studied
the genomic profile of tumors from family mem-
bers. Finally, we evaluated the contribution of
recently identified low-risk loci in the susceptibil-
ity to CRC in these families.
MATERIALS AND METHODS
Families
Seven families with a history of CRC that seg-
regates in a dominant fashion were studied. Five
of the families (na16, na58, na61, na68, and
na209) fulfilled the AC-I (Table 1). The other
two families (na41 and na46), while not AC-I pos-
itive, were characterized by familial aggregation
of CRC and by early-onset disease (51 and 55
years of age). In a number of the families, several
other malignancies were also reported in family
members, including ovarian, breast, endometrial,
thyroid, gastric, and pancreatic cancers. Further-
more, a number of the younger members of the
families had been diagnosed with polypoid pre-
cursor lesions by endoscopic surveillance.
The pedigree information for the families was
collected through the Netherlands Foundation for
the Detection of Hereditary Tumors (http://












na16 18 (13) þ 44 3 3 Breast
na41 31 (20) �a 60 6 9 –
na46 21 (13) �a 58 5 6 Pancreas
na58 19 (15) þ 51 4 2 Lung, endometrium
na61 21 (17) þ 52 3 4 Gastric
na68 26 (13) þ 53 4 8 –
na209 33 (24) þ 51 6 2 Thyroid, breast, endometrium
Number of individuals indicates the number of individuals included in the linkage analysis. The number in the parentheses is the number of individu-
als genotyped with a 10K SNP array.
AC-I indicates Amsterdam criteria I.
Mean age at diagnosis is the mean age at time of diagnosis of CRC in individuals within the analyzed families.
Number of CRCs indicates the number of family members diagnosed with CRC.
Number of CRAs indicates the number of family members diagnosed with CRA.
aFamilies were characterized by familial aggregation of CRC and early-onset disease (51 and 55 years for na41 and na46, respectively).
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www.stoet.nl). Pedigree drawings are available
upon request. One de novo APC mutation (exon
9: c.1192_1193delAA, p.Lys398GlufsX5), associ-
ated with attenuated Familial Adenomatous Poly-
posis, was detected in a branch of family na61. In
the other families, no pathogenic germ line muta-
tions were identified in APC, MLH1, MSH2,
MSH6, PMS2, MUTYH, EXO1, MLH3, TGFBRII,
or MED1. Tumors were tested for microsatellite
instability using the marker set recommended by
the National Cancer Institute Workshop on
Microsatellite Instability (Boland et al., 1998),
and eight of nine tumors were analyzed with
three additional mononucleotide repeat markers
(BAT40, MSH3, and MSH6). All the tumors
from affected members of the seven families that
were available for MSI testing (9 tumors) were
MSS, except for one tumor from a member of
family na16. In this family, one family member
had an MSI-low tumor, and two other family
members had MSS tumors. Two additional
tumors stained positive using immunohistochem-
istry for MLH1, MSH2, MSH6, and PMS2.
This study was approved by the Medical Ethi-
cal Committee of the Leiden University Medical
Center, Leiden, The Netherlands (protocol P01-
019), in accordance with the tenets of the decla-
ration of Helsinki.
Genotyping
Peripheral blood samples were collected from
112 family members. DNA was extracted and
quantified using standard techniques. All family
members were genotyped using Affymetrix Gen-
eChipV
R
Human Mapping 10K 2.0 single-nucleo-
tide polymorphism (SNP) arrays (Affymetrix,
Santa Clara, CA). Arrays were processed accord-
ing to the manufacturer’s protocols. We have esti-
mated the genotyping error rate in five duplicate
experiments. The mean genotyping error rate
between the duplicates was only 0.0051.
Linkage Analysis
We estimated the power of the seven families
to identify a disease locus using Simlink, assum-
ing a single-locus dominant trait with a piecewise
linear penetrance. The maximum penetrance was
set at 80%, and the disease allele frequency was
assumed to be 0.001 (Boehnke and Ploughman,
1997). The estimated maximum logarithm of
odds (LOD) score for each family was 2.25, 4.44,
3.16, 4.32, 3.61, 2.30, and 4.51 for na16, na41,
na46, na58, na61, na68, and na209, respectively.
We applied two different methods to perform
the linkage analysis. In the first method, families
were analyzed individually using Mendel (Lange
et al., 2001) and SimWalk2 (Sobel and Lange,
1996), as described previously (Middeldorp et al.,
2007). In brief, uninformative SNPs and Mende-
lian-inconsistent errors were removed. Parametric
linkage analysis using two flanking markers was
performed in Mendel; both affected-only analysis
and parametric linkage analysis using liability
classes were performed. In the affected-only anal-
ysis, family members diagnosed with CRC or
with adenomas before the age of 50 years were
classified as affected, and all other family mem-
bers were set to unknown. Liability classes were
based on the incidences of CRC and adenoma in
the members of Lynch syndrome families in the
Netherlands that do not carry a disease causing
mutation in one of the DNA MMR genes (de
Jong et al., 2005). Four age groups were defined
(age at diagnosis <30, 30–45, 45–60, and 60
years), with penetrances set at 0.1000, 0.3000,
0.6000, and 0.8000 with corresponding phenocopy
rates of 0.0001, 0.0010, 0.0100, and 0.0500 for
CRC, and 0.0200, 0.0600, 0.2000, and 0.6000 for
colorectal adenomas (CRAs). We considered
LOD scores greater than three as a significant
linkage and LOD scores greater than two as a
suggestive linkage.
In the second method, we combined the data
from all families to calculate nonparametric link-
age (NPL) scores and heterogeneity LOD
(HLOD) scores. This method has been described
previously by Kemp et al. (2006a) and Papaem-
manuil et al. (2008). Briefly, Mendelian-inconsis-
tent errors were removed, and SNPs showing
evidence of linkage disequilibrium (LD) were
excluded. All families were analyzed together
with multipoint linkage analysis. Nonparametric
linkage analysis and parametric linkage analysis
were performed using SNPLINK (Webb et al.,
2005). The parametric analyses were performed
under both dominant and recessive models of in-
heritance. Four liability classes were used based
on age at diagnosis (<50, 50–59, 60–69, and >70
years). Individuals with CRAs were considered
equivalent to individuals with CRC who were 15
years older, that is, someone with CRA at age 45
was counted as having CRC at age 60. Two anal-
yses were performed, one based on CRC and one
analysis in which affected individuals were
defined by having either CRC or CRA.
GENETIC ANALYSIS OF LARGE FCC FAMILIES 541






Comprehensive Genetic Analysis of Seven Large Families 
with Mismatch Repair Proficient Colorectal Cancer
56
The two methods that we used differ in their
linkage statistics. Mendel uses either the
Lander–Green or the Elston–Stewart algorithm,
depending on whichever is more efficient for the
pedigree structure. SNPlink uses Allegro and
Merlin to perform linkage analysis; these pro-
grams both use the Lander-Green Hidden Mar-
kov Model algorithm. Moreover, Mendel can
handle larger families compared to SNPlink. We
used both methods of analysis to minimize the
chance of having missed possible linkage regions.
Analysis of Low-Risk Variants
We genotyped all available family members of
the seven familial colorectal cancer (FCC) fami-
lies and 310 unrelated healthy controls to analyze
10 CRC risk loci that were recently identified by
GWA studies, including rs12953717 (18q21),
rs3802842 (11q23), rs6983267 (8q24), rs16892766
(8q23), rs4779584 (15q13), rs10795668 (10p14),
rs4444235 (14q22), rs9929218 (16q22), rs10411210
(19q13), and rs961253 (20p12) (Broderick et al.,
2007; Tomlinson et al., 2007, 2008; Zanke et al.,
2007; Houlston et al., 2008; Jaeger et al., 2008;
Tenesa et al., 2008). Healthy controls were
derived from the Laboratory for Diagnostic Ge-
nome Analysis at the Leiden University Medical
Center (The Netherlands) and included individu-
als that tested mutation-negative (presymptomati-
cally) for noncancer-related diseases. SNP
genotyping was performed by allele-specific PCR
KASPar chemistry (KBiosciences, UK) following
the manufacturer’s protocol for all SNPs (primer
details are available upon request), except for
rs10795668 (10p14). Genotype calling was done
using ABI PRISM 7900HT technology (Applied
Biosystems, CA).
Genotyping of rs10795668 (10p14) was per-
formed using high-resolution melting curve analy-
sis implemented on a LightCycler (Roche,
Woerden, NL), and genotypes were analyzed
using LightCycler software (version 1.5.0; Roche).
Primer sequences and assay conditions are avail-
able upon request.
We studied the association of the 10 low-risk
variants with CRC, taking into account that the
individuals are related, and therefore their geno-
types are correlated (Thornton and McPeek,
2007; Uh et al., 2009). We compared the allele
frequencies in the affected family members to
the allele frequencies in the healthy family mem-
bers and healthy controls.
To study whether carrying a high number of
low-risk alleles correlated with disease in the
families, we determined the number of risk al-
leles for all family members, counting heterozy-
gotes and homozygotes for the risk allele as 1 and
2, respectively. Generalized estimation equations
(GEEs) with the identity matrix as the working
correlation were used to examine the possible
relationship between affected status and the
number of risk alleles in family members. This
method accounts for the fact that family members
have correlated genotypes. The Wald test was
used to test for associations. Moreover, GEEs
were used to examine whether the families carry
more risk alleles than would be expected based
on population frequencies of the variants.
Tumor Profiling
We analyzed three carcinomas and five adeno-
mas from individuals belonging to seven large
families with a history of CRC for genomic aber-
rations including chromosome gains, chromosome
losses, and loss of heterozygosity (LOH). Five of
these tumors were derived from the families
(na16, na41, na46, na58, and na209) that we stud-
ied using linkage analysis. The other three
tumors originated from two other families (na11
and na50), both fulfilling the AC-I but having a
low a priori power for linkage analysis due to lim-
ited sample availability. We used Illumina Bea-
darrays in combination with the linkage-mapping
panel IV_B4b (Illumina, San Diego, CA). Gold-
enGate assays were performed following the man-
ufacturer’s instructions with the following minor
modifications: 1 lg of input DNA was used for
multi-use activation and resuspended in 60 ll of
RS1 (Fan et al., 2003). Genotypes were extracted
using GenCall (version 6.0.7, Illumina) and GTS
Reports (version 4.0.10.0, Illumina). Copy num-
ber and copy-neutral LOH (cnLOH) profiles
were generated by analyzing the allelic state of
the tumors and the corresponding normal tissue
in the ‘‘Beadarray SNP’’ package with the LAIR
algorithm (Oosting et al., 2007; Corver et al.,
2008). Criteria for the scoring of copy number
aberrations were based on previous experiments
(Oosting et al., 2007). LOH was defined as
regions of three or more consecutive SNPs show-
ing LOH. In practice, regions of LOH always
presented as stretches of markers showing LOH.
Samples were handled according to the medical
ethical guidelines described in the Code Proper
Secondary Use of Human Tissue established by
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The aim of this study was to further our under-
standing of the genetics that underlie MMR pro-
ficient familial CRC. Therefore, we analyzed
seven large Dutch CRC families, and we studied
the genomic profile of tumors from family mem-
bers. Clinical characteristics of the seven families
analyzed in this study are shown in Table 1.
These families included 28 CRC patients and 30
family members with CRAs. The number of
CRC patients per family ranged from three to
five in successive generations. The mean age at
diagnosis of CRC was 53 years old (range, 28–82
years). The mean age at diagnosis of CRA was 50
years old (range, 34–72 years). In all but one fam-
ily, individuals from three generations were diag-
nosed with CRC. In family na209, individuals
from two generations were diagnosed with CRC.
Genotyping and Linkage Analysis
Using Affymetrix 10K SNP arrays, we geno-
typed 112 individuals from the seven families,
including both healthy and affected family mem-
bers. The mean SNP call rate was >95% (84.1–
99.4%). The high number of SNPs combined
with large informative pedigrees made the data
analysis highly computationally complex. We pre-
viously established a procedure for such complex
linkage analysis using existing programs, and we
validated our method in a Lynch syndrome fam-
ily with a known MLH1 germ line mutation
(Middeldorp et al., 2007). Here, we applied this
method to our seven families under study. Fami-
lies were analyzed individually, because every
family by itself had good a priori power to iden-
tify linked loci. This approach reduces the impact
of locus heterogeneity in the analysis. We per-
formed both affected-only parametric linkage
analysis and parametric linkage analysis using
liability classes. No clear regions of linkage
(LOD � 3.0) or suggestive linkage (LOD � 2.0)
were identified in either analysis in any of the
seven families (results not shown). LOD scores
greater than one were identified frequently. How-
ever, these were peaks in the LOD scores of
only single SNPs. No regions, including consecu-
tive markers with LOD scores greater than one,
were identified in any of the families.
Subsequently, we analyzed all the families to-
gether using a different previously validated link-
age analysis method (Kemp et al., 2006a;
Papaemmanuil et al., 2008). Using this method,
we performed two different analyses. In the first
analysis, we restricted the analysis to the family
members with CRC, whereas, in the second anal-
ysis, we also included the individuals with CRA.
The first analysis did not yield any clear regions
of linkage or suggestive linkage. However, in the
second analysis, in which individuals with carci-
nomas and adenomas were both included, four
chromosomal regions with HLOD scores of �1.5
were identified (Fig. 1). The HLOD scores are
shown in Table 2. The four chromosomal regions
with HLOD scores close to 1.5 were 3q21.3
(HLOD ¼ 1.49), 6q21 (HLOD ¼ 1.59), 8q24.2
(HLOD ¼ 1.48), and 14q22.1 (HLOD ¼ 1.30).
Association analysis of 10 low-risk variants
revealed significant associations with CRC for
rs16892766 (8q23.3; P ¼ 0.03) and rs12953717
(18q21.1; P ¼ 0.03). The risk allele frequency for
rs16892766 was 14.3% in the affected family
members, compared to 6.8% in their healthy rela-
tives. The allele frequency for rs12953717, the
nonrisk allele, was 68.5% in the affected family
members, whereas it was only 50% in the healthy
family members. The mean number of risk al-
leles carried by family members with CRC was
9.4 (range, 4–14). The unaffected family mem-
bers carried an average of 9.0 (range, 4–13) risk
alleles. The average number of risk alleles in
unrelated controls was 9.2 (range, 4–13). Hence,
no significant correlation was observed between
the number of risk alleles and the CRC status of
the family members (P ¼ 0.38). We did neither
observe a general enrichment of risk alleles in
the families with a history of CRC compared to
the unrelated controls.
Tumor Analysis
Using DNA isolated from formalin-fixed paraf-
fin-embedded tissue from five adenomas and
three carcinomas and Illumina 6K SNP arrays, we
evaluated eight tumors for genome-wide copy
number aberrations and LOH (Table 3). We
identified a few aberrations in the CRAs. One ad-
enoma had no chromosomal aberrations, whereas
three other adenomas displayed one chromosomal
aberration each, and the fifth adenoma exhibited
four aberrations. Different chromosomal regions
were targeted, including loss of chromosomes 5
and 13, gain of chromosomes 7, 8, and 13, and
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cnLOH of chromosome 12. Gain of chromosome
7 and chromosome 13 has been described as
prevalent in adenomas (Cardoso et al., 2006;
Jones et al., 2007). The aberrations observed at
chromosomes 5, 8, and 12 are less common.
The carcinomas we studied displayed many
more chromosomal aberrations than the adeno-
mas. The three CRCs displayed 8, 9, and 18
chromosomes with aberrations, respectively (Ta-
ble 3). The aberrations include genetic changes
commonly seen in CRC, such as loss of chromo-
some 18q, gain of chromosome 13q, gain of chro-
mosome 8q, and gain of chromosome 20q (Diep
et al., 2006). However, other aberrations, includ-
ing gain of chromosome 6p and loss of chromo-
some 20p, were also observed.
DISCUSSION
Despite the clear familial CRC phenotype and
the high estimated a priori power to detect link-
age, our analyses did not reveal a novel region of
significant linkage in any of the seven large CRC
families studied. However, our results do support
linkage to a previously reported region on 3q21.3,
linked to CRC susceptibility, on the basis of an
HLOD score of 1.49 (corresponding to a locus-
specific P value of 0.01) (Kemp et al., 2006a;
Papaemmanuil et al., 2008). The smallest region
of overlap with the different linkage reports in
this region is 3q22.1–q22.3, as shown in Figure 2.
Collectively, these data provide evidence for a
novel CRC susceptibility locus mapping to 3q22.
Failure to demonstrate strong evidence of linkage
is indicative of the risk conferred by the 3q21.3
locus being modest as opposed to the high-risk
profile associated with classical MMR gene muta-
tions. In previous studies, �40 genes located in
this region have been screened for mutations
(Papaemmanuil et al., 2008; Picelli et al., 2008).
Although no coding mutations have been identi-
fied to date, this does not preclude the possibility
that the functional basis of the disease locus is
mediated through alternative sequence mecha-
nisms, such as regulatory sequences or
microRNAs.
TABLE 2. Maximum HLOD or NPL Scores Determined
by the Linkage Analysis
Chromosome Alpha HLOD NPL
Affected ¼ carcinoma
3p14.1 1.00 1.13 1.82
9q21.33 1.00 1.18 1.78
11q24.2 1.00 1.28 1.68
14q13.3 1.00 1.16 2.26
Affected ¼ carcinomas/adenomas
3q21.3 0.57 1.49 3.65
6q21 0.54 1.59 3.93
8q24.2 1.00 1.48 2.00
14q22.1 0.51 1.30 3.93
The table shows the results of the linkage analysis in which affected
individuals were defined by having CRC (top), and the results of anal-
ysis in which affected individuals were defined by having either CRC
or CRA (bottom).
Figure 1. Genome-wide HLOD scores for the combined analysis of all families with both carcinomas and adenomas included in the analysis.
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In addition to 3q, 14q24.2 has been suggested
to be linked to CRC. Although we found some
evidence for linkage to 14q22.1, our region of
linkage does not overlap with the previously pub-
lished locus (Djureinovic et al., 2006). Other link-
age regions that have been previously reported,
albeit nonsignificant on a genome-wide basis
include regions on 7q, 9q, 11q, and 22q. No CRC
linkages with these loci were supported by our
results. The absence of replication of linkage in
these regions could be due to differences in fam-
ily ascertainment, because we restricted our anal-
ysis to large pedigrees rather than nuclear CRC
families, which were used in previous studies.
Furthermore, it is highly unlikely that we failed
to demonstrate a significant linkage as we used
multiple statistical strategies to maximize the
probability of identifying a disease locus.
Our results provide evidence supporting the
hypothesis that a single highly penetrant genetic
risk factor is unlikely to make a major contribu-
tion to the excess familial risk associated with
MSS cancers. This establishes that a model based
on a combination of moderate-risk or multiple
low-risk factors is more likely. Rare alleles confer-
ring moderate risk are very difficult to identify
through association-based analyses. To date, most
efforts to identify nonhigh-penetrance variants
have been directed to common low-risk variants
using GWA studies. We studied the impact of
the 10 currently known low-risk variants on fami-
lial risk in seven large CRC families. The variant
rs16892766 (8q23.3) is significantly associated
with CRC in these families. Intriguingly, this var-
iant has recently been found to have a modifier
effect in Lynch families (Wijnen et al., 2009).
Paradoxically, the SNP rs12953717 (18q21.1)
TABLE 3. Chromosomal Aberrations Found in Colorectal Adenomas and Carcinomas
Family Tumor type Histology MSI status Chromosome gain Chromosome loss LOH/AI
16–4 Adenoma Tubular MSS 13q  a
41–3 Adenoma Tubular NA   
11–2 Adenoma Tubular, villous MSS  5q14.3–23.3 –
46–1 Adenoma Villous MSS  13q 

































MSI indicates the microsatellite stability of the tumor; MSS means that the tumor was microsatellite stable. NA indicates that MSI status could not
be assessed. LOH/AI indicates chromosomal regions displaying loss of heterozygosity or allelic imbalance in the absence of copy number altera-
tions. Minus sign () indicates that no chromosomal aberrations were present.
aTumor in which LOH could not be analyzed for chromosomes 5, 6, 7, 8, and 9.
Figure 2. Linkage results for chromosome 3q. The linkage regions
determined by Papaemmanuil et al. (2008) Picelli et al. (2008), and
our study are shown here. SRO indicates the smallest region of
overlap.
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association was counter to that seen in unselected
cases. Although this may reflect interaction with
another (unknown) risk factor in the CRC fami-
lies, the observation may simply be reflective of
the small number of individuals analyzed in this
study. Similarly, no relationship between the
number of risk alleles that family members carry
and their CRC status was identified. Collectively,
these data indicate that the currently identified
low-risk variants are insufficient to account for
the type of familial clustering of CRC seen in the
families we analyzed.
Analysis of genome-wide copy number aberra-
tions and LOH showed that adenomas display
only a few chromosomal aberrations, as has been
previously described (Jones et al., 2007). More-
over, our results do not suggest the existence of a
specific chromosomal target region for tumor ini-
tiation that would point to a susceptibility locus
responsible for CRC in the families we analyzed.
In contrast, the carcinomas we studied displayed
many chromosomal aberrations. The profiles of
the carcinomas show similarities with the patterns
of aberrations observed in sporadic CRC, but
additional aberrations were also observed.
When postulating that the regions identified
using linkage analysis harbor tumor suppressor
genes, it is likely that these regions are targeted
early in the tumor by chromosomal aberrations.
However, in the adenomas, we did not identify
any aberrations at 3q21.3, 6q21, 8q24.2, or
14q22.1, the regions with the highest LOD
scores, except for one gain at chromosome arm
8q in tumor 58–9. However, a gain at chromo-
some 8q is a frequently observed event in CRC.
Overall, the profiles identified do not resemble
the profile of tumors from Lynch syndrome
patients, MUTYH-associated polyposis patients, or
Familial Polyposis Syndrome patients. Although
the profiles do show some resemblance to spo-
radic CRC profiles, other aberrations were identi-
fied, including gain of 6p and loss of 20p
(Middeldorp et al., 2008; van Puijenbroek et al.,
2008).
In conclusion, we did not find evidence for a
high-penetrance genetic factor that can explain
the increased CRC risk in these families. How-
ever, linkage results for 3q support previous
reports that this locus might harbor a moderate-
or high-risk CRC allele. However, tumor analysis
did not identify a chromosomal loss or LOH at
this region on 3q, as would be expected in case
of a tumor suppressor function. No enrichment in
the number of low-risk alleles was observed in
the families we studied. The genomic profiles of
the tumors seem distinct from other familial syn-
dromes and show resemblance to sporadic CRC.
Overall, these data suggest that factors other than
a high-penetrance risk factor, such as low- or
moderate-risk factors, may explain the increased
cancer risk in a subset of familial CRC.
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Abstract
Recent genome-wide association studies have identified
several loci that confer an increased risk of colorectal
cancer (CRC). We studied the role of the 8q24.21
(rs6983267), 18q21.1 (rs12953717), 15q13.3 (rs4779584),
11q23.1 (rs3802842), 8q23.3 (rs16892766), and 10p14
(rs10795668) risk variants in a series of 995 Dutch CRC
cases and 1340 controls. The CRC cases were selected on
basis of having a family history of CRC and/or early-on-
set disease. The detailed clinical and molecular data
available on the cases allowed us to examine the rela-
tionship between risk variants and clinicopathologic
characteristics. We replicated the association with an in-
creased risk of CRC cancer for all loci, except 10p14. The
association with the variant on chromosome 15q13.3
was confirmed for the first time. The risks associated
with variants in our series were higher (not significant)
than those previously reported, consistent with our se-
ries reflecting genetic enrichment. Moreover, we show
that familial CRC cases possess an increased number
of risk alleles compared with solitary CRC cases (ear-
ly-onset; mean age at diagnosis of 48.5 years). We also
identified a significant increase in the number of risk
alleles in families with early-onset disease (≤50 years)
compared with late-onset families (>50 years). In soli-
tary CRC patients, enrichment for risk alleles was not
observed, suggesting that other causes of increased
CRC risk play a role in these cases. Overall, our results
suggest that clustering of low-risk variants may explain
part of the excess risk in CRC families. (Cancer Epide-
miol Biomarkers Prev 2009;18(11):3062–7)
Introduction
Around a third of all colorectal cancer (CRC) has been
shown to be attributable to heritable factors (1). High Pen-
etrance mutations, such as those in the mismatch repair
genes (MLH1, MSH2, MSH6, and PMS2) causing the
Lynch syndrome, APC in Familial Adenomatous Polypo-
sis, and MUTYH in MUTYH-associated polyposis, only
account for ∼5% of CRC (2-4). Although the underlying
basis of the residual excess familial risk is presently unde-
fined, it is likely that coinheritance of several common al-
leles each conferring a low CRC risk contribute to this
excess familial risk.
Recent genome-wide association studies have vindi-
cated this hypothesis and several loci have been robust-
ly shown to be associated with an increased risk of
developing CRC. The first of these was a variant at
8q24.21 defined by the single nucleotide polymorphism
(SNP) rs6983267 (5-8). This variant was also shown to
be associated with increased risks of both prostate and
ovarian cancer (9, 10). Recently, this locus has also been
associated with the development of multiple colorectal
adenomas (11). Three SNPs on 18q21.1 were reported
to be associated with an increased CRC risk. These three
variants (rs4939827, rs12953717, and rs4464148) map to
an intronic sequence of SMAD7, an antagonist of trans-
forming growth factor-β signaling (12, 13). A third locus
associated with an increased CRC risk was identified on
chromosome 15q13.3 (14). Previously, linkage of this lo-
cus to CRC was reported in three Ashkenazi families
(15, 16). The strongest association for this locus was re-
ported with rs4779584, close to the genes SCG5, GREM1,
and FMN1. A fourth association was identified in a
gene-rich region on 11q23 with SNP rs3802842 (13, 17).
Furthermore, SNP rs10795668 (located at 10p14) and
SNP rs16892766 (located at 8q23.3) were reported to be
associated with an increased risk of CRC (18). This latter
variant at 8q23.3 is linked to EIF3H, a translation initia-
tion factor. Current data suggest that each of these loci
act independently in a dose-dependent manner with
those individuals possessing multiple risk variants hav-
ing relatively substantive risks over those carrying few
risk alleles (17).
Association of these six risk loci with several clinical or
pathologic parameters has been described. For rs3802842
(11q23) and rs4939827 (18q21.1), the risk of developing
rectal cancer was found to be greater than the risk of
Received 6/19/09; revised 9/7/09; accepted 9/11/09; published OnlineFirst 10/20/09.
Grant support: Dutch Cancer Society (grant number UL2005-3247) and the NutsOhra
Foundation.
Note: Supplementary data for this article are available at Cancer Epidemiology,
Biomarkers & Prevention Online (http://cebp.aacrjournals.org/).
Requests for reprints: Tom van Wezel, Department of Pathology, Leiden University
Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands. Phone: 31715266813;
Fax: 31848331048. E-mail: T.van_Wezel@lumc.nl
Copyright © 2009 American Association for Cancer Research.
doi:10.1158/1055-9965.EPI-09-0601







Enrichment of low penetrance susceptibility loci 
in a Dutch colorectal cancer cohort
66
developing colonic cancer (13). Moreover, Tomlinson et al.
(18) reported that the association with rs10795668 (10p14)
was stronger for rectal cancer than for colonic tumors. The
association of the locus at 8q24.21 was described to be
stronger for patients under the age of 50 years than for
those 50 years of age or older (8). Similarly, the effect of
rs16892766 (8q23.3) on CRC risk has also been described
to be stronger in younger individuals (<60 years; ref. 18).
Finally, Tuupanen et al. (19) identified a tendency for as-
sociation of rs6983267 (8q24.21) with microsatellite stable
(MSS) cancer and a family history of extracolonic cancers.
The effect of the variants at these six loci has also been
studied in Lynch syndrome patients, carrying a mutation
in one of the mismatch repair genes. In Lynch patients,
rs16892766 (8q23.3) is associated with an elevated CRC
risk. For rs3802842 (11q23.1), an elevated risk of devel-
oping CRC was described for female Lynch patients
only (20).
To further inform on the relationship of variants at these
six loci with the development of CRC, we have genotyped
8q24.21, 18q21.1, 15q13.3, 8q23.3, 11q23.1, and 10p14 var-
iants in a cohort of Dutch CRC cases, enriched for a positive
family history and/or an early onset of disease. Detailed
clinical and pathologic data on the cases has allowed us
to examine the relationship between clinicopathology and
genotype in the setting of familial disease.
Materials and Methods
Study Population. We studied 995 index cases, all of
which were diagnosed with CRC (48% male, 52% female),
and 1340 controls (47% male, 53% female). These cases
fulfill the clinical criteria for microsatellite instability
(MSI) testing, installed in the Netherlands since 1997
and formalized in 2008, based on early onset of the dis-
ease and/or familial clustering of CRC (Supplementary
Table S1). Most cases were sent in through the clinical ge-
netics department. Only one case per family was included
in our cohort. Samples were collected mostly in a period
from 1997 to 2007. The samples largely originate from the
southwestern part of the Netherlands. Eighty-two percent
of all tested tumors were MSS, whereas 7% had a low lev-
el of MSI (MSI-L), and 12% were MSI-H. Of the MSI-H
tumors, 93% were MSI-H on a sporadic basis. Overall,
the cohort includes 10 Lynch syndrome patients.
Controls were 894 healthy blood donors from the
southwest region of the Netherlands. Additional 446 con-
trols were derived from individuals that presented at the
Laboratory for Diagnostic Genome Analysis at the Leiden
University Medical Centre for presymptomatic testing for
noncancer syndromes and tested mutation-negative for
these syndromes. Age was not known for all controls.
Therefore, the control cohort might include some young
individuals that develop CRC later in life. This would re-
duce the power of our analysis and therefore could have
resulted in an underestimation of the associations.
We genotyped the following SNPs in the CRC cases
and the controls: rs16892766, rs6983267, rs10795668,
rs3802842, rs4779584, and rs12953717.
The study was approved by the local Medical Ethical
Committee (protocol P01.019). Samples were handled ac-
cording to the medical ethical guidelines described in the
Code Proper Secondary Use of Human Tissue established
by the Dutch Federation of Medical Sciences.8
DNA Isolation. DNA was extracted from either pe-
ripheral blood or from formalin-fixed paraffin embedded
(FFPE) normal tissue. DNA was extracted from blood
samples using an automated procedure (Gentra Systems).
DNA from FFPE tissue was isolated using xylol, ethanol,
and overnight incubation at 56°C in 120 μL of PK1 lysis
buffer and 5 μL Proteinase K. The suspension was then
incubated for 10 min at 100°C and centrifuged for 10
min at 13,000 rpm. The supernatant containing the
DNA was carefully transferred to a new tube. DNA was
quantified using the picogreen method (Invitrogen-
Molecular Probes).
MSI Analysis. Eight microsatellite markers were eval-
uated to determine the MSI status of the tumors. As re-
commended by the National Cancer Institute Workshop
on MSI for Cancer Detection and Familial Predisposition,
two mononucleotide repeats (BAT25 and BAT26) and
three dinucleotide repeats (D2S123, D5S346, and
D17S250) were analyzed, supplemented with three mono-
nucleotide repeat markers (BAT40, MSH3, and MSH6; ref.
21). Tumors were classified as MSS when no instability
was seen for any of the eight markers. When instability
was seen in <30% of the markers, tumors were classified
as MSI-L. When >30% of the markers showed instability,
the tumors were classified as MSI-H.
Genotyping. Genotyping of the variants rs12953717,
rs3802842, rs6983267, and rs16892766 was done using
the KASPar method following the manufacturer's proto-
col (KBioscience). PCR, with two allele-specific forward
primers and one common reverse primer, was done in a
GeneAmp PCR system 9700 (Applied Biosystems). De-
tection was done in an ABI PRISM 7900HT (Applied
Biosystems).
Genotyping of rs10795668 was done using a TaqMan
SNP Genotyping Assay for samples that were derived
from FFPE tissue according to the manufacturer's protocol
(Applied Biosystems). The leukocyte DNA samples were
genotyped using high-resolution melting curve analysis.
Primers for high-resolution melting curve analysis were
designed using Primer3. In short, 5 μL PCR reactions
were analyzed on a LightCycler (Roche) using the Light-
Cycler software (version 1.5.0, Roche). PCR reactions con-
sisted of 10 ng DNA, iQ Supermix (Bio-Rad), 1 μmol/L
SYTO9 (Invitrogen), and 2 pmol primers.
For rs4779584, all leukocyte DNAwas genotyped using
the KASPar method, whereas the high-resolution melting
8 http://www.federa.org
Table 1. Scoring system for family characteristics
Category Description
I Amsterdam Criteria II positive families*
II At least two FDR affected with CRC, at least
one diagnosed ≤50 y in one or two generations
III Solitary CRC patient
IV At least three FDR affected with CRC, diagnosed
>50 y in one or two generations
V Two FDR affected with CRC, diagnosed >50 y in
one or two generations
Abbreviation: FDR, first-degree relative.
*Including largely non-Lynch or so-called Lindor Type X families (29).
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curve analysis method was applied to the samples isolat-
ed from FFPE tissue. Samples that failed to produce a ge-
notype were reanalyzed using the TaqMan SNP
genotyping assay (Applied Biosystems). Primer details
are available upon request.
To check the quality of the genotyping, >5% of the
samples were analyzed in duplicate. The concordance
was >98%. All SNP genotype frequencies in our cohort
fit the Hardy-Weinberg equilibrium as assessed using a
χ2 test.
To facilitate data management and analysis, we devel-
oped a relational database that is based on MS Access and
structured query language.
Clinicopathologic Characteristics. For all cases, infor-
mation was available for several clinical genetic and path-
ologic parameters. This information included age at
diagnosis, microsatellite status, tumor grade, location of
the tumor (left of the flexura lienalis versus right of the
flexura lienalis), additional development of adenomas,
and family history characteristics. Information on the
presence of adenomas was derived from Pathological An-
atomical District Automated Archives, a nationwide net-
work and registry of histopathology and cytopathology in
the Netherlands (22). The latter was scored with the
scheme displayed in Table 1.
Statistical Analysis. Genotype frequencies in the CRC
cases and controls were tested for deviations from ex-
pected frequencies under Hardy-Weinberg Equilibrium
using a χ2 test using a significance level of 5% (one degree
of freedom). Odds ratios (OR), including their 95% confi-
dence intervals (CI), were calculated using logistic regres-
sion analysis. Bonferroni's correction for multiple testing
was applied. Associations between CRC risk loci and clin-
ical and pathologic parameters were assessed using a χ2
test (one degree of freedom) in CRC cases only.
Power calculation was done under the assumption of
an additive model and an α of 0.05.
We used a Cochran-Armitage test of trend using or-
dered categorical data to study the effect of possessing
an increased number of risk alleles (counting one for het-
erozygotes and two for homozygotes). The most common
number of risk alleles was used as a reference to calculate
ORs. These statistical analyses were done in SPSS 16.0.
Pairwise interactions between the SNPs were studied
using Plink (v1.05; ref. 23).
Results and Discussion
We studied the effects of rs16892766 (8q23.3), rs6983267
(8q24.21), rs10795668 (10p14), rs3802842 (11q23.1),
rs4779584 (15q13.3), and rs12953717 (18q21.1) in a Dutch
familial CRC cohort. This cohort is enriched for a posi-
tive family history for CRC and/or early onset of
disease. The main characteristics of the study cohort
are detailed in Table 2.
Association Analysis. Variant rs6983267 (8q24.21) was
significantly associated with an increased risk of CRC in
our familial cohort, with an allelic OR of 1.29 (95% CI,
1.14-1.49; P = 7.2 × 10−5; Table 3). We also replicated the as-
sociation of variant rs12953717 (18q21.1) with CRC risk in
our cohort, with an allelic OR of 1.23 (95% CI, 1.09-1.38;
P = 8.6 × 10−4). Curtin et al. (24) also described associations
Table 2. Characteristics of the study population
Cases Controls
Gender
Male 453 (48%) 633 (47%)
Female 492 (52%) 707 (53%)
Age at diagnosis
≤50 y 291 (42%)





Right sided 218 (33%)











Category I 66 (13%)
Category II 105 (21%)
Category III 144 (28%)
Category IV 102 (20%)
Category V 66 (13%)
Other 23 (5%)
Table 3. Association between CRC risk and low-risk variants
SNP Chromosome region Minor allele* Allele
frequencies†




rs6983267 8q24.21 G 0.58 0.52 1.29 (1.14-1.46) 7.2 × 10−5‡ 1.24 (1.17-1.33)§ 95%
rs12953717 18q21.1 T 0.45 0.40 1.23 (1.09-1.39) 8.6 × 10−4‡ 1.17 (1.12-1.22)∥ 75%
rs4779584 15q13.3 T 0.24 0.18 1.45 (1.24-1.69) 3.8 × 10−6‡ 1.23 (1.14-1.34)§ 81%
rs3802842 11q23.1 C 0.31 0.27 1.26 (1.11-1.43) 4.4 × 10−4‡ 1.11 (1.08-1.15)¶ 38%
rs10795668 10p14 A 0.31 0.31 1.02 (0.88-1.17) 0.84 0.89 (0.86-0.91)§ 45%
rs16892766 8q23.3 C 0.10 0.09 1.23 (1.00-1.50) 0.05 1.25 (1.19-1.32)§ 53%
NOTE: GWAS OR, OR identified in previous genome-wide association studies. Power was calculated assuming an additive model and an α of 0.05.
*According to the HapMap CEU frequencies.
†In our cohort.
‡Associations remained significant after correction for multiple testing.
§Tomlinson et al., 2008.
∥Jaeger et al., 2008.
¶Tenesa et al., 2008.
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between the risk alleles on 8q24.21 and 18q21.1 and CRC
risk in a cohort that included familial CRC. For rs4779584
(15q13.3), a strong association with CRC risk was identi-
fied, with an allelic OR of 1.45 (95% CI, 1.22-1.67; P = 3.8
× 10−6). To the best of our knowledge, these results provide
the first replication of the association between the locus at
15q13.3 and CRC risk. A strong association was also iden-
tified for rs3802842 on chromosome 11q23.1 (allelic OR,
1.26; 95% CI, 1.11-1.44; P = 4.4 × 10−4). The results for
rs3802842 have previously been reported for 783 of 995
samples (17). An allelic OR of 1.23 for rs16892766
(8q23.3) was found in our cohort (95% CI, 1.00-1.51; P =
0.05). This association does not remain significant after cor-
rection for multiple testing. The results for rs16892766
(8q23.3) have previously been reported for 783 of 953 of
the samples (18). Overall, the ORs identified in our cohort
tend to be increased compared with the ORs described in
the initial genome-wide association studies, consistent
with our series reflecting genetic enrichment (Table 3).
Although the ORs are consistently increased, the CIs
overlap, indicating that the differences are not statistically
significant.
Unlike the previous loci, we were unable to replicate
the association between rs10795668 (10p14) and CRC risk.
In our cohort, the locus on 10p14 was not associated with
an increased risk of CRC (allelic OR, 1.02; 95% CI, 0.88-
1.17; P = 0.84). The absence of an association between this
locus and CRC risk may be explained by a lack of power
to detect the association in our study, although the power
to detect association with a minor allele frequency of 0.33
and an OR of 0.89 was 45% in our study, and association
with rs3802842 (11q23.1) was detected with a prior power
of 38%. A second explanation could be a difference be-
tween the Dutch population compared with the English
population. Of note, this locus on chromosome 10p14
was also not captured by meta-analysis of two large
genome-wide association studies (25).
Clinicopathologic Characteristics. We studied the as-
sociation of the six risk loci mentioned above with several
clinicopathologic parameters including the following:
gender, age at diagnosis, polyp development, tumor
stage, family characteristics (Table 1), tumor location,
and MSI status. In our cohort, the association between
rs12953717 (18q21.1) and CRC risk is stronger in cases
with left-sided cancer (OR, 1.43; 95% CI, 1.22-1.68) com-
pared with cases with right-sided cancer, where the
association could not be detected (OR, 1.02; 95% CI,
0.82-1.27; P = 0.03). Further analysis shows that the asso-
ciation of rs12953717 and CRC is, among the left-sided
cancers, stronger for the tumors located at the rectosig-
moid junction or in the rectum (OR, 1.58; 95% CI, 1.28-
1.95) compared with left-sided tumors proximal of the
rectosigmoid junction (OR, 1.30; 95% CI, 1.04-1.61; P =
0.04). Similarly, a stronger effect of rs12953717 on CRC
risk was seen for familial CRC cases with at least two
first-degree relatives affected with CRC (OR, 1.51; 95%
CI, 1.25-1.83) compared with solitary CRC cases (early-
onset; mean age at diagnosis of 48.5 years; OR, 0.86;
95% CI, 0.65-1.14; P = 8.6 × 10−4). No relationship was
identified between tumor location and family characteris-
tics (P = 0.16), indicating that these two parameters are
independently associated with rs12953717. No statistical-
ly significant associations between rs12953717 (18q21.1)
and the other clinicopathologic parameters (including
gender, age at diagnosis, polyp development, tumor
stage, and MSI status) were found. For all other loci, no
significant associations were found between the variants
and gender, age at diagnosis, tumor location, family
characteristics, polyp development, tumor stage, or
MSI status. However, ORs for rs12953717 (18q21.1),
Table 4. ORs for cumulative number of risk alleles
No. risk alleles No. cases (%) No. controls (%) OR (95%CI) P
0 13 (1.8) 18 (2.9) 0.65 (0.31-1.36) 0.25
1 47 (6.7) 67 (10.7) 0.63 (0.41-0.96) 0.03
2 135 (19.2) 157 (25.0) 0.77 (0.57-1.04) 0.09
3 197 (28.0) 176 (28.0) 1.00 (reference)
4 162 (23.0) 132 (21.0) 1.10 (0.81-1.49) 0.56
5 102 (14.5) 60 (9.6) 1.52 (1.04-2.22) 0.03
≥6 47 (6.7) 18 (2.9) 2.33 (1.31-4.17) 4.2 × 10−3
Total 703 (100) 628 (100) PTrend = 1.1 × 10
−7
NOTE: The results shown in this table are illustrated in Fig. 1.
Figure 1. Number of risk alleles in the CRC cases and the
controls. A. The distribution of the number of risk alleles in
the CRC cases and the controls. B. The OR for each category.
The most common number of risk alleles (three) was set as a
reference. *, P < 0.05.
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rs4779584 (15q13.3), and rs16892766 (8q23.3) were in-
creased in MSS cases compared with MSI-H cases,
although these differences were not significant. These
results suggest that the role of low-risk variants play in
MMR-deficient tumors is reduced compared with
MMR-proficient tumors, despite the sporadic nature
of the MSI-H cases in our cohort. And although
rs16892766 (8q23.3) is significantly associated with an
increased CRC risk in MMR mutation carriers (20), its role
in MMR-deficient tumors with a sporadic nature seems
reduced. Several associations between the risk loci and
clinicopathologic parameters have previously been
described, including associations between rectal cancer
and 11q23.1 and 18q21.1, between early disease onset and
both 8q24.21 and 8q23.3, and between MSS tumors and
8q24.21 (8, 13, 18, 19). However, we were unable to repli-
cate any of these associations in our cohort.
Risk Allele Distribution. We investigated the effect of
possessing an increased number of risk alleles on CRC
risk (Table 4). We counted the number of risk alleles
per individual and then compared the distribution in
CRC cases versus controls. We identified a significant
increase in the number of risk alleles in CRC cases com-
pared with controls (PTrend = 1.1 × 10
−7). Moreover, there
was a gradual increase in the OR with an increased
number of risk alleles, although not all increases in the
OR were significant. For individuals possessing six or
more risk alleles, an OR of 2.3 (95% CI, 1.31-4.17) was
observed. These results are illustrated in Fig. 1. Our
findings are in line with previous reports on the cumu-
lative effect of these risk alleles on CRC risk (17). Similar
cumulative effects have been described for other cancers,
including prostate cancer and head and neck cancer
(26-28).
Remarkably, a significant difference in the number of
risk alleles was observed between solitary cases (early-
onset; mean age at diagnosis of 48.5 years) and familial
CRC cases (at least two affected first-degree relatives).
The familial CRC cases had significantly more risk alleles
compared with solitary CRC cases (PTrend = 0.03), suggest-
ing that low-risk variants indeed cluster in families
affected with CRC (Fig. 2). In addition, the latter finding
suggests that other genetic models (such as a recessive
origin) might play a role in solitary CRC cases. Addition-
ally, we found that families with an early onset of the
disease (≤50 years of age) had significantly more risk
alleles (PTrend = 0.04) than families with a late onset of
the disease (>50 years of age). These results suggest that
possessing an increasing number of risk alleles decreases
the age of onset of the disease. However, similar relation-
ship between the number of risk alleles and disease onset
was not seen at the individual level.
Analysis of pairwise interactions did not yield evidence
for an interaction between any of the risk alleles. These
results are consistent with the analyses in a recent
meta-analysis, where all comparisons were based on at
least 13,000 individuals (25).
In conclusion, we replicated the association between
CRC risk and loci on chromosomes 8q23.3, 8q24.21,
11q23.1, 15q13.3, and 18q21.1. This is the first study to
replicate the association between CRC risk and the locus
on 15q13.3, although the association with a locus on
chromosome 10p14 could not be replicated in our co-
hort. The ORs for rs6983267 (8q24.21), rs12953717
(18q21.1), rs4779584 (15q13.3), and rs3802842 (11q23.1)
tend to be higher than those seen in the genome-wide
analysis, possibly reflecting enrichment for positive
family history of CRC in our cohort. Moreover, we
saw enrichment in the number of risk alleles in patients
with at least two first-degree family members affected
with CRC compared with solitary CRC patients. Similar
enrichment was identified in families with early-onset
disease (≤50 years of age) compared with families with
late-onset of CRC (>50 years of age). Overall, our results
suggest clustering of low-risk variants in familial CRC,
which is likely to contribute to the observed excess risk
in relatives of patients.
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Figure 2. Relationship between number of risk alleles and
family characteristics. A. The distribution of the number of risk
alleles per individual in solitary cases and familial cases (with
at least two first-degree relatives affected with CRC). B. The
distribution of risk alleles in families with an age at diagnosis
50 y or younger and families with an age at diagnosis older than
50 y of age. In both graphs, the distributions differ significantly
from each other (A, PTrend = 0.03; B, PTrend = 0.04).
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Abstract
Genetic instability is known to drive colorectal carcinogenesis. Generally, a distinction
is made between two types of genetic instability: chromosomal instability (CIN) and
microsatellite instability (MIN or MSI). Most CIN tumours are aneuploid, whereas MSI
tumours are considered near-diploid. However, for MUTYH-associated polyposis (MAP) the
genetic instability involved in the carcinogenesis remains unclear, as near-diploid adenomas,
aneuploid adenomas and near-diploid carcinomas have been reported. Remarkably, our
analysis of 26 MAP carcinomas, using SNP arrays and flow sorting, showed that these
tumours are often near-diploid (52%) and mainly contain chromosomal regions of copy-
neutral loss of heterozygosity (LOH) (71%). This is in contrast to sporadic colon cancer,
where physical loss is the main characteristic. The percentage of chromosomal gains (24%)
is comparable to sporadic colorectal cancers with CIN. Furthermore, we verified our scoring
of copy-neutral LOH versus physical loss in MAP carcinomas by two methods: fluorescence
in situ hybridization, and LOH analysis using polymorphic markers on carcinoma fractions
purified by flow sorting. The results presented in this study suggest that copy-neutral LOH
is an important mechanism in the tumorigenesis of MAP.
Copyright  2008 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
Keywords: MUTYH ; tumour profiling; copy-neutral LOH; SNP arrays; MAP carcinomas;
colorectal adenomatous polyposis; colorectal cancer
Introduction
MUTYH-associated polyposis (MAP) is the first col-
orectal cancer syndrome shown to be inherited in an
autosomal recessive fashion. Biallelic mutations in the
base excision repair (BER) gene MUTYH have been
shown to cause colorectal adenomatous polyposis, and
correlate with a high risk of developing carcinomas
[1]. BER is a DNA repair mechanism that guards
oxidative DNA damage and other metabolic DNA
damage. Upon oxidative DNA damage, MUTYH
removes incorrectly incorporated adenines opposite
to an 8-oxo-guanine. Consequently, MAP patients
show somatic G : C → T : A mutations in crucial genes
such as APC and KRAS. In APC, these G : C →
T : A transversions seem to occur primarily in GAA
sequences [1,2]. In KRAS, a specific GGT → TGT
mutation (c.34 G → T, p.Gly12Cys) is found in up
to 64% of MAP carcinomas [3]. Interestingly few p53
and SMAD4 mutations are found in MAP carcinomas,
whereas these genes are frequently affected in sporadic
colorectal cancer [3]. Although MUTYH deficiency
triggers carcinogenesis by G : C → T : A transversions,
the exact role of MUTYH deficiency in the tumour
progression in MAP patients is still unknown.
For colorectal cancers, different types of genetic
instability are known to drive carcinogenesis. The two
main types of genetic instability are microsatellite
instability (MIN or MSI) and chromosomal instabil-
ity (CIN). CIN is defined as an accelerated rate of
chromosomal missegregation resulting in an aberrant
chromosomal content, and is found in the vast major-
ity of sporadic colorectal cancers [4]. On the other
hand, ∼15% of the sporadic colorectal cancers show
MSI, due to MLH1 promoter hyper-methylation [5].
Moreover, MSI is typically seen in the carcinomas of
Lynch syndrome patients. Colon carcinomas that dis-
play neither CIN nor MSI have also been described
[6]. More recently, abnormal epigenetic modification
has been described in colorectal cancer, exhibiting the
CpG island methylator phenotype (CIMP) [7,8].
The genomic profile of MAP tumours has been
described in three studies to date. Using flow
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cytometry, Lipton et al found MAP carcinomas to
be predominantly near-diploid. Comparative genomic
hybridization (aCGH) of two near-diploid MAP car-
cinomas showed no detectable chromosomal gains
or losses. Furthermore, they analysed chromosomes
1p, 2p, 5q, 10p, 15q, 18q and 20q for LOH, using
microsatellite markers, and reported a high frequency
of LOH for chromosome 18q but low levels of LOH
for the other regions [3]. Recently, the same research
group identified only a small number of copy number
changes in MAP adenomas [9]. These changes were
mainly restricted to chromosomes 1p, 13, 17p, 19 and
22. Additionally, in a single MAP adenoma, copy-
neutral LOH (cnLOH) of whole chromosome 7 and 12
was reported. On the other hand, Cardoso et al iden-
tified chromosomal copy number aberrations in MAP
adenomas using aCGH analysis. The most prevalent
aberrations identified were gains at chromosomes 7
and 13, as well as physical losses on chromosomes
17p, 19p and 22q [10]. However, the ploidy status of
these adenomas was not determined.
Although these studies seem to be contradictory,
Lipton et al studied carcinomas, whereas the other
studies analysed adenomas. In addition, different tech-
nical platforms were used, i.e. flow cytometry vs.
aCGH after amplification of laser capture microdis-
sected DNA.
In order to gain further insight into the genetic insta-
bility involved in MAP carcinogenesis, we analysed
formalin-fixed paraffin-embedded tumour tissue from
26 carcinomas for patterns of chromosomal losses and
gains and copy-neutral LOH using SNP arrays [11,12].
Materials and methods
Samples
From 19 MAP patients, 26 formalin-fixed paraffin-
embedded (FFPE) carcinomas and corresponding nor-
mal tissue were selected (Table 1). This series of
carcinomas included metastases of primary colon car-
cinomas (t10 and t11). Corresponding normal tissue
was either histological normal colon tissue or tissue
from unaffected lymph nodes. The carcinomas origi-
nated from 11 biallelic Y165C mutation carriers, two
biallelic P391L mutation carriers, three Y165C/G382D
compound heterozygotes, one 1105delC/G382D, one
P391L/G382D and one P391L/R233X compound het-
erozygote. Clinical details of patients 2, 3, 8, 9, 10,
12, 13, 14, 15, 16 and 17 were previously described
Table 1. Characteristics of the MAP carcinomas
Tumour Patient MUTYH mutation Site CRC∗ Age at diagnosis Tumour stage DNA index
t1 1 Y165C/Y165C Distal 52 I 0.9 + 1.7†
t2 2 Y165C/Y165C Distal 49 II 1.1 + 1.4†
t3 3 Y165C/Y165C Proximal 39 II 1.0
t4 4 Y165C/Y165C Proximal 49 III 1.0 + 1.5†
t5 5 Y165C/Y165C Distal 56 I 1.6
t6 6 Y165C/Y165C Proximal 53 II 1.0
t7.1 7 Y165C/Y165C Proximal 43 II 1.0 + 1.5†
t7.2 7 Y165C/Y165C Distal 43 II 1.0 + 1.5†
t8.1 8 Y165C/Y165C Proximal 41 III na
t8.2 8 Y165C/Y165C Proximal 41 III na
t8.3 8 Y165C/Y165C Proximal 41 III 1.0
t8.4 8 Y165C/Y165C Distal 41 III 1.0
t9 9 Y165C/Y165C Ileum 77 II 1.0
t10 10 Y165C/Y165C Metastases‡ 45 IV 1.5 + 2.7§
t11 11 Y165C/Y165C Metastasis‡ 64 IV 1.5
t12 12 Y165C/G382D Proximal 67 III 1.0
t13.1 13 Y165C/G382D Proximal 43 II 1.0 + 1.1†
t13.2 13 Y165C/G382D Proximal 46 II 1.0
t14 14 Y165C/G382D Proximal 59 II 1.0
t15.1 15 P391L/P391L Proximal 37 III 1.1 + 1.4†
t15.2 15 P391L/P391L Proximal 37 III Na
t16 16 P391L/P391L Distal 58 II 1.0
t17.1 17 1105delC/G382D Distal 42 I 1.1
t17.2 17 1105delC/G382D Distal 42 I 1.0
t18 18 R233X/P391L Proximal 48 II 1.4
t19 19 G382D/P391L Proximal 51 III 1.1
The tumours were located before (proximal) or after (distal) to the splenic flexura of the colon. T11 is a metastasis of an earlier colon carcinoma.
T10 consists of two metastases of a colorectal carcinoma from patient 10.The DNA index was measured by multiparameter DNA flow cytometry.
When two populations were identified in the keratin-positive fraction, the DNA index of both tumour fractions is shown in the table. Tumour
staging was performed according to the TNM classification (http://tnm.uicc.org).
na, could not be analysed for technical reasons.
∗ All tumours were colorectal with the exception of t9 (ileum).
† Multiple clones.
‡ Exact location of the primary tumour in the colon not known.
§ Two metastases of a primary colorectal carcinoma with DNA index 1.5 and 2.7, respectively.
J Pathol 2008; 216: 25–31 DOI: 10.1002/path
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by Nielsen et al [13] (as the respective numbers 13, 4,
11, 12, 14, 20, 18, 16, 35, 34 and 30). Twenty-two pre-
viously published sporadic CRCs [14] were included
as reference controls.
The study was approved by the local Medical
Ethical Committee (protocol P01.019); samples were
handled according to the medical ethical guidelines
described in the Code Proper Secondary Use of
Human Tissue established by the Dutch Federation of
Medical Sciences (www.federa.org). Tumour samples
were enriched for tumour tissue by taking 0.6 mm
tissue punches, using a tissue microarrayer (Beecher
Instruments, Sun Prairie, WI, USA) guided by a
haematoxylin and eosin (H&E)-stained slide. DNA
was isolated by the previously described method,
and subsequently cleaned using the Genomic Wizard
kit (Promega, Leiden, The Netherlands) [15]. DNA
concentrations were measured with the picogreen
method (Invitrogen–Molecular Probes, Breda, The
Netherlands).
Flow cytometry and cell sorting
For 23 carcinomas, the DNA index was determined
by flow cytometry, as described previously with
minor modifications [16]. In short, cell suspensions
were prepared from FFPE samples and stained for
keratin (APC), vimentin (RPE) and DNA (DAPI).
Samples were analysed on a LSRII flow cytome-
ter (BD Biosciences, San Jose, CA, USA). From
five MAP carcinomas (t2, t4, t10, t12 and t18) and
one sporadic carcinoma (sp1), those cell fractions
that were vimentin-positive, keratin-negative (V+K−)
and vimentin-negative, keratin-positive (V−K+) were
flow-sorted using a FACSAria cell sorter (BD Bio-
sciences).
Single nucleotide polymorphism arrays
Illumina BeadArrays were used in combination with
the linkage mapping panel IV B4b (Illumina, San
Diego, CA, USA) [11], which consists of four panels.
Panel I covers chromosomes 1, 2, 3 and 22; panel II
covers chromosomes 5, 6, 7, 8 and 9; panel III covers
chromosomes 10, 11, 12, 13, 14, 15 and 21; and panel
IV covers chromosomes 4, 16, 17, 18, 19, 20, X and
Y. The GoldenGate assay was performed according to
the manufacturer’s protocol, with minor adjustments:
1 µg input DNA was used for multi-use activation
and resuspended in 60 µl RS1 [17]. Genotypes were
extracted using GenCall (version 6.0.7) and GTS
Reports (version 4.0.10.0; Illumina). Tumours t3, t9,
t10 and t14 could only be analysed for copy number
abnormalities, since corresponding normal tissue was
unavailable to determine cnLOH. For t1, t17.2 and t18
only three panels could be analysed, due to limited
availability of the FFPE tumour DNA. We corrected
for this missing information in our calculations.
Analysis of copy numbers and loss of
heterozygosity
Copy number and cnLOH profiles were generated by
analysing the carcinomas and corresponding normal
tissue in ‘Beadarray SNP’ [12]. Criteria for the scoring
of copy number aberrations were based on previous
experiments [12]. LOH was determined as follows.
The ratio between the GenCall Score (GCS) and the
GenTrain Score (GTS) was computed as a relative
measure for the quality of the clustering of the SNP.
All high-quality heterozygous SNPs (GCS/GTS >0.8)
in the normal sample were included in the analysis. For
homozygous SNPs and those with a GCS/GTS <0.8
in the tumour, LOH was assigned. LOH at one or two
SNPs was ignored. In practice, regions of LOH always
presented as stretches of markers showing LOH. When
both a copy number change and LOH were detected
at a specific region, the detected LOH was considered
to be a consequence of the copy number alteration.
If no copy number change was detected, LOH was
interpreted as cnLOH.
For verification, conventional LOH analysis was
performed for chromosomes 17p and 18q, using
microsatellite markers (D17S938, D17S921, D18S877,
D18S65, D18S460 and D18S1137) in pure tumour
DNA of five MAP carcinomas obtained after flow sort-
ing. Normal DNA was used as a reference. As a posi-
tive control, one sporadic carcinoma with known phys-
ical loss of chromosomes 17p and 18q was included.
A standard PCR protocol was used for amplification.
Mixtures of 9.5 µl HiDi formamide, 0.5 µl ROX 500
size standard and 2.0 µl PCR product were run on
an ABI 3130 Genetic Analyser (Applied Biosystems)
and analysed using GeneMapper version 4.0 (Applied
Biosystems).
Interphase fluorescence in situ hybridization (FISH)
FISH was performed on flow-sorted nuclei that were
spotted onto glass slides, as described previously
[18]. The nuclei of five carcinomas were hybridized
with a BAC on 17p13.1 (RP11-199F11, spanning
the p53 locus), a BAC on 18q21.1 (RP11-748M14,
spanning the SMAD2 locus) and centromere probes
for chromosome 17 and 18. For all carcinomas 50
nuclei were scored. For heterogeneous tumours, each
cell population that represented at least one-third of the
scored nuclei was considered as a separate fraction.
Statistics
The amount of chromosomal aberrations identified in
the MAP carcinomas and the sporadic carcinomas
was compared using a Mann–Whitney U-test for
independent samples. The analyses were performed
using SPSS 12.0.1.
Results
We studied a series of 26 Dutch carcinomas from
19 biallelic MUTYH mutation carriers. All patients
J Pathol 2008; 216: 25–31 DOI: 10.1002/path
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were diagnosed with >10 colon polyps (median age at
diagnosis 49 years, range 37–77 years), ranging from
10–50 polyps to polyposis with >50–100 polyps. The
carcinomas were predominantly located proximal to
the splenic flexura (15/24 reported) (Table 1). Most
carcinomas were stage II (11/26 or 42%) or stage III
(9/26 or 35%); 68% of the MAP carcinomas contained
a somatic mutation in KRAS (16/17 mutations: c.34
G > T, p.Gly12Cys). A low level of mutations (12%)
in the mutation cluster region of APC was identified
and all carcinomas were microsatellite-stable (data not
shown).
Using SNP arrays suitable for analysis of FFPE
tissue, we were able to study the 26 carcino-
mas for genome-wide copy number abnormalities
and genome-wide copy-neutral loss of heterozygos-
ity (cnLOH) (see Supplementary Table 1, available at:
http://www.interscience.wiley.com/jpages/0022-3417/
suppmat/path.2375.html). Remarkably, this analysis
revealed that 71% of all changes in the MAP car-
cinomas concerned cnLOH, whereas only 29% com-
prised copy number abnormalities (mainly chromo-
somal gains). On average, 5.1 (range 1–14) cnLOH
events were identified per carcinoma. The cnLOH
involved chromosome arms or complete chromo-
somes, but cnLOH of smaller chromosomal regions
was also frequently identified. The regions most com-
monly affected by cnLOH in these tumours were chro-
mosome 17p (57%), 18q (52%) and 15q (52%). Copy-
neutral LOH was also frequently present at chromo-
some 6p (36% of the carcinomas). Lower frequencies
of cnLOH were found for chromosomes 4p (24%), 4q
(29%), 6q (23%), 8p (23%), 10q (24%), 18p (24%),
21q (24%) and 22q (29%) (Figure 1, Supplementary
Table 1).
The MAP carcinomas we studied displayed only a
few copy number abnormalities (on average 2.5, range
0–9). This is in contrast to sporadic colorectal cancer,
where many chromosomal gains and losses are gener-
ally seen [4]. In all patients, the tumours showed five
or fewer changes, except for patients 10 and 11, who
showed eight, nine and six aberrations, respectively.
Gain of chromosome 13q was the most prevalent aber-
ration, seen in 9/26 (35%) carcinomas. Chromosome
11q was amplified in 6/26 (23%) carcinomas. Very
limited physical chromosomal loss occurred in the
MAP carcinomas (Figure 1, Supplementary Table 1).
The absence of gross chromosomal copy number
alterations in our series of MAP carcinomas may
reflect a near-diploid genome. For 23 carcinomas,
we were able to measure ploidy status using flow
cytometry. This analysis concluded that 12/23 (52%)
MAP carcinomas were, indeed, near-diploid (DNA
index, 1.0 ± 0.1). We found three cases with a near-
triploid DNA index (1.5 ± 0.1). In addition, flow
cytometry revealed that seven carcinomas contained
two fractions, each with a different DNA index. In all
seven of these carcinomas, one of the fractions was
near-diploid, while the other fraction had a DNA index
of 1.5 in five of the seven cases. Tumour 10 consisted
of two metastases from the same primary tumour, each
with a different DNA ploidy (Table 1).
We further compared the 19 MAP carcinomas to
the CIN profile of sporadic carcinomas (Figure 1).
For accurate comparison, we used a series of 22
microsatellite-stable sporadic carcinomas with CIN
that were analysed previously using the same SNP
methodology [14] and displayed the typical CIN
profile of sporadic carcinomas [4]. Our comparison
showed that the amount of cnLOH in MAP carcinomas
Figure 1. Chromosomal aberrations in MAP carcinomas versus sporadic CRCs. (A, B) The bars indicate the percentage of the
26 MAP carcinomas and 22 sporadic carcinomas, respectively, that exhibit an event of gain, loss or cnLOH of a chromosome.
This percentage has been calculated for the respective chromosome arms. White bars, chromosomal gains; checked bars, physical
losses of chromosomes; black bars, cnLOH. (C) In this graph the number of cnLOH events versus the number of physical losses
is depicted for the 19 MAP carcinomas for which all genomic information was collected (see Materials and methods) versus
22 sporadic carcinomas. White squares, sporadic carcinoma; black squares, MAP carcinoma. The numbered squares represent
multiple carcinomas that share the same amount of copy-neutral LOH and physical chromosomal loss
J Pathol 2008; 216: 25–31 DOI: 10.1002/path
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is significantly increased compared to sporadic carci-
nomas (p < 0.001). Moreover, the amount of phys-
ical chromosomal losses is significantly (p < 0.001)
decreased compared to sporadic carcinomas
(Figure 1). No differences were seen in the number of
chromosomal gains between MAP carcinomas and the
sporadic carcinomas. The majority of chromosomal
events that are targeted by cnLOH in MAP comprise
physical loss instead of cnLOH in sporadic CRC.
The observed pattern of cnLOH versus physical loss
was confirmed for five representative MAP carcinomas
(t2, t4, t10, t12 and t18) after flow sorting, by FISH
for chromosome 17p and 18q on tumour nuclei, in
combination with LOH analysis using microsatellite
markers. One sporadic carcinoma was included as a
control (Table 2). The SNP arrays revealed that four of
these five MAP carcinomas exhibited cnLOH on chro-
mosome 17p (t2, t4, t12 and t18) and three exhibited
cnLOH on chromosome 18q (t2, t12 and t18). Two
MAP cases and the sporadic CRC displayed physi-
cal loss of chromosomes 17p and/or 18q. All FISH
results that could be obtained were in agreement with
our estimation based on the DNA index in combi-
nation with the SNP array results. For example, in
the tumours with a near-diploid genome content, two
copies of chromosome 17p and 18q were identified by
FISH in case of cnLOH and in tumours with a near-
triploid genome three copies were identified in case
of cnLOH (Figure 2). However, within MAP carci-
noma t18 (DI = 1.4) only half of the tumour nuclei
showed three chromosomal arms of 18q, indicating
intratumour heterogeneity. The sporadic carcinoma
also harboured two cell populations, with different
copy numbers on chromosomal arms 17p and 18q.
LOH was unambiguously identified for all informative
microsatellite markers in all these cases, also in the
cases with cnLOH in the context of a triploid genome
content (implying the presence of three copies of a
single allele), except for D17S921 in the diploid frac-
tion of MAP carcinoma t4, which showed retention.
These results are concordant with the results obtained
with the SNP array analysis.
Discussion
Three studies have reported on the genetic profiles
of MAP tumours [3,9,10]. Unfortunately, the results
of these studies are seemingly contradictory. Copy
number changes in adenomas have been reported, as
well as near-diploidy in adenomas and carcinomas. In
order to gain more insight into the genetic instabil-
ity in MAP tumours we studied a series of 26 MAP
carcinomas using SNP array analysis in FFPE tissue.
In contrast to sporadic colorectal cancer, copy-neutral
LOH (cnLOH) appears to be a prevalent characteristic
of MAP carcinomas, while only a few copy number
abnormalities were identified (4). However, the per-
centage of chromosomal gains (24%) is comparable to
sporadic colorectal cancers with CIN. Such a genomic
Figure 2. Microsatellite LOH analysis and fluorescent in situ
hybridization on chromosome 18q21.1 after flow sorting of
MAP carcinoma t12 (see also Table 2). (A) FISH showed
two centromeric chromosome 18 signals (red) and two
signals on 18q21.1 (green) for MAP carcinoma t12 (DNA
index = 1.0). (B) Microsatellite LOH analysis (D18S877) on
the flow-sorted MAP carcinoma t12 is shown: (upper panel)
vimentin-positive, keratin-negative (normal) fraction; (lower
panel) the vimentin-negative, keratin-positive (tumour) fraction.
Unambiguous LOH is seen of allele 1 in the tumour. In
combination with the FISH result shown in (A), copy-neutral
LOH for chromosome 18q can be concluded
tumour profile of colon cancer has, to our knowledge,
not been described before. With the recent availabil-
ity of SNP arrays, more detailed information can be
obtained on genome-wide cnLOH and several studies
now report on cnLOH in cancers [19,20]. However,
no study has described cnLOH to the extent seen in
our series of MAP carcinomas.
The relative absence of chromosomal loss in
our series of MAP carcinomas indeed reflects a
J Pathol 2008; 216: 25–31 DOI: 10.1002/path
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Table 2. Confirmation of copy-neutral LOH by FISH and microsatellite analysis





Chr. 17 D17S938 D17S921 FISH 17p
SNP array
Chr. 18 D18S877 D18S65 D18S460 D18S1137
FISH
18q
t2 K+ Dip 1.1 17p cnLOH∗ LOH LOH na 18pq cnLOH∗ LOH na na LOH na
t2 K+ An 1.4 17p cnLOH∗ LOH LOH 3/3 18pq cnLOH∗ LOH na LOH na na
t4 K+ Dip 1 17pq cnLOH∗‡ U R 2/2 18pq phLoss∗ na LOH LOH U 2/2†
t4 K+ An 1.5 17pq cnLOH∗‡ U LOH 3/3 18pq phLoss∗ LOH LOH LOH U
t10 K+ 1.5 17p phLoss U U na 18q phLoss LOH LOH U na na
t12 K+ 1 17p cnLOH LOH LOH 2/2 18pq cnLOH LOH na LOH na 2/2
t18 K+ 1.4 17p cnLOH U LOH 3/3 18pq cnLOH LOH LOH U LOH 2/2, 3/3
sp1 K+ 1 17p phLoss U LOH 2/1, 1/1 18pq phLoss LOH na U na 2/2, 1/1
Microsatellite LOH analysis and FISH after flow sorting of five MAP carcinomas and one sporadic carcinoma was concordant with our estimation
based on the DNA index and SNP array results. Chr., chromosome, K+, keratin-positive, vimentin-negative (tumour) fraction after flow sorting;
Dip, diploid fraction; An, aneuploid fraction; PhLoss, physical loss; cnLOH, copy-neutral LOH. For the LOH analysis: LOH, loss of heterozygosity;
R, retention of both alleles; U, uninformative; na, could not be analysed for technical reasons. For the FISH results, the first number indicates the
amount of centromeres and the second number indicates the amount of chromosomal arms 17p and 18q, respectively.
∗ Assay performed on unsorted tumour material.
† The FISH for t4 on chromosome 18q was, due to technical limitations, not performed on flow-sorted tumour nuclei, but on a tissue slide.
‡ cnLOH of complete chromosome 17.
near-diploid genome. Ploidy analysis using flow
cytometry concluded that 12/23 (52%) MAP carcino-
mas analysed were near-diploid (DNA index, 1.0 ±
0.1). Lipton et al [3] found a near-diploid genome in
12/13 MAP carcinomas tested, with one carcinoma
showing a polyploid status. We found three cases with
a near-triploid DNA index (1.5 ± 0.1). In addition,
flow cytometry revealed that seven carcinomas con-
tained two fractions, each with a different DNA index.
In all seven of these carcinomas, one of the frac-
tions was near-diploid, while the other fraction had
a DNA index of 1.5 in five of the seven cases. Inter-
estingly, the distribution of the DNA ploidy of the
MAP carcinomas is very different from sporadic col-
orectal cancers, which are primarily highly aneuploid.
A DNA index of ∼1.5 is uncommon in sporadic CRC,
although near-triploidy has been described for sporadic
CRC [21,22]. We confirmed the scoring of our SNP
results in a purified set of tumours by a combination
of FISH and LOH analysis, using polymorphic chro-
mosomal microsatellite markers on chromosomes 17p
and 18q. In the tumours with a near-diploid genome
content, two copies of chromosome 17p and 18q were
identified by FISH in case of cnLOH, and in tumours
with a near-triploid genome three copies of a single
allele were identified in case of cnLOH. Possible lim-
ited sensitivity in detecting copy number aberrations,
especially in heterogeneous tumours, is unlikely in
view of the FACS sorting in combination with FISH
and conventional LOH analysis. Moreover, the results
we obtained on the sporadic CRC are reassuring in this
respect, since these are analysed and scored in exactly
the same way as the MAP tumours.
Recently, we studied by SNP analysis of FFPE
tissue a series of microsatellite-unstable sporadic and
Lynch syndrome colon carcinomas, often with a near-
diploid DNA content. All MSI-H carcinomas showed
few chromosomal aberrations. CnLOH was infrequent
in these tumours and usually confined to the locus
harbouring a pathogenic mutation in MLH1, MSH2
or PMS2 [23]. These results further underline the
uniqueness of the phenotype of the MAP carcinomas.
Interestingly, the cnLOH events identified in the
MAP carcinomas frequently involve the same chromo-
somes affected by physical loss in sporadic colorectal
cancer, indicating that the same tumorigenic pathway
may be involved in tumour initiation and progression.
For example, chromosomes 17p and 18q are com-
monly affected by physical loss in sporadic colorectal
cancer, whereas cnLOH is identified primarily on these
chromosome arms in MAP carcinomas. How frequent
the genes that are targeted in sporadic colorectal can-
cer on these respective chromosomes, e.g. p53 and the
SMAD genes, are targeted in MAP carcinomas remains
elusive. Lipton et al found only three p53 (located
on chromosome 17) somatic mutations in 14 MAP
carcinomas analysed, although immunohistochemistry
for p53 over-expression (indicative for mutation) was
positive in four tumours that were negative for muta-
tion testing. SMAD4 mutations on 18q were not found
in the MAP carcinomas analysed by Lipton et al [3],
although analysis of two chromosome 18q microsatel-
lite markers showed a high frequency of 18q LOH in
7/14 cases analysed.
Our studies also indicate that chromosome 15q is
often targeted by cnLOH in the MAP carcinomas.
Physical loss of this chromosome has been associated
with distant metastasis of sporadic colorectal cancer
[4].
Copy-neutral LOH can arise via mitotic recombi-
nation, non-disjunction, or deletion and reduplication
events. In our series, we identified cnLOH on whole
chromosomes and on parts of chromosomes. The high
prevalence of cnLOH in MAP carcinomas suggests
a relationship between mitotic recombination and the
MUTYH deficiency. However, it is difficult to explain
why MAP cancers show few copy number aberrations.
First, the occurrence of copy-neutral LOH might be
J Pathol 2008; 216: 25–31 DOI: 10.1002/path
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directly linked to BER malfunctioning. Secondly, in
parallel to a mismatch repair deficiency, the mutational
burden might be relatively high due to the BER defect,
favouring mitotic recombination but not physical loss.
Therefore, further research into this possible relation
is important.
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Abstract
Many hereditary non-polyposis colorectal cancers (CRCs) cannot be explained by Lynch syn-
drome. Other high penetrance genetic risk factors are likely to play a role in these mismatch 
repair (MMR)-proficient CRC families. Because genomic profiles of CRC tend to vary with 
CRC susceptibility syndromes, our aim was to analyze the genomic profile of MMR-proficient 
familial CRC to obtain insight into the biological basis of MMR-proficient familial CRC.
We studied 30 MMR-proficient familial colorectal carcinomas, from 15 families, for genomic 
aberrations, including gains, physical losses, and copy-neutral LOH (cnLOH) using SNP array 
comparative genomic hybridization. In addition, we performed somatic mutation analysis for 
KRAS, BRAF, PIK3CA, and GNAS. 
The frequency of 20q gain (77%) is remarkably increased when compared to sporadic CRC, 
suggesting that 20q gain is involved in tumor progression of familial CRC. There is also a 
significant increase in the frequency of cnLOH and, as a consequence, a reduced frequency 
of physical loss compared to sporadic CRC. The most frequent aberrations observed included 
gains of 7p, 7q, 8q, 13q, 20p, and 20q, and physical losses of 17p, 18p, and 18q. Most of 
these changes are also observed in sporadic CRC. Mutations in KRAS were identified in 26% 
of the MMR-proficient CRCs and mutations in BRAF were identified in 12%. No mutations 
were identified in PIK3CA or the chromosome 20 candidate gene GNAS. 
In conclusion, while the global patterns of MMR-proficient familial CRC resemble sporadic 
CRC, the chromosomal instability patterns exhibit a distinct pattern of aberrations with incre-




Clinical criteria are used for the identification of Lynch syndrome patients. These so-called 
Amsterdam Criteria and Bethesda criteria include type of cancer, family history, and age at 
onset of disease.[1,2] Analysis of families that fulfill the strict Amsterdam Criteria I (AC-I) has 
proved to be successful in identifying germ-line mutations in mismatch repair (MMR) genes 
to be responsible for the increased CRC susceptibility in Lynch syndrome families. Mutations 
in MMR genes lead to deficient mismatch repair, which is reflected by microsatellite instability 
in tumors from Lynch syndrome patients. However, no mutations are identified in the MMR 
genes MLH1 and MSH2 in over half of the patients that meet the AC-I, suggesting that Lynch 
syndrome cannot explain all AC-I positive families.[3] Some of these AC-I positive families 
might have mutations in MSH6, PMS2, or undetected mutations in MLH1 or MSH2; however, 
this will not explain all AC-1 positive families. Similarly, approximately 40% of families that fulfill 
the less stringent Amsterdam Criteria II do not display microsatellite instability, a characteristic 
of MMR deficiency, in their tumors.[4] Moreover, it has been estimated that approximately 32% 
of the excess CRC risk that is associated with a positive family history of CRC remains unex-
plained by known genes.[5] In these families, it is likely that other high penetrance genetic risk 
factors play a role. Analysis of the incidence of cancer in these families showed that they have 
an increased risk of CRC compared to the general population, albeit to a lesser extent than 
Lynch syndrome families.[5-7] Lindor and colleagues observed that MMR-proficient AC-I posi-
tive families have an increased risk for CRC but not for other cancers. Furthermore, members 
of MMR-proficient AC-I positive families tend to develop CRC at an older age than individuals 
in MMR-deficient AC-I positive families.[6] Aaltonen et al. estimated that first-degree relatives 
(FDRs) of probands with microsatellite stable cancer had a 1.3-fold increase in CRC risk.[5] In 
addition, a recent study reported that FDRs of CRC patients with microsatellite stable tumors 
had an increased risk for CRC and observed a strong correlation between the risk of CRC and 
the number of affected FDRs.[7] Linkage analysis in CRC pedigrees and affected siblings has 
been performed to identify novel high penetrance risk factors. Several chromosomal regions 
have been linked to colorectal cancer susceptibility, including 3q21-q24, 7q31, 9q22.2-31.2, 
11q23.2, 11q13.4, 14q24.2, and 22q12.1.[8-15] However, none of these studies have led to 
the identification of a novel CRC susceptibility gene yet. 
Target genes for somatic mutations tend to vary by cancer type. In CRC, p.V600E (c.1199T>A) 
mutations in BRAF are predominantly seen in tumors that have sporadic promoter hyperme-
thylation of MLH1.[16] BRAF mutations are, on the other hand, rare in the tumors of Lynch 
syndrome patients. Similarly, in MUTYH-associated polyposis G>T transversions are ob-
served, with GAA>TAA mutations in APC and specific GGT>TGT mutations in codon 12 of 
KRAS (c.34 G>T, p.Gly12Cys). Tumors in Lynch syndrome patients, in contrast, often carry 
mutations in codon 13 of KRAS (c.38 G>A, p.Gly13Asp).[17,18] In addition to somatic mu-
tations, distinct patterns of genetic instability are associated with specific CRC syndromes. 
Lynch syndrome carcinomas are characterized by microsatellite instability and copy-neutral 
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loss of heterozygosity (cnLOH) at the locus of the mutated mismatch repair gene, and rarely 
have large chromosomal aberrations.[19,20] In contrast, at the genomic level, carcinomas of 
MUTYH-associated polyposis patients are characterized by a high level of cnLOH throughout 
the genome. In addition, the cancer cells are generally near-diploid or near-triploid.[21] Simi-
larly, characteristic genomic aberrations are observed in breast cancers from patients with a 
germ-line mutation in BRCA1 or, to a lesser extent, BRCA2.[22-24] Therefore, genomic profi-
ling of familial CRCs may provide insight into the biological basis of CRC in these families.
We studied the pattern of genomic aberrations in carcinomas from MMR-proficient familial 
CRC patients. Our goal was to generate a profile of genomic aberrations in MMR-proficient 
familial CRC that might provide insight into the biological basis of the increased CRC suscep-
tibility of these families. 
Material and Methods
Tumor samples
Thirty MMR-proficient familial colorectal carcinomas and corresponding histologically normal 
tissues were selected (Table 1). The formalin-fixed paraffin-embedded (FFPE) tumors origi-
nate from fifteen families. All families have a positive history of CRC, with either one or two 
affected generations. Two families fulfill the AC-I and in the other families, at least two family 
members are affected with CRC. Two tumors from each of the fifteen families were analyzed. 
Tumor samples were enriched for tumor tissue by taking 0.6 mm tissue punches from the 
tumor field using a tissue microarrayer (Beecher Instruments, Sun Prairie, WI, USA), guided 
by a haematoxylin and eosin (H&E)-stained slide. DNA was isolated using a method, descri-
bed previously; subsequently, DNA was cleaned using the Genomic Wizard kit (Promega, 
Leiden, the Netherlands).[4] DNA concentrations were measured using the picogreen method 
(Invitrogen-Molecular Probes, Breda, the Netherlands).
Tumors were tested for microsatellite instability using the marker set recommended by the 
National Cancer Institute Workshop on Microsatellite Instability, supplemented with three ad-
ditional mononucleotide repeat markers (BAT40, MSH3, and MSH6), as described previously.
[4,25] All of the tumors were microsatellite-stable (MSS). 
The study was approved by the local Medical Ethical Committee (protocol P01.019); sam-
ples were handled according to the medical ethical guidelines described in the Code Proper 
Secondary Use of Human Tissue established by the Dutch Federation of Medical Sciences.1
SNP array profiling
We analyzed thirty carcinomas from fifteen CRC families for genomic aberrations, including 
gains, physical losses and cnLOH. We used Illumina Beadarrays in combination with the link-









GoldenGate assay was performed at the Leiden Genome Technology Center2 following the
manufacturer’s instructions, with minor adjustments: 0.5 μg input DNA was used for multi-use 
activation and resuspended in 60 μl RS1.[26] Genotypes were extracted using BeadStudio 
(V3.2, Illumina, San Diego, CA, USA). Genomic profiles were generated from the tumors and 
their corresponding normal tissue using the “Beadarray SNP” package, as described previ-
ously.[19,21,27] 
The nature of the tissue, archival FFPE tissue, did not allow us to study germ line copy num-
2 http://www.lgtc.nl
Family Colorectal cancersa Other cancersb Affected with CRC Generationsc AC-Id Relationshipe
F1 C46, C55, C56, C69 / 4 of 10 sibs 1 - FDR (sibs)
F2 C34, C50, C60 / 3 of 14 2 - TDR
F3 C48, C53 Thyroid55 2 of 4 sibs 1 - FDR (sibs)
F4 C51, C60, C76, C77, C83 / 5 of 8 2 - FDR
F5 C40, C56 + unknown Unknown unknown unknown unknown unknown
F6
C56, C58, C63, C72, C73, 
C76f
Breast, Ovary67
5 of 11 sibs 1 - FDR (sibs)
F7
C48, C52, C54, C55, C55, 
C60, C60, C66, C68 
Lung65, Breast52, 
Breast55, Breast49 9 of 24 2 +
Fourth-degree 
relatives
F8 C52, C61, C73 / 3 of 10 2 - FDR (sibs)
F9 C51, C53 / 2 of 7 sibs 1 - FDR (sibs)
F10 C53, C54, C63, C65 / 4 of 5 sibs 1 - FDR (sibs)
F11 C49, C51, C76 / 3 of 4 2 + FDR (sibs)
F12 C50, C71 Pancreas65 2 of 6 sibs 1 - FDR (sibs)
F13 C42, C42, C60, C64 / 4 of 15 2 - FDR (sibs)
F14 C28, C36, C50, C56 Thyroid58 4 of 14 2 - TDR
F15 C52, C65, C66, C78
Leukemia54, Eusop/
Gastric68, Gastric45 4 of 12 2 - TDR
Table 1. Characteristics of the cohort of MMR-proficient CRC families.
a Colorectal cancer cases in the families, including the corresponding age at diagnosis for each CRC; b 
Other cancers diagnosed in the families, including the corresponding age at diagnosis for each tumor; 
c The number of generations affected with CRC in the family; d Fulfillment of the Amsterdam Criteria I; e 
The relationship of the two family members from which the tumors were analyzed in this study. FDR, first-
degree relative; SDR, second-degree relative; and TDR, third-degree relative; f One family member had 
two colorectal cancers (C56 and C76).
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ber changes. Such small inherited germ line deletions and amplifications might be the under-
lying cause of the inherited risk for CRC in these patients. SNP arrays with a higher resolution 
should be used to study these types of copy number changes; however, these arrays are not 
yet suitable for DNA isolated from FFPE tissue.
Homozygosity mapping
To study the possibility of a recessively inherited risk locus in MMR-proficient familial CRC 
patients, we analyzed the normal tissue DNA for regions of homozygosity. For each SNP 
the chance of homozygosity was calculated as 1 minus the frequency of the heterozygote 
genotype. These calculations used the frequency of the heterozygote genotype found in the 
Hapmap project for the CEU population.[28] A measure for the extent of homozygosity was 
derived by multiplying the chances for homozygosity for each SNP in a consecutive stretch of 
homozygous SNPs. The extent of homozygosity along the chromosomes was visualized as 
a weighted grey value (darker grey corresponds with an increasing extent of homozygosity), 
with a cut-off of 10-3, representing stretches of at least ten homozygous SNPs with minor al-
lele frequencies of approximately 0.5. 
Somatic mutation analysis
Tumor samples were screened for mutations in KRAS exons 1 and 2, BRAF exon 15, and 
PIK3CA exons 9 and 20 by Sanger sequence analysis. PCR was performed on DNA extracted 
from FFPE material using iQ supermix (Bio-Rad Laboratories, Veenendaal, the Netherlands) 
using standard conditions.[29] Sequence analysis was performed at the Leiden Genome 
Technology Center. 
Tumor samples were analyzed for the hotspot mutation in GNAS (c.601C>T, p.Arg201Cys) 
using the Taqman SNP Genotyping assay, following the manufacturer’s protocol (Applied Bio-
systems), in a LightCycler 480 (Roche Applied Science, Almere, The Netherlands). 
Some DNA fragments isolated from the FFPE tissues failed to amplify because of the limited 
fragment size that can be amplified from FFPE tissue. Details of the reaction conditions are 
available upon request. Primer sequences are provided in supplementary table 1.
Mutation frequencies were compared with the mutation data obtained from the Sanger Insti-
tute COSMIC (Catalogue of Somatic Mutations in Cancer) database3.[30]
Results and discussion
We analyzed 30 colorectal carcinomas from 15 families with a history of CRC, using Illumina 
6K Beadarrays, to study the genomic profile of MMR-proficient familial CRC. Characteristics 
of the studied cohort are detailed in Table 1. The studied families were predominantly affected 









mia, gastric cancer, thyroid, breast, ovarian, lung, and pancreatic cancers.
The mean age at diagnosis of CRC was 56.4 years (range 28-77). All carcinomas had a mi-
crosatellite stable (MSS) phenotype. The majority of CRCs were Dukes B (14/28) or C (8/28) 
and nearly all were left-sided (25/29). The tumor location varies in different CRC syndromes. 
Seventy percent of the tumors of Lynch syndrome patients are located in the right side of the 
colon, whereas almost all familial adenomatous polyposis (FAP) cancers develop in the left 
side of the colon.[31-33] In addition, carcinomas from patients with MUTYH-associated poly-
posis are predominantly localized in the proximal (right) colon.[34] Familial MSS tumors have 
been reported to be predominantly located on the left side of the colon, which is consistent 
with the distribution we observed in our study.[35] 
We analyzed the 30 MMR-proficient familial colorectal carcinomas for genome-wide chromo-
somal gains, physical losses, and cnLOH.[21] To study possible family specific tumor phe-
notypes, two carcinomas from each family were analyzed. We observed between 0 and 23 
genomic aberrations in the MMR-proficient familial CRCs, with a mean of 11.4 aberrations 
per carcinoma. In addition, we observed a gradual increase in the number of aberrations per 
tumor from Dukes stage A to stage D. However, we did not detect a significant correlation 
between the number of aberrations and the Dukes stage of the tumor. This might be explained 
by the low number of Dukes stages A and D carcinomas in our series. 
In a previous study, Rahman et al. reported an average of 5.9 copy number aberrations per 
MMR-proficient familial CRC, using comparative genomic hybridization. In addition, half of the 
MMR-proficient familial CRCs displayed less than 5 aberrations.[36]  In order to compare our 
results with this earlier study, we counted the number of copy number aberrations (excluding 
cnLOH) in our series. In our series of MMR-proficient familial CRCs, there was on average 
7.5 copy number aberrations per carcinoma, which is increased compared to the study of 
Rahman et al. We observed fewer than 5 copy number aberrations in 30% (9/30) of the CRCs. 
The most frequent aberrations, which we observed in at least 30% of the MMR-proficient 
familial CRCs, included gains of chromosome 7p (40%), 7q (33%), 8q (30%), 13q (57%), 20p 
(37%) and 20q (77%); and physical losses of 17p (37%), 18p (37%), and 18q (53%) (Figure 
1). The observed aberrations that were most frequent in the MMR-proficient familial CRCs are 
well-known colorectal cancer aberrations, which are typically observed in sporadic colorectal 
cancers.[37,38] 
We compared the profile of aberrations in our MMR-proficient familial CRCs series to that of 
sporadic CRC, MAP carcinomas, and Lynch carcinomas series that we analyzed previously, 
using the same methodology.[19,21,38] The frequencies of gains at 8q and 13q, physical 
losses at 17p and chromosome 18, and cnLOH at 5q are similar in MMR-proficient familial 
CRC and sporadic CRC. Gains of chromosomes 7 and 20 were observed more frequently 
in MMR-proficient familial CRC than in sporadic CRC. On the contrary, physical loss of 8p is 
observed less frequently in the familial carcinomas. cnLOH of 8p and 17p is observed more 
frequently in familial CRC than in sporadic CRC. We observed many aberrations that occur 
in only 10% to 20% of the familial tumors, suggesting heterogeneity among MMR-proficient 
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familial CRC (Figure 1).
The observed frequency of 20q gain (77%) is remarkably high in the series of MMR-proficient 
familial CRC compared to sporadic CRC. Based on the literature and our work, a frequency 
of 30-50% has been reported for 20q gain in sporadic CRC.[37,38] When compared with the 
20q gain frequency in a series of sporadic CRCs (36%), which was previously analyzed using 
the same methodology, we found that the frequency of 20q gain is significantly increased in 
MMR-proficient familial CRC (p=3.4 x 10-3).[38] In addition, we extended the comparison to 
a previously reported large series of sporadic CRCs, in which both tumor and paired normal 
tissue were analyzed by SNP array CGH. [39] While the frequency of 20q gain in this large 
Japanese series of sporadic CRC is higher (56%), there is still a significant increase of 20q 
gain in familial CRC (p=4.7 x 10-2).[39] Furthermore, our results are in line with a study of 
Finnish colorectal cancers, which reported an 85% frequency of 20q gain in MMR-proficient 
familial CRCs using CGH.[40] In addition, a 70% frequency of 20q gain was reported in a 
group of early-onset MSS CRC patients.[41] This high frequency of 20q gain suggests that 
20q is involved in tumor progression, particularly in MMR-proficient familial CRC. Several ge-
nes on 20q, including AURKA, TH1L, ADRM1, and TCFL1, have already been described to be 
differentially expressed in tumors with 20q gain when compared to tumors without 20q gain.
[42] Analysis of the coding sequence of eleven CRCs by Sjöblom et al. identified three acti-
vating missense mutations in GNAS, which is located on 20q13.32.[43] Therefore, we analy-
zed our cohort of MMR-proficient familial CRC for the most frequent mutation (p.Arg201Cys, 
c.601C>T) in GNAS; however, we did not identify any mutation.
Unlike sporadic CRCs, the MMR-proficient familial CRCs displayed increased levels of cn-
LOH genome-wide and, as a consequence, reduced physical loss. In the MMR-proficient 
familial CRCs, 37% of the aberrations were gains, 31% were physical losses, and 32% were 
cnLOH. This distribution is different from sporadic CRC, where 31% of the aberrations are 
gains, 55% are physical losses, and only 14% are cnLOH.[38] The percentage of cnLOH is 
significantly increased in MMR-proficient familial CRC over that of sporadic CRC (p=6.1 x 
10-3). Additionally, the percentage of physical losses is significantly reduced in familial CRC 
compared to sporadic CRC (p=0.034).
Interestingly, we have previously shown that cnLOH is associated with tumor types that are 
deficient in DNA repair. cnLOH is the most frequent type of aberration (71%) in MUTYH-asso-
ciated polyposis (MAP) colorectal carcinomas, which is caused by base excision repair defici-
ency.[21] Furthermore, in Lynch syndrome carcinomas, which are caused by DNA mismatch 
repair deficiency, cnLOH is predominantly observed at the locus of the mutated MMR gene.
[19] While the MMR-proficient familial CRCs profile does not resemble the MAP carcinoma 
nor the Lynch syndrome carcinoma profile, the increased level of cnLOH suggests that an 









Figure 1. Chromosomal aberrations in MMR-proficient familial colorectal carcinomas
(A, B) The bars indicate the percentage of the 30 mismatch repair proficient familial colorectal carcinomas 
and 22 sporadic carcinomas that exhibit an event of gain, loss or cnLOH of a chromosome. This percen-
tage has been calculated for the respective chromosome arms. White bars, chromosomal gains; checked 
bars, physical losses of chromosomes; black bars, cnLOH. Panel B shows the results from a previous 
study of Lips et al.[38]
In addition to comparing the MMR-proficient familial CRC profile with the sporadic CRC pro-
file, we compared the genomic profiles of tumors within one family to identify possible family-
specific genomic profiles. Aberrations that were most frequently shared by tumors from family 
members included the common aberrations at 13q, 17p, 18q, and 20q. There was a high 
incidence of 20q gain, which was shared by both tumors in over half of the families. Less 
frequently shared affected regions include 5q, 8p, 8q, 14q, and 15q. No distinctive profile of 
aberrations was observed in any of the families. The tumor phenotypes of all families roughly 
fit the overall genomic profile that was observed for MMR-proficient familial CRCs. 
In two families, cnLOH of 8p was shared (F3 and F7) and in one family physical loss of part 
of 8p was shared (F14) by the tumors. In three families (F3, F7, and F13) aberrations at 8q 
were shared, however, gains, physical losses, as well as cnLOH were observed in these 
tumors. Three families (F1, F7, and F12) shared physical loss or cnLOH at the region on 5q 
that encompasses the APC gene. In addition, both tumors that were analyzed from three fa-
milies (F6, F14, and F15) exhibited physical loss or cnLOH of 14q. Finally, chromosome 15q 
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displayed aberrations in both tumors from three families (F6, F11, and F15); however, gains, 
physical losses, and cnLOH were observed. 
Homozygosity analysis
We searched normal tissue for regions of homozygosity that are shared within a family or 
between multiple individuals across families. These homozygous regions might suggest the 
presence of a recessively inherited gene, similar to MUTYH. In six of our fifteen families only 
one generation was affected with CRC, which suggests a recessive mode of inheritance. 
Moreover, in a previous study, we observed a homozygous region in MAP patients that had 
a shared haplotype that encompassed the MUTYH gene (results not shown).[21] In the cur-
rent study, we did not identify any shared homozygous regions in the MMR-proficient familial 
CRCs, with the exception of a small region on chromosome 21q22.13. However, we found 
that this region was often homozygous in tumors from MAP and Lynch syndrome patients, 
suggesting that this region of homozygosity is not specific for MMR-proficient familial CRC.
[19] 
Somatic mutation analysis
We also studied the MMR-proficient familial CRCs for somatic mutations in KRAS, BRAF, 
and PIK3CA. Mutations in KRAS were identified in 5 of 19 tumors (26%). Three mutations 
were identified in codon 12 (one c.34G>T, p.Gly12Cys; and two c.35G>A, p.Gly12Asp), one 
in codon 13 (c.38G>A, p.Gly13Asp), and one in codon 63 (c.187G>A, p.Glu63Lys) of the 
KRAS gene. In BRAF, we detected mutations in codon 600 in 3 of the 26 tumors (12%) ana-
lyzed. Two of these mutations were V600E transversions (c.1199T>A, p.Val600Glu) and the 
third was a V600A transition (c.1199T>C, p.Val600Ala). None of the tumors carried mutations 
in both KRAS and BRAF, which has been observed in previous studies also.[16,36,44] The 
frequency of mutations in KRAS is lower and in BRAF is slightly increased compared to a 
previous study of MMR-proficient familial CRC (40% and 4%, respectively).[44] The frequency 
for both KRAS and BRAF mutations is similar to the reported mutation frequency in sporadic 
CRC (COSMIC, 32% and 12%, respectively).[30] We also screened exons 9 and 20 of PIK-
3CA for mutations; however, we did not detect a mutation in any of the 16 tumors that could 
be analyzed. These results are consistent with a previous report, in which PIK3CA mutations 
were found in only 4% of MSS familial CRCs.[45] The reported PIK3CA mutation frequency in 
sporadic CRC was higher (between 11% (COSMIC) and 32%).[30,46] 
In conclusion, we show that the chromosomal instability patterns of MMR-proficient familial 
CRC are distinct from sporadic CRC, with significantly increased levels of 20q gain and geno-
me-wide cnLOH. However, the overall aberration pattern resembles sporadic CRC. 
The increased level of cnLOH in familial MMR-proficient CRC suggests a weak DNA repair 
defect. The high frequency of 20q gain suggests that there is an important role for this chro-








ver, no gene on 20q has been reported to be mutated in familial CRC.[40] Further evaluation 
of 20q will be valuable and could include mutation analysis of candidate genes or next-gene-
ration sequencing of the entire region. 
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Abstract
Chromosomal aberrations are a common characteristic of
cancer and are associated with copy number abnormalities
and loss of heterozygosity (LOH). Tumor heterogeneity, low
tumor cell percentage, and lack of knowledge of the DNA
content impair the identification of these alterations espe-
cially in aneuploid tumors. To accurately detect allelic
changes in carcinomas, we combined flow-sorting and single
nucleotide polymorphism arrays. Cells derived from archival
cervical and colon cancers were flow-sorted based on
differential vimentin and keratin expression and DNA content
and analyzed on single nucleotide polymorphism arrays. A
new algorithm, the lesser allele intensity ratio, was used to
generate a molecular measure of chromosomal aberrations
for each case. Flow-sorting significantly improved the detec-
tion of copy number abnormalities; 31.8% showed an increase
in amplitude and 23.2% were missed in the unsorted fraction,
whereas 15.9% were detected but interpreted differently.
Integration of the DNA index in the analysis enabled the
identification of the allelic state of chromosomal aberrations,
such as LOH ([A]), copy-neutral LOH ([AA]), balanced
amplifications ([AABB]), and allelic imbalances ([AAB] or
[AAAB], etc.). Chromosomal segments were sharply defined.
Fluorescence in situ hybridization copy numbers, as well as
the high similarity between the DNA index and the allelic state
index, which is the average of the allelic states across the
genome, validated the method. This new approach provides
an individual molecular measure of chromosomal aberrations
and will likely have repercussions for preoperative molecular
staging, classification, and prognostic profiling of tumors,
particularly for heterogeneous aneuploid tumors, and allows
the study of the underlying molecular genetic mechanisms and
clonal evolution of tumor subpopulations. [Cancer Res
2008;68(24):10333–40]
Introduction
Chromosomal aberrations are common characteristics of human
cancer and arise early during tumorigenesis. These aberrations are
believed to be one of the driving forces behind tumor progression
(1, 2). The process results in aneuploid cancer cells, which can be
observed by genomic copy number abnormalities (CNA), allelic
imbalances, loss of heterozygosity (LOH), and abnormal DNA
content. Recently, a meta-analysis showed that these aberrations
are associated with a worse prognosis in colorectal cancer (3).
CNAs can be detected by array CGH (aCGH) or single nucleotide
polymorphism (SNP) arrays (4–6). SNP arrays are preferred over
aCGH because they additionally identify copy-neutral LOH (cnLOH;
ref. 7), balanced CNAs (equal multiplication of both alleles), and
allelic imbalances in which one allele is duplicated or amplified.
For example, Kloth and colleagues showed that 75% of the LOH
events found by SNP array were unnoticed using aCGH on the
same cohort of cervical cancer cell lines (8). Furthermore, we and
others have shown that reliable genotypes and profiles of CNAs and
LOH can be generated from the fragmented DNA derived from
formalin-fixed, paraffin-embedded (FFPE) cancer tissue using SNP
arrays (5, 9–11).
The generated data is usually interpreted relative to the average
DNA content of a tumor. For that reason, only relative copy
numbers can be detected. Because tumors often show extensive
genomic CNAs with almost doubled, near-tetraploid genomes (12),
the extent of CNAs could be misinterpreted. For example, without
knowledge of the DNA index, the CNA profiles from near-tetraploid
tumors can be difficult to distinguish from those of near-diploid
tumors. Consequently, only five or more copies will be interpreted
as a gain, four copies will be misinterpreted as neutral and two or
three copies as a loss. To improve copy number analysis, use of the
DNA index has been suggested (13). Yamamoto and colleagues (14)
analyzed cell lines and acute leukemia with limited CNAs and a
mostly hyperdiploid DNA content (15). A recent study from Lyng
and colleagues clearly showed the necessity for measuring the DNA
index for calculation of absolute copy numbers from aCGH data
(16). Also, varying proportions of normal cells (inflammatory and
stromal cells) impair the detection of genomic and genetic
alterations in tumor samples. For example, for the detection of
LOH, samples should contain at least 50% tumor cells (17–19).
Furthermore, solid tumors often contain subpopulations of tumor
cells that harbor different chromosomal aberrations and may differ
in their DNA index. Microdissection, either manually or by laser
capture, is only a partial solution to the sampling problem in solid
tumors because it is not possible to select tumor cells based on
ploidy. Also, microdissection has a low cell yield and is
prohibitively time-consuming when the neoplastic cells are highly
intermingled with normal cells.
Fluorescence-activated cell sorting has proven to be an excellent
tool for the purification of cell subpopulations from human tumors
(20–23). Furthermore, since the development of robust dissociation
methods in the early 1980s, flow cytometry has been widely used to
determine the DNA content of solid tumors. Although these studies
initially required fresh or frozen tumor samples, we developed a
technique that markedly improved the yield and resolution of flow
Note: Supplementary data for this article are available at Cancer Research Online
(http://cancerres.aacrjournals.org/).
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cytometric DNA content measurements of FFPE samples (24). This
technique allows simultaneous flow-sorting of tumor and stromal
cells based on differential expression of vimentin and keratin, as
well as DNA content, and was successfully applied to study cervical,
gastric, and colon cancers (25–27).
In the present study, we show that the combined use of
multiparameter DNA flow-sorting and SNP array analysis signifi-
cantly improves the detection of CNAs in archival FFPE cervical
and colon cancers. For analysis, we used a novel algorithm, lesser
allele intensity ratio (LAIR), which is incorporated in beadarraySNP
(5). LAIR integrates the DNA index in the analysis and defines the
allelic state of CNAs such as LOH (e.g., [A], cnLOH [AA], amplified
LOH [AAA]), balanced amplifications (e.g., [AABB], [AAABBB]), and
allelic imbalances (e.g., [AAB], [AAAB]). It provides a molecular
measure of chromosomal aberrations which might serve as a
clinical marker (28), and can be useful in preoperative molecular
staging of rectal cancer (29).
Materials and Methods
Tumor dissociation. Cervical and colorectal tumors were obtained
from the FFPE tissue bank of the Department of Pathology, Leiden
University Medical Center (LUMC), Leiden, the Netherlands. Samples
were handled according to the medical ethical guidelines described in
the Code Proper Secondary Use of Human Tissue established by the
Dutch Federation of Medical Sciences.1 Paraffin sections taken from all
samples were H&E-stained and reviewed by two pathologists (G.J. Fleuren
and H. Morreau). Cell suspensions were prepared as described (24) from
either 6 to 10 60-Am sections or 2 4-mm tissue punches from each
paraffin block.
Antibodies. Clone MNF116 [anti–keratin 5, 6, 8, and 17, IgG1 (DAKO)]
was used at working concentrations of 2 Ag/mL for 1  106 cells and
10 Ag/mL for 5  106 cells. Clones AE1/AE3 [anti–pan-keratin, premixed
20:1, IgG1 (Chemicon)] were used at working concentrations of 5 Ag/mL for
1  106 cells and 25 Ag/mL for 5  106 cells. Clone V9-2b (anti-vimentin,
IgG2b), originally developed at our department, was used as a diluted culture
supernatant (1:5 or 1:1, depending on the cell concentration). Goat F(ab2)¶
anti-mouse IgG1-FITC and goat F(ab2)¶ anti-mouse IgG2b-RPE (Southern
Biotechnology Associates) were both diluted 1:100 in PBATw.
Staining. One million cells were incubated with 100 AL of a monoclonal
antibody mixture containing clones MNF116, AE1/AE3, and V9-2b overnight
at 4jC. The next day, cells were washed twice with ice-cold PBATw and
centrifuged at 500  g for 5 min at 4jC. The cells were then incubated with
100 AL of premixed FITC- or RPE-labeled secondary reagents. After 30 min
on ice, cells were washed twice with ice-cold PBATw and incubated with
500 AL of DNA staining solution containing 10 Amol/L of propidium iodide
(PI; Calbiochem) and 0.1% DNase-free RNase (Sigma) diluted in PBATw.
Cells were kept at room temperature for 30 min to activate the RNase and
were then incubated at 4jC overnight to allow for stoichiometric staining
of the DNA.
For DNA index validation, two tissue blocks from an archival cervical
carcinoma were taken and thick sections were cut at different time intervals
and prepared for multiparameter DNA analysis as described. In total, nine
independent measurements were performed, of which the DNA index and
coefficient of variation (CV) of the G0G1 populations was calculated.
Flow cytometry and sorting. For analysis, data from 20,000 single cell
events were collected using a standard FACScalibur (BD Biosciences) flow
cytometer, equipped with a 15 mW Argon-ion laser (488 nm) and a 12 mW
diode laser (635 nm; ref. 30). The FL3-A versus FL3-W pulse-processor was
used to enrich for single cell events during acquisition and analysis. For
data analysis, DNA index, and CV calculation, the WinList 6.0 and ModFit
3.1 software packages were used (Verity Software House, Inc.). N-color
compensation was used for postacquisition spectral cross-talk correction
according to the manufacturer’s instructions, without the use of hyperlog
transformation or log bias.
For flow-sorting, the cell concentration was increased to 5  106
cells/mL. The PI concentration was simultaneously increased to 50 Amol/L.
G0G1 vimentin-negative, keratin-positive tumor cells and G0G1 vimentin-
positive, keratin-negative stromal cells were flow-sorted using a FACSAria
flow-sorter at 40 psi (BD Biosciences) with a 100-Am nozzle at a frequency of
f52 kHz. The 488 laser line was used for excitation. The FACSAria purity
mode was used during sorting. These settings allowed us to typically flow-sort
800 103 cells in 5 mL Falcon tubes. The following detector and filter settings
were used during sorting: FITC fluorescence, detector E, 530/30 nm BP filter;
R-PE fluorescence, detector D, 575/26 nm BP filter; PI fluorescence, detector
C, 610/20 nm BP filter. A detector C-Area versus detector C-Width dot plot
was used to gate out doublet and aggregates during sorting. After sorting, cells
were centrifuged at 4,000  g for 10 min before DNA was extracted.
For fluorescence in situ hybridization (FISH) analysis of flow-sorted
cells (20 psi, 100 Am nozzle), samples were labeled for keratin, vimentin and
DNA using APC- and RPE-conjugated antibodies, and 4¶,6-diamidino-2-
phenylindole as DNA stain. This approach reduced background fluores-
cence during the examination of the interphase nuclei after hybridization.
DNA isolation. DNA was isolated as described (31) and DNA was further
purified using the Promega Protein Precipitation solution (Promega)
according to the manufacturer’s instructions. DNA concentrations were
determined using the Picogreen method (Invitrogen).
SNP array analysis. SNP arrays were performed at the Leiden Genome
Technology Center2 as described (32) with minor modifications: 1 Ag of
DNA was used as the input in a multi-use activation step and was sub-
sequently dissolved in 60 AL of resuspension buffer. Genotypes and the Gene
1 http://www.federa.org/
Figure 1. LAIR is a measure of the contribution of two informative alleles. LAIR
is 1 when the contribution of both alleles of a certain SNP in the tumor, as
compared with the total intensity, is similar to that of paired alleles of the
reference sample (balanced, left dotted line ; two copies [AB], four copies
[AABB], etc.). LAIR is 0 when no signal is found for one of the alleles in the tumor
(LOH, right dotted line ; one or more copies [A], [AA], and [AAA], etc.). Allelic
imbalances (imbalanced) are indicated by intermediate values depending on the
copy number ratio between the two alleles: [AAABB], [AAAAB], [AAAB], and
[AAB] are shown equidistantly (n = number of copies).
2 http://www.lgtc.nl/
Cancer Research
Cancer Res 2008; 68: (24). December 15, 2008 10334 www.aacrjournals.org
Chapter 7
103
Call Score were extracted using GeneCall version 6.0.7 (Illumina). Only
genotypes with a GCS <0.5 were used to eliminate low-quality calls from
this analysis.
Reference normal sample with the highest average quality score was
chosen. LOH within a tumor sample was determined by comparison to the
reference sample. Informative SNPs, SNPs at which the reference sample is
heterozygous, were checked for homozygosity and LOH was indicated when
two neighboring informative SNPs were homozygous in the tumor sample.
The beadarraySNP package (5) was adapted to combine copy number
profiles, allele-specific intensities, and the DNA index.
First, a segmentation procedure is applied to find genomic regions that
have the same copy number (33). Secondly, LAIR, a measure of the
contribution of the two original alleles, is calculated for all informative
SNPs. This value is close to 1 when the contribution of both alleles of an
SNP to the total intensity in the tumor is similar to that of the reference
sample. The value is close to 0 when there is no signal for either of the
alleles in the tumor (LOH). Allelic imbalances will show intermediate
values (Fig. 1). By using the assumption that regions with LAIR close to 1
should have an even copy number and that the total calculated DNA index
should be similar to the measured DNA index obtained by flow cytometry,
it is possible to determine the allelic copy number in each genomic region.
We refer to this as the allelic state. The following allelic states [modified
from Nancarrow and colleagues (34)] can be distinguished: (a) [AB],
normal; (b) [A], abnormalities with copy number 1, called LOH, resulting
from the loss of either the A or B allele; (c) [AA], a diploid abnormality
with either the genotype AA or BB, which is referred to as cnLOH; (d)
[AAA] or [AAAA], etc., or amplified LOH, in which only the A or B allele is
present at the locus and is present in three or more copies; (e) [AABB] or
[AAABBB], etc., or balanced amplifications resulting in a 4n, 6n or higher
genomic region with equal amounts of both alleles; and ( f ) allelic
imbalances for [AAB], [AAABB], or [AAAABB], etc., for which the copy
number at the locus is three or higher and both alleles are present at
unequal amounts.
Generally, all SNPs on the array are equidistantly spaced across the
genome. Thus, the average copy number of the allelic states of all SNPs, the
allelic state index, was calculated and found to be an accurate measure of
the copy number of the tumor. The allelic state index closely matched the
DNA index measured by flow cytometry.
Interphase FISH analysis of flow-sorted cells. Interphase FISH
analysis was performed as previously described (35) on 500 to 2,000 cells.
The following probes were used: alphoid satellite centromeric probes for
chromosome 4 (PYAM 11.39, kindly provided by Dr. A. von Bergh,
Department of Clinical Genetics, Erasmus MC, Rotterdam, the Netherlands),
chromosome 6 (p308), chromosome 8 (D8Z2), and chromosome 18 (L1.84;
kindly provided by Dr. K. Szuhai, Department of Molecular Cell Biology,
LUMC, Leiden, the Netherlands). The probes were biotin-16-dUTP–labeled
(Roche Diagnostics) by standard nick translation. The BAC probes 149A7
(4q), 86C11 (6p), 10G10 (8q), 536K17 (8q), 748M14 (18q), and 154H12
(18qter; gift from Dr. K. Szuhai) were similarly labeled with digoxigenin-12-
dUTP (Roche Diagnostics).
The centromere CEP17 Alpha SpectrumGreen and Vysis LSI TP53 SO
SpectrumOrange (17p) probes were purchased from Abbot Molecular, Inc.
Hybridization and immunodetection were performed as advised by the
manufacturer with an additional denaturation step for 8 min at 80jC.
Results
Flow cytometry and sorting. Flow cytometric analysis of six
solid tumors showed DNA histograms with two G0G1 fractions,
which shows the presence of an aneuploid population in all cases.
Representative DNA histograms and dot plots are shown in Fig. 2.
After gating of the vimentin-positive, keratin-negative populations,
a single population of tumor stromal cells remained in all cases
(CV, 4.48 F 0.78%). In the vimentin-negative, keratin-positive cell
fraction of five cases, a single DNA aneuploid population was
found. The DNA index ranged from 1.30 to 1.91 (Supplementary
Table S1). The vimentin-negative, keratin-positive population of
sample 5 showed two distinct populations with a near-diploid DNA
index of 0.97 and an aneuploid DNA index of 1.86 (Fig. 2B ; CV,
5.71 F 1.30%). All vimentin-positive, keratin-negative cell popula-
tions, also those present in the normal samples (lymph nodes,
endometrium) showed a single G0G1 fraction. The vimentin-
positive, keratin-negative and the vimentin-negative, keratin-
positive G0G1 fractions from all FFPE cancer samples were
flow-sorted. From the normal samples, the vimentin-positive,
keratin-negative G0G1 fractions were flow-sorted. Cell yields ranged
from 0.5  106 to 2.5  106 and from 0.2  106 to 2.5  106 cells for
the keratin-positive and vimentin-positive fractions, respectively
(Supplementary Table S1). Independent measurements (n = 4
and n = 5) on two tissue blocks showed the robustness of the
method. The DNA index ranged from 1.83 to 1.91 and the CVs from
3.19% to 5.81% for the G0G1 fractions.
Figure 2. Flow-sorting of tumor cell
subpopulations from cervical and colorectal
carcinoma FFPE tissue. A, cervical cancer
sample shows a unimodal DNA histogram
after gating of the vimentin-negative,
keratin-positive cell fraction. B, colorectal
sample shows a bimodal DNA histogram
after keratin gating, containing two DNA
fractions: a near-diploid fraction with a DNA
index of 0.97 and an aneuploid fraction with
a DNA index of 1.87. Cell suspensions
were simultaneously stained for keratin
(epithelial cells, FITC), vimentin (stromal
cells, R-PE fluorescence), and DNA (PI
fluorescence). Sorting was restricted to the
G0G1 populations (vertical bars, right ).
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Figure 3. The allelic state of the autosomes for all cases provides a detailed measure of chromosomal aberrations. Cervical carcinomas, cases 1 to 3 (A); colon
carcinomas, cases 4 to 6 (B ). For each chromosome, the number of bar(s) to the right of the ideogram indicates the copy number. The bars are only depicted for
informative SNPs (heterozygous in normal tissue). Red , the A allele; blue , B allele. Orange and cyan bars , clonal heterogeneity of this locus. For example;
case 1, chromosome 7—a mixture of [AB] and [AABB] allelic states; see also Supplementary Fig. S2. Note the striking clonal relation between the near-diploid and
near-tetraploid fractions of case 5. Besides endoreduplication of most chromosomes, including LOH ([AA]) on chromosome 5, the breakpoints on chromosomes 5, 8,
17, and 20 are identical.
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Signal amplitudes and improved detection of chromosomal
alterations. Using the beadarraySNP package, LOH profiles and
relative copy numbers were generated for all cancers. Vimentin-
positive, keratin-negative stromal cells from the archival tissue
were used as a reference because these showed a high genotypic
concordance (>98.8%) with paired normal fractions (lymph nodes
or endometrium) and contained normal diploid genomes.
To evaluate the effect of flow-sorting for the macrodissected
cervical tumors, the unsorted and flow-sorted tumor fractions were
compared (Supplementary Table S2). Flow-sorting considerably
improved signal amplitudes and identification of chromosomal
segments with LOH (Supplementary Fig. S1). In total, 119 segments
were identified: 24 with gains, 33 with physical losses; 12 showed
cnLOH, and 50 showed retention. Of these segments, 92 were
identical in the sorted and unsorted fractions, although 22 of
the CNAs (31.8%) showed an increase in amplitude. Of all of the
abnormalities, 16 were missed in the unsorted fraction (23.2%),
whereas 11 were detected but were differently interpreted (15.9%).
Five of these misinterpretations were probably due to tumor
heterogeneity, e.g., a change from retention to gain or loss or from
gain to cnLOH.
Integration of DNA index in CNA and LOH analyses. In
addition to the percentage of tumor cells, the DNA index of the
tumor cells will influence the interpretation of the copy number
profiles. Therefore, we integrated the DNA index into the analysis.
Based on the genotype and allele intensity of the SNP in the paired
normal sample, we calculated the LAIR value and estimated the
absolute allelic copy number or the allelic state of each
chromosomal abnormality (see Materials and Methods) and
provided an accurate molecular measure of chromosomal aberra-
tions (Fig. 3) of these tumors. The allelic state index was almost
equal to the DNA index measured by flow cytometry in all cases.
FISH on flow-sorted tumor cells of cases 2, 5, and 6 validated the
calculated copy numbers (Table 1).
The aneuploid cervical cancers (Fig. 3A) showed frequent
aberrant allelic states, including LOH, on chromosomes 4p, 6p, 8p,
and 11q, whereas gains on chromosomes 1q, 3q, 7q, 8q, 11q, 13q,
and 17q were found in all three cases. Strikingly, all three
cases were found to harbor four copies [AAAA] of a residual
region on chromosome 6p (including HLA class I). LAIR analysis
showed gains and losses involving chromosomes 5, 8, 13q, 17, 18,
and 20 in the three colon cancers (Fig. 3B). Detailed analysis
of all cases can be found in Supplementary Fig. S2 and Table S2.
Chromosomal segments with CNAs were sharply defined. For
example, the allelic imbalance [AAAAAABB] on chromosome 19
was restricted to a 3 Mb region.
LAIR analysis remarkably improved the detection and interpre-
tation of CNAs for the aneuploid tumors. Figure 4 shows examples
of chromosomes 8 and 18. For aneuploid case 6, through
integration of the DNA index (1.54), on chromosome 8q, an allelic
imbalance with three copies [AAB] was identified and on 8p
LOH [A]. The copy number of chromosome 18 (n = 2, [AA])
was confirmed by interphase FISH (Fig. 4A). Similarly, the patterns
of CNAs on chromosomes 8 and 18 in case 5 seem to be identical,
but their allelic states differ after integration of the DNA index
(Fig. 4B and C).
Intratumor heterogeneity. In case 5 (colon cancer), two
vimentin-negative, keratin-positive tumor fractions with a different
DNA index were clearly distinguished (0.97 and 1.86 for
the near-diploid and aneuploid fraction, respectively; Fig. 2).
To study their clonal relation, both fractions were analyzed
for genomic aberrations. Fifteen chromosomes (1–5p, 7, 9–12,
14–16, 18, 20–22) were duplicated in the aneuploid fraction
compared with the near-diploid fraction (Fig. 3; Supplementary
Fig. S2). For example, the allelic states of chromosomes 1, 2, and
3 were duplicated from [AB] to a balanced gain [AABB] in
the aneuploid fraction. Similarly, LOH [A] at 8p, 15, and 18 in the
near-diploid fraction was duplicated to cnLOH [AA] in the
aneuploid fraction. FISH confirmed the chromosome 18 copy
numbers (Fig. 4B and C).
On chromosomes 8q, four copies with [AAAB] in the near-
diploid fraction, and with [AAAAABB] in the aneuploid fraction
were found, suggesting duplication with an additional loss of an A
allele (Fig. 4B and C). Allelic imbalances [AAB] and [AAAAB] on
chromosomes 6p and 13, respectively, in the aneuploid fraction,
showed an unchanged [AB] and cnLOH [AA] allelic state in the
near-diploid fraction (Supplementary Fig. S2). FISH confirmed
the copy number of chromosome 6 in the near-diploid fraction
Table 1. Summary of FISH analysis of flow-sorted G0G1 tumor cells
Locus Probe Case*
1 2 3 4 5, near-diploid fraction 5, aneuploid fraction 6
4q28.3 149A7 — — — — 2/2 85%, 4/4 13% 4/4 —
6p25.1 86C11 — 3/3
c
31%, 4/4 67% — — 2/2 4/4 34%, 4/2 57% 4/4
8q22 10G10 — 2/2 33%, 3/3 63% — — 2/2 52%, 4/4 31%, >4/>4 12% (52) >4/>4
b
4/4 75%, 4/3 15% (20)
8q23.3 536K17 — 2/2 42%, 3/3 52% — — 2/2 86%, >4/>4 10% >4/>4
b
4/4 85%, 4/3 10% (20)
Smad2 748M14 — 3/3 38%, 4/4 50% (24) — — 2/2 36%, 1/1 61% 2/2 2/2
18qter 154H12 — 3/3 42%, 4/4 58% (26) — — 2/2 50%, 1/1 43% 2/2 2/2
DNA index 1.84 1.91 1.82 1.30 0.97 1.86 1.54
Allelic state index 1.86 1.88 1.88 1.32 0.96 1.95 1.54
NOTE: The DNA index and the allelic state index are given for each fraction (—, not determined).
* One hundred nuclei were counted, unless otherwise noted in parentheses.
cCopy numbers are given as n/n representing centromere signal/probe signal.
b>4 = more than four copies.
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Figure 4. FISH confirmation of allelic state copy number and tumor heterogeneity. A, case 6, allelic state analysis of chromosomes 8 and 18 and
interphase FISH for chromosome 18q on vimentin-positive, keratin-negative and vimentin-negative, keratin-positive nuclei. Two centromere 18 signals (red)
and two signals (green ) in the SMAD2 region are visible. B, case 5, near diploid (DNA index, 0.97) fraction. Copy numbers of the allelic states at 8q
([AAAB]) and 18 ([A]) are confirmed by FISH. On chromosome 8, four centromere signals (red ) and four 8q signals (green ) are visible, and on chromosome
18, one centromere signal and one 18q signal. Inset, vimentin-positive, keratin-negative interphase nucleus showing two centromere signals and two 18q
signals. C, case 5, aneuploid fraction (DNA index, 1.86) and FISH for chromosomes 8 and 18 of the aneuploid fraction. Chromosome 8 shows seven
centromere signals and seven 8q signals. Chromosome 18 shows two centromere signals and two 18q signals. Note the striking similarity between the
chromosomal aberrations of different colon tumor fractions. Chromosomes 8 and 18 are from different OPA panels, causing the small difference in the level
of the red segmentation line. D, intratumor heterogeneity observed by FISH. The allelic state of chromosome 6p of case 2 was [AAAA] according to LAIR
analysis (a low LAIR score; red bars ). FISH analysis of flow-sorted vimentin-negative, keratin-positive tumor cells showed that this population is composed
of a mixture of two fractions: one fraction (67%) containing four copies of 6p25/4 centromeric copies and one fraction (33%) containing three copies
of 6p25/3 centromeric copies. The vimentin-positive, keratin-negative fraction was shown to be normal (2/2, [AB]). [A], [AAB], etc., indicate the allelic
state; black dots, normalized copy number with a red segmentation line for all SNPs; horizontal blue dashes, LAIR (calculated on informative SNPs) scale
from 0 to 1; vertical bars; green, LAIR  1 (retention); red, LAIR  0 (LOH); blue, intermediate LAIR (f0.2 to f0.8, allelic imbalance). Probes:
centromere 6, p308 (red); 6p, 86C11 (green ); centromere 8, D8Z2 (red); 8q, 536K17 (green ); centromere 18, L1.84 (red); 18q, 748M14 (green ); 18qter,
154H12 (green ).
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(data not shown); however, FISH revealed a nearly equal mixture of
2n and 4n abnormalities on chromosome 6p in the aneuploid
fraction (Table 1). These abnormalities may be a mixture of either
[AA] and [AABB] or [AB] and [AAAB], leading to the detected
[AAB]. Similarly, in case 2 (cervical squamous cell carcinoma),
the allelic state estimate of chromosome 6p is [AAAA] (Fig. 3;
Supplementary Fig. S2), whereas FISH analysis of the flow-sorted
G0G1 aneuploid vimentin-negative, keratin-positive tumor fraction
clearly revealed a mixture of a 3n and 4n population, with allelic
states [AAA] in 31% and [AAAA] in 67% of the nuclei, respectively
(Fig. 4D).
Discussion
We showed the feasibility of combining high-throughput SNP
arrays and flow-sorting of tumor cell subpopulations from different
formalin-fixed archival samples. Our approach significantly im-
proved the simultaneous detection of numerical and structural
chromosomal aberrations, allowing clear discrimination between
allelic imbalances and LOH, and definition of aberrant chromo-
somal segments. Signal amplitudes of the losses and gains were
generally higher when compared with those of the unsorted
samples. Furthermore, <20% of the chromosomal abnormalities
were missed in the unsorted cervical tumor fractions, whereas 16%
were interpreted differently, either due to intratumor heterogeneity
or to low tumor percentage. In the sorted samples, absolute LOH
([A]) or cnLOH ([AA]) was frequently identified, creating a sharp
definition of a chromosomal segment.
We determined the allelic states of flow-sorted tumor fractions
and confirmed copy numbers by FISH for several loci. The
concordance between the DNA index and the allelic state index
verified the method. In line with Nancarrow and colleagues (34), we
propose the use of the following nomenclature: I, LOH for the loss
of one allele, resulting in the allelic state [A]; II , cnLOH for the
allelic state [AA]; III, amplified LOH for the allelic states [AAA],
[AAAA], etc.; IV, balanced amplification for 4n [AABB] or 6n
[AAABBB], etc.; and V, allelic imbalances for [AAB], [AAABB],
[AAAABB], etc. We prefer allelic imbalance over amplification
because allelic imbalance is more neutral and not suggestive of
the molecular mechanism that was responsible for the observed
abnormality. For example, an [AAB] status can be caused by a
single gain of an A allele within an overall diploid genomic
background; however, for a highly aneuploid tumor, this status can
arise from endoreduplication of [AB] to an [AABB] status, followed
by an additional loss of a B allele during tumor progression.
For accurate estimates of the allelic states of CNAs in FFPE
aneuploid tumors, we showed that integration of the DNA index in
conjunction with SNP arrays (8, 27) is crucial. Otherwise, most, if not
all, CNAs will be misinterpreted, which is also supported by the
findings of Lyng and coworkers on aCGH (16). For example, the
patterns of CNAs on chromosomes 8 and 18 of the near-diploid and
the aneuploid fractions of case 5 seem to be identical, but their allelic
states are shown to differ after integration of the DNA index (Fig. 4).
For near-diploid tumors, the allelic state of a tumor fraction will likely
be correctly interpreted (14). Determination of the DNA index alone is
feasible inmost laboratories. However, for highly intermingled tumors
(infiltrate and stroma) or for tumors containing different tumor
subpopulations, flow-sorting seems to be mandatory.
An important potential of flow cytometry is the identification
and sorting of multiple clones based on differences in DNA
content. This advancement has not yet been achieved by any other
enrichment or purification method. This approach allows for
the study of intratumor heterogeneity, chromosomal aberrations
which develop during tumor progression and clonal relationships
between tumor subpopulations (20, 36). A clear example is
case 5, in which the near-diploid and aneuploid tumor fractions
probably originated from a common hypothetical near-diploid
precursor fraction. Most chromosomes were endoreduplicated
from [AB] in the near-diploid fraction to [AABB] in the aneuploid
fraction (Fig. 3). Subsequent parallel divergence of the two clones
resulted in the current fractions. For example, on chromosome 13,
physical loss and mitotic recombination could have led from [AB]
in the common precursor to cnLOH [AA] in the near-diploid
fraction. The [AAAAB] status of chromosome 13 of the aneuploid
fraction could have resulted from endoreduplication with subse-
quent loss of the B allele, and doubling of the A alleles.
In addition, the aneuploid fraction showed a mixture of two
subpopulations for chromosome 6p, which were only identified
after FISH analysis. At this locus, the near-diploid fraction showed
a normal allelic state [AB]. Given the high DNA index (1.86), an
average of three copies, an intermediate LAIR-score ([AAB]) and
FISH analysis, these aneuploid subpopulations likely contained
allelic states [AA] (cnLOH) and [AABB], respectively, clearly
demonstrating heterogeneity within the tumor fraction. Similar
intratumor heterogeneity within tumor cell fractions was shown for
case 2 (Fig. 4D). These delicate differences in chromosomal copy
numbers might indicate the ongoing generation of tumor
subclones due to chromosomal instability (37). These differences
also show that intratumor heterogeneity is more extensive than is
generally observed by ploidy and LAIR analysis because both
techniques register the dominant clone(s). Intratumor heterogene-
ity has also been identified by aCGH (16). However, LAIR analysis
has increased value relative to classical methods. It allows for a
more accurate estimate of the true allelic state of a chromosome
or regions of chromosomes, which, for example, could result in
discrimination between three chromosomal copies [AAB] and a
balanced mixture of two allelic states, [AB] and [AABB].
Integration of copy number and ploidy analysis creates a detailed
view of chromosomal aberrations during tumor progression. In all
three aneuploid cervical carcinoma samples, LAIR analysis revealed
amplified LOH, [AAAA], of the HLA region on chromosome 6p.
This region is known to be frequently targeted by LOH in cervical
cancer (8, 38, 39). From these events, it might be concluded that
LOH on chromosome 6p occurred in a near-diploid precursor
fraction, followed by mitotic recombination and endoreduplication,
leading to aneuploidy. The identification of the chromosomal
break points of the amplified LOH on 6p also indicates the
possibility of accurately studying the smallest regions of overlap.
The consequences of allelic state analysis for the classification of
tumors and profiling, as well as for allelic dosage determination
of cancer-related genes, remain to be established in a large cohort
of flow-sorted tumors. For example, in a near-diploid tumor with
predominantly diploid chromosomes, a locus with the allelic
imbalance [AAB] will be interpreted as a gain of the A allele,
whereas in a tumor with a predominantly near-tetraploid [AABB]
genomic background, [AAB] will be interpreted as an additional
loss of a B allele after endoreduplication. One could speculate on
the relation between the allelic dosage and RNA expression of
the genes on segments with CNAs (40). For the [AAB] segment, the
effect might be the opposite in a near-diploid background as
compared with an aneuploid background.
Allelic State Analysis of Chromosomal Aberrations






Genome-wide allelic state analysis of flow-sorted tumor fractions 
provides an accurate measure of chromosomal aberrations
108
In conclusion, we have explicitly shown that a combined
approach of flow-sorting and high-throughput SNP array profiling
with DNA index integration (a) significantly improves the detection
of numerical and structural chromosomal aberrations in formalin-
fixed tumor samples, (b) allows the definition of the allelic states of
complex CNAs and, (c) provides an individual molecular measure
of chromosomal aberrations. Interestingly, a recent meta-analysis
showed that chromosomal aberrations are associated with a worse
prognosis in colorectal cancer (3) and should be evaluated as a
prognostic marker in clinical trials. Our new procedure could be
implemented to define chromosomal aberrations and the allelic
state of regions that are identified in whole genome association
studies and which are associated with a cancer risk (41). Finally,
our combined method may provide further insight into the
dynamics of genomic instability during clonal evolution in
heterogeneous human carcinoma samples and can be imple-
mented in large-scale retrospective studies and studies in which
detailed genome-wide information is required.
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Concluding Remarks and Future Perspectives
The aim of the work described in this thesis was to identify novel genetic risk factors for colo-
rectal cancer (CRC). We applied several approaches to identify such novel CRC risk factors. 
Our approaches can broadly be divided into germ-line genetic analyses and somatic genomic 
analyses. 
Using the germ-line approach, linkage analysis in seven large familial CRC families provided 
supportive evidence for region on 3q, which has previously been linked to CRC susceptibility. 
However, no novel regions of linkage were identified. Study of low-risk CRC susceptibility loci 
revealed an enrichment of risk alleles in familial CRC patients as compared to sporadic CRC 
patients. In solitary patients with an early age at onset of disease no such enrichment of risk 
alleles was observed. These results suggest that clustering of low-risk factors explains part of 
the excess risk observed in CRC families.
Somatic genomic analysis showed that carcinomas from MUTYH-associated polyposis (MAP) 
patients have a profile of aberrations that is distinct from sporadic CRC and from Lynch syn-
drome carcinomas. The most distinguishing factor is the high frequency of LOH in the ab-
sence of copy number alterations (copy-neutral LOH; see also page 15) in MAP carcinomas. 
In analogy to the distinct genomic profiles of Lynch carcinomas and MAP carcinomas, we 
studied the genomic profile of mismatch repair (MMR) proficient familial CRC. The profiles of 
these MMR proficient familial carcinomas show an increased frequency of 20q gain and an 
increased frequency of genome-wide cnLOH compared to sporadic CRC, while the overall 
profile largely resembles the profile of sporadic CRC. These results suggest an important role 
for 20q in tumor progression in familial CRC.
Germ-line genetic analyses
Familial CRC of which the underlying genetics are currently unknown is likely to represent 
a heterogeneous group, including both cases with a strong familial clustering of CRC which 
are likely to have an inherited basis as well as cases with a more sporadic form of CRC that 
aggregated in the family as a result of shared environment and lifestyles or simply by chance.
[1,2] Using germ-line approaches, we searched for rare high penetrance risk factors and we 
studied the role of common low penetrance risk variants in CRC families.
Linkage analysis in seven large DNA mismatch repair (MMR) proficient CRC families did not 
provide a novel region of significant linkage that could harbor a high penetrance risk factor 
(chapter 3). However, our results support linkage to 3q21-q24, a region that has previously 
been identified as a CRC susceptibility locus.[3,4] Other regions that were previously repor-
ted to be linked to CRC susceptibility using linkage analysis, including 7q31, 9q22.2-31.2, 
11q23.2 and 11q13.4, 14q24.2, and 22q12.1, were not supported by our linkage results.[5-9] 
This might be explained by differences in family ascertainment, since the other studies analy-
zed nuclear families or sib-pairs.
Three independent studies, including our study, now reported linkage of the 3q region to CRC 
susceptibility, with a smallest region of overlap encompassing 3q22.1-q22.3.[3,4,10] Together, 
these studies provide evidence for a novel CRC risk factor on 3q22.  However, none of the 
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studies found strong evidence of linkage, suggesting that the risk of this locus is moderate. 
Mutation analyses of 46 genes in this region in previous studies did not identify pathogenic 
mutations.[3,4,10] The genes were screened for pathogenic mutations using a common ap-
proach by analyzing all exonic sequences, intron/exon boundaries, 5’- and 3’-untranslated 
regions (UTRs) and the promoter sequences of genes. The type of mutations that is generally 
searched for is truncating mutations. However, less obvious types of genetic alterations can 
be responsible for CRC predisposition. A recent study in CRC families, for example, showed 
that a heterozygous germ-line deletion of the last exons of TACSTD1, upstream of MSH2, 
causes epigenetic inactivation of MSH2 in TACSTD1-expressing tissues and thereby predis-
poses these families to colorectal cancer.[10] These results demonstrate the potential profit 
of broader screening approaches for mutations, insertions, and deletions (see also future 
perspectives section below).
We performed association analyses to study the role of low-risk variants in familial CRC (chap-
ter 4). Six loci that were identified in genome wide association studies (GWAS) were analyzed 
and the association with CRC risk could be replicated for five of these loci (located on chromo-
somes 8q23.3, 8q24.1, 11q23.1, 15q13.3, and 18q21.2). The odds ratios for these loci were 
increased, although not significantly, as compared to initial GWAS. This is likely a result of 
the familial nature of our cohort. The association between rs10795668 (10p14) and CRC risk 
was not observed in our Dutch familial CRC cohort, possibly due to either a lack of power or a 
population difference between our cohort and the English cohort in the initial GWAS.
Interestingly, we observed a significant increase in the number of risk alleles in cases com-
pared with controls and an increase in odds ratio with increasing numbers of risk alleles. 
These results are in line with previous studies in unselected CRC patients.[12] Moreover, we 
observed an increased number of risk alleles in the patients with a family history of CRC as 
compared to solitary cases with an early age of onset of CRC, where no enrichment of risk 
alleles was observed. This shows that although low-risk alleles initially were thought to play a 
role in ‘sporadic’ CRC, they also play a role in FCC families. Therefore, clustering of low-risk 
variants may explain part of the excess risk in CRC families. Our results were recently con-
firmed by a study of Finnish familial CRC patients, that also observed an increased number 
of risk alleles in familial CRC patients compared to a group of sporadic CRC patients.[11] In 
solitary cases, however, other genetic models are likely to play a role; rare recessive high-risk 
variants might provide an explanation for their increased CRC risk, as reflected by a lack of 
affected first-degree relatives and their early onset of disease.
A further example of a role for common low-risk variants in familial CRC was provided by ana-
lysis of the seven large CRC families that we also studied with linkage analysis. We detected 
a significant association between rs16892766 and rs12953717 and CRC within these families 
(chapter 3). Moreover, two of the risk variants (rs16892766 and rs3802842) appeared to have 
a modifier role in Lynch syndrome families.[13] In line with these results, a meta-analysis of 
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currently known, together account for 6% of the excess familial risk on basis of an additive 
model.[14] 
Overall, our linkage analysis results and those results of others do not support a model in 
which a single highly penetrant gene explains the excess risk in familial colorectal cancer. 
All linkage analysis efforts over the last decade did not yet provide a novel high-risk factor, 
suggesting that the underlying genetics of the remaining familial CRC may be more complex. 
To further analyze the possibility of a high penetrance factor following a recessive model of 
inheritance, we analyzed the seven MMR proficient CRC families by homozygosity mapping. 
Very recently, preliminary results provided a candidate region on chromosome 5 that could 
harbor a CRC susceptibility locus. In ongoing and future studies, we will analyze this region 
in further detail. 
Our association studies showed that low-risk variants may explain part of the excess risk in 
CRC families. Moderate risk factors might explain part of the excess risk in the remaining CRC 
families, but these are very difficult to identify with the current methods because of their assu-
med relatively low population frequency and their moderate penetrance. With the appearance 
of novel sequencing methods the identification of rare variants involved in CRC predisposition 
becomes feasible, for example using exome-sequencing or whole genome sequencing in 
highly selected cases (further discussed below in the future perspectives section).
However, while it is tempting to explain the excess CRC risk by genetic factors, the observed 
aggregation of CRC in large families could also be partly explained by environmental factors 
that are shared by family members. Moreover, the families could represent sampling artifacts 
and thus show aggregation of CRC largely by chance, although based on the cancer burden 
in these families, this seems less likely.
Also for other complex diseases, it was observed that much of the estimated heritability is 
not explained by the low-risk variants identified through genome wide association studies (re-
viewed by [15]). Several explanations for this so-called “missing heritability” were proposed. 
The missing heritability might be explained by risk variants with a low minor allele frequency 
(below 5%) which are not captured in genome-wide association studies and exert risks that 
are too low to be detected in linkage analyses.  Structural variation like inversions or translo-
cations might also partly explain the missing heritability. In addition, the estimated heritability 
could be an overestimation of the actual heritability of disease.[15] All these aspects could 
also apply to colorectal cancer.




Figure 1. Spectrum of CRC.
In up to 35% of all CRC, hereditary factors play a role. About 5% of all CRC can be explained by known 
CRC syndromes. Common low risk variants account for 6% of the excess familial risk and linkage ana-
lyses identified 3q22 as a candidate region for a CRC susceptibility locus. In the remaining familial CRC 
cases other factors probably underlie the CRC susceptibility.
Several other approaches were applied by other groups to further study the nature of CRC 
susceptibility. Two recent studies analyzed homozygosity levels in colorectal cancer patients 
to study the role of consanguinity in CRC predisposition. Up till now, MUTYH-associated poly-
posis is the only known recessively inherited colorectal cancer syndrome. The results of both 
studies are inconclusive, since contradicting results were obtained. On one hand, the study 
of Bacolod et al. observed more and longer homozygosity regions in 74 colorectal cancer 
patients as compared to 264 controls, suggesting a role for recessively inherited CRC predis-
position.[12] The number of homozygous regions (>4 Mb) per patient was low. The regions 
differed among the patients and were spread throughout the genome. On the other hand, a 
large study of Spain et al. did not provide evidence for increased homozygosity in CRC pa-
tients in a cohort comprising 921 cases and 929 controls.[13] The latter results show that the 
larger part of genetic CRC susceptibility likely follows a dominant mode of inheritance and that 
a minor part is explained by recessively inherited factors. A study of regions of homozygosity 
in specific subgroups of CRC patients in which a recessive inheritance mode is expected, 
such as solitary CRC patients with an early age of onset, might, however, be a good strategy 
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The loci discovered in the genome-wide association studies inform on novel genes and/or 
pathways involved in CRC and might point to common molecular mechanisms involved in 
cancers.[14] Unraveling the biological mechanisms explaining the association between the 
identified risk loci and CRC will provide important novel insights in the etiology of colorectal 
cancer. In silico analyses to investigate the causality showed that many associated variants 
are in linkage disequilibrium (LD) with DNA sequence changes that influence gene expression 
rather than with nonsynonymous sequence changes that lead to altered proteins.[14] This 
might relate to the high population frequency and the low-risk these variants confer; different 
levels of expression likely exert more subtle effects than altered proteins. 
Interestingly, five out of the ten identified low-risk factors are SNPs that are in linkage dise-
quilibrium (LD) with genes of the TGF-β superfamily signaling pathway, including the genes 
SMAD7, GREM1, BMP2, BMP4, and RHPN2.[15] This further underlines the important role 
that the TGF-β pathway plays in CRC susceptibility; germ-line mutations in SMAD4 and 
BMPR2 were already known to be involved in Juvenile Polyposis and several members of 
the TGF-β pathway, including SMAD4 and TGFBR2, are targeted by somatic mutations in 
colorectal tumors.[16,17] 
An alternative approach to perform association studies as compared to using tagging SNPs, 
was adopted by Webb et al. who studied associations with gene-centric SNPs.[18] These 
gene-centric SNPs included 7000 genome-wide nonsynonymous SNPs, which alter the en-
coded amino-acid sequence. However, this study did not yield any significant association 
between CRC risk and any of the nonsynonymous SNPs, which a priori are more likely to 
have functional impact than synonymous SNPs. An explanation for the absence of associati-
ons could be that natural selection on alleles in coding regions has rendered the risk alleles 
rather rare.[18] 
Somatic genomic analyses
In this thesis, we applied single nucleotide polymorphism (SNP) arrays to study colorectal 
tumors for genome-wide chromosomal copy number aberrations and loss of heterozygosity 
(LOH). Our aim was to generate a profile of genomic aberrations in MMR proficient familial 
CRC that might provide further insight in the biological basis of the increased CRC suscepti-
bility in these families. Furthermore, these profiles might identify a candidate region that could 
harbor a CRC susceptibility factor.
Although many comparative genomic hybridization (CGH) studies of CRC have been perfor-
med over the last years (an overview is provided in chapter 1, table 2), most studies analyzed 
sporadic CRC, whereas few studies analyzed hereditary or familial CRC. Moreover, the majo-
rity of the studies used metaphase-based CGH or arrayCGH which only provides information 
on copy number aberrations. Genome-wide SNP arrays were used to a much lesser extent, 
even though these arrays provide information on both copy number and genome-wide LOH in 
the absence of copy number aberrations (copy-neutral LOH or cnLOH). In addition, we sho-
wed that, using SNP arrays, the genomic profiling of tumors can be further improved by analy-
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zing flow-sorted tumor cells and incorporation of the DNA index in the analysis. We developed 
a novel algorithm, the lesser allele intensity ratio (LAIR), which can accurately determine the 
allelic state of all chromosomes. Upon incorporation of the DNA index of the tumors, LOH, 
cnLOH, balanced amplifications, and allelic imbalances can be distinguished (chapter 7). In 
addition to the assessment of allelic states, this method can address tumor heterogeneity.
The great value of genome-wide cnLOH analysis is illustrated by our study of MAP carcino-
mas (chapter 5). The main characteristic of these tumors was the high frequency of cnLOH; 
whereas physical loss occurred to a much lesser extent (Figure 2). This is in contrast to 
sporadic CRC, in which physical loss is frequent and few regions of cnLOH are observed.[19] 
The tumors from Lynch syndrome patients, which we studied previously, showed a charac-
teristic profile, lacking gross chromosomal aberrations but only exhibiting a small region of 
copy neutral LOH around the locus of the mutated mismatch repair gene (Figure 2).[20] Also 
for many other cancers regions of cnLOH have described, including basal cell carcinoma and 
retinoblastoma (reviewed by [21]).
Compared to the unique and distinct profiles of genomic aberrations that were observed in 
MAP carcinomas and Lynch syndrome carcinomas, the group of MMR proficient familial colo-
rectal carcinomas that was studied showed resemblance to sporadic CRC but with an incre-
ased frequency of 20q gain and genome-wide cnLOH (chapter 6). The most frequent aberra-
tions in MMR proficient familial CRC included gains of chromosome 7, 8q, 13q, 20p and 20q, 
physical losses of 17p, 18p, and 18q. Remarkably, an increased frequency of 20q gain (77%) 
was observed as compared to the frequency in sporadic CRC (30-50%), in which it is con-
sidered to be an early event during tumorigenesis.[23,26] Moreover, an increased frequency 
of genome-wide cnLOH was observed at the expense of the frequency of physical losses in 
MMR proficient familial CRCs as compared to sporadic CRC. The observed high frequency 
of 20q gain in familial CRC confirmed a previous report on chromosomal aberrations in a Fin-
nish cohort of familial CRC.[22] In this study 99 familial CRCs were compared to 186 sporadic 
CRCs using genome-wide allelotyping with microsatellite markers and copy number analysis 
using CGH on a subset of tumors. They observed gain of 20q in 85% of familial CRCs. They 
could, however, not confirm their results in a series of 67 familial and 96 sporadic CRCs from 
the UK.
Further analysis of chromosome 20q seems valuable and could include somatic sequen-
ce analysis of candidate genes or sequence analysis of the entire region. Gene expression 
analysis could provide information on differentially expressed genes. In a recent study, gene 
expression levels of genes located on 20q were compared between sporadic colorectal ade-
nomas and carcinomas to identify oncogenes involved in adenoma to carcinoma progression. 
Several genes were found to be differentially expressed in carcinomas with gain of 20q as 
compared to carcinomas without such gain.[23] These genes could be also involved in fami-
lial CRCs, although the genetic targets could be very well be different from sporadic CRC. 
Moreover, profiles of imprinting on 20q could be studied, since for example GNAS (located on
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Figure 2. Profile of genomic copy number aberrations and cnLOH in colorectal cancer.
The bars indicate the percentage of carcinomas that exhibit an event of gain, loss or cnLOH of a chro-
mosome. This percentage has been calculated for the respective chromosome arms. White bars, chro-
mosomal gains; checked bars, physical losses of chromosomes; black bars, cnLOH. The profile of Lynch 
syndrome carcinomas (upper panel) is derived from Van Puijenbroek et al.[20]
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Even though the genetic analysis of familial CRC did provide few distinct features for this 
group of MMR proficient familial CRC, tumor analysis provides a valuable approach to inves-
tigate CRC susceptibility. A successful example concerns the identification of mutations in 
MUTYH as the cause of polyposis (now termed MUTYH-associated polyposis), which came 
from the observation that tumors exhibited specific G>T DNA sequence transversions.[25] 
This provides a clear example of the value of tumor analysis of familial CRC. Additionally, 
before the identification of BRCA2 as a breast cancer susceptibility gene, 13q deletions were 
already observed to be more frequent in familial breast cancer patients.[26]
Future perspectives
Future studies to identify novel genetic factors involved in CRC susceptibility, will require no-
vel approaches because, despite of all efforts that were made over the last decades, a large 
part of the heredity remains unexplained. First, the search for novel genetic colorectal cancer 
risk factors has so far been focused mainly on genotypic variants. The study of copy number 
variants (CNV) may also yield novel CRC risk factors. As already discussed above, deletion 
of the last exons of TACSTD1 is associated with CRC predisposition, because this deletion 
causes epigenetic inactivation of MSH2 in TACSTD1-expressing tissues.[10] In addition, ge-
nomic (micro-)deletions showed already to be instrumental for the identification of cancer 
predisposing genes in for example retinoblastoma, Von Hippel-Lindau disease, and Wilms’ 
tumor associated with WAGR syndrome (Wilms tumor, Aniridia, Genitourinary anomalies, and 
mental Retardation syndrome).[32-35] More recently, analysis of CNVs by array compara-
tive genomic hybridization has led to the identification of a causative gene for example for 
CHARGE syndrome (Coloboma, Heart anomaly, choanal Atresia, Retardation, Genital and 
Ear anomalies syndrome).[36] In addition, association studies could be performed for CNVs 
that are polymorphic in the general population. Several associations between DNA copy num-
ber variants and common complex diseases have already been described (reviewed by [27]).
For example, a significant association was found between a low number of copies of a poly-
morphism in the human beta-defensin gene HBD-2 (or DEFB4) and Crohn’s disease, with a 
corresponding odds ratio of 3.06 (95% CI 1.46–6.45).[38] Other CNV associations were repor-
ted with HIV/AIDS susceptibility, rheumatoid arthritis, systemic autoimmune disease, systemic 
lupus erythematosus, psoriasis, and asthma, with odds ratios ranging from 1.34-5.27.[27] 
Secondly, a useful next strategy could be to sequence the “exome” of colorectal cancer pa-
tients, including all protein encoding regions of the genome, or even to sequence the whole 
genome of CRC patients. Exome sequencing has already been applied successfully by Ng 
et al. on the exomes of 12 individuals.[28] Ng et al. studied the exomes of eight HapMap 
individuals and four unrelated individuals affected with Freeman-Sheldon syndrome, a rare 
autosomal dominant disease caused by mutations in MYH3. Filters were applied to identify 
the possible deleterious variant among all identified variants. Non-causal variants were remo-
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Presumably common variants were removed by removing dbSNP catalogued variants and 
by removing the variants identified in the eight HapMap individuals. After application of these 
filters, MYH3 was the only gene that was left on the candidate list.[28] The genetic homogen-
eity of the affected individuals and the availability of the HapMap individuals were important 
factors in the successful identification of MYH3. When applying this strategy for the identifica-
tion of novel CRC susceptibility factors, probable genetic heterogeneity will have a significant 
impact on the performance and larger sample sizes will be required. Several genetic variants 
are likely to remain after filtering of the identified variants. To determine the significance of 
identified mutations, functional analyses could be performed. 
Thirdly, in addition to a gene-centric approach, microRNA (miRNA) sequences could be stu-
died for alterations. MiRNAs are small non-coding RNA sequences involved in post-transcrip-
tional regulation of gene expression. Evidence for aberrant expression of miRNAs in human 
cancers is growing, indicating that they are involved in tumorigenesis (reviewed by [40]). Ho-
wever, both a global increase of miRNA levels in prostate cancer as global inhibition of miRNA 
processing have been described in cancer, suggesting a complex relation between miRNAs 
and tumorigenesis. A list of miRNAs involved in colorectal cancer has already been described.
[29] Whether miRNAs are involved in CRC susceptibility still needs to be studied.
Fourthly, epigenetic changes or susceptibility to epigenetic changes might be involved in 
CRC predisposition and analysis of the epigenome could therefore be a fruitful approach. For 
example, germ-line methylation of the MLH1 promoter region has been described in colorec-
tal cancer patients.[42,43] However, the mode of inheritance of such epigenetic mutations 
remains unclear. Few examples of apparent inheritance of epigenetic states exist and it is 
generally believed that epigenetic modification are reset in germ cells.[30]
Finally, the role of the recently identified low-risk variants in tumor initiation (and progression) 
should be determined in future studies. This will provide important novel insights in the etio-
logy of colorectal cancer and insight in the biological mechanisms involved in CRC suscepti-
bility. Additional analyses need to be performed to identify the causal variants at the different 
loci and to unravel the biological mechanisms that cause the increased CRC risk. This will be 
a challenging task, since several of the identified risk alleles are located in regions that are wit-
hout known genes (so-called gene deserts). Resequencing of the locus on 18q21.1 has iden-
tified Novel 1 to be the causal variant on this locus.[31] Variant rs6983267 is likely to be itself 
the causal variant, as determined by resequencing and linkage disequilibrium analysis in this 
region.[45]  Further analyses of the region on 18q21.1, already showed that its causal allele 
(Novel 1) is associated with a reduced expression of SMAD7 in a Xenopus laevis model.[31] 
The variant rs6983267 (8q24.1) is located in a transcriptional enhancer region that is bound 
by TCF7L2 (also referred to as TCF4), a transcriptional effector of the Wnt signaling pathway. 
The alleles of rs6983267 were found to differentially bind the transcription factor TCF7L2. It 
was shown that the region around rs6983267 physically interacts with MYC, but no robust 
association could be detected between rs6983267 and MYC mRNA expression.[46,47] Howe-
ver, a role for MYC is still likely, since MYC is a known target of TCF7L2 and is an important 
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oncogene in colorectal tumorigenesis. A strong indication for a role in somatic tumor evolution 
for rs6983267 was found by Tuupanen et al., who observed that in case of allelic imbalance 
at 8q24, the risk allele was favored in about two-thirds of the tumors.[32] Similar analyses for 
the other low-risk variants that were identified in recent genome-wide association studies will 
provide more and probably new insight into mechanisms of CRC initiation and progression.
In conclusion, the results described in this thesis suggest that it is unlikely that the excess 
risk in many of the MMR proficient familial CRC cases is explained by dominant high-risk 
genetic factors. Single young patients without a family history of CRC might be explained by 
a recessive origin of disease. In MMR proficient CRC families, one or more moderate risk fac-
tors might play a role. Research should therefore be directed more towards identifying novel 
factors conferring a moderate risk, even though these factors are more difficult to find. Recent 
advances in sequencing technology as well as novel knowledge of mechanisms involved in 
CRC development provided by the recently identified low-risk factors might facilitate the iden-
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The aim of the work described in this thesis was to identify novel genetic factors that pre-
dispose to colorectal cancer (CRC). CRC is one of the most common malignancies in the 
Western world, currently affecting about 11,000 individuals in the Netherlands each year. The 
risk of developing CRC is influenced by both genetic and environmental factors. Inherited 
predisposition plays a role in up to 30% of all CRC, whereas in only about 6% of all cases the 
genetics underlying the increased cancer risk are known. Identification of novel genetic CRC 
risk factors will improve our insight in the etiology of the disease. Moreover, it allows identi-
fying individuals at increased risk for CRC. These individuals can then be offered tailor-made 
colonoscopic surveillance schemes to detect precursor lesions, thereby preventing them to 
develop into a malignancy.
In chapter 1, a general introduction into the known genetic and environmental risk factors for 
CRC is provided. The high penetrance genes that give rise to hereditary CRC syndromes 
like Lynch syndrome and Familial Adenomatous Polyposis are described, as well as low level 
genetic risk loci for colorectal cancer. Chapter 1 also describes the different paths of tumori-
genesis seen in colorectal cancer. The different forms of genetic instability are discussed and 
new fields in CRC research, prevention, and treatment are briefly reviewed.
Linkage analysis is a suitable method to identify high penetrance susceptibility loci in families 
affected with a disease. Traditionally, linkage analysis is performed with multi-allelic microsa-
tellite markers. However, with the availability of high density SNP arrays, these arrays have 
been brought into use for linkage analysis. The information content of these dense arrays 
is higher as compared to microsatellite markers. Moreover, SNP arrays can be processed 
with higher throughput. The use of high density arrays in large families, however, yields a 
computational complex analysis that challenges existing linkage programs. In chapter 2, we 
developed a procedure for linkage analysis in large pedigrees using high density SNP arrays 
using existing software. We validated our procedure in a Lynch syndrome family with a known 
MLH1 germ line mutation. In chapter 3, we applied this procedure to seven large colorectal 
cancer families in which known CRC syndromes had been excluded, to identify novel genetic 
regions linked to CRC predisposition. The linkage scan did not yield novel CRC susceptibi-
lity candidate regions, but our results support the previously reported linkage to a region on 
chromosome 3q. In addition, further analysis using homozygosity mapping recently revealed 
a candidate region for harboring a CRC susceptibility locus. We will analyze this region in 
further detail. To further explore genetic factors that could explain the increased CRC risk in 
the seven mismatch repair proficient CRC families, we also examined the presence of low risk 
variants in the families. Although no enrichment for low-risk variants could be observed in the 
families, two loci (8q23.3 and 18q21.1) were associated with CRC risk in the families. Collec-
tively, our data indicate that the currently identified low-risk variants are insufficient to account 
for the type of familial clustering of CRC seen in the families we analyzed. Finally, analysis of 
the genomic tumor profiles of the affected family members revealed that these profiles res-
emble genomic profiles of sporadic colorectal cancer. Overall, these data suggest that factors 








the increased cancer risk in a subset of familial CRC.
In chapter 4, we studied the role of six CRC susceptibility loci (on chromosome 8q24.21, 
18q21.1, 15q13.3, 11q23.3, 8q23.3, and 10p14) in a CRC cohort that was enriched for a 
positive family history of CRC and/or early onset of disease. We found an association with 
CRC risk for five out of the six susceptibility loci. In addition, we studied the relation between 
these risk alleles and clinical and pathological parameters, including gender, age at diagnosis, 
family characteristics, and tumor location. The locus on chromosome 18q21.1 appeared to 
be stronger associated with left-sided cancer as compared to right-sided cancer. Additionally, 
a stronger effect of this locus on CRC risk was seen for familial CRC cases with at least two 
first-degree affected relatives as compared to solitary CRC cases. Analysis of the number 
of risk alleles per individual revealed that the CRC risk increases with the possession of an 
increasing number of risk alleles. Furthermore, familial CRC cases carried significantly more 
risk alleles as compared to solitary CRC cases, suggesting that other causes of increased 
CRC risk, e.g. recessive factors, play a role in solitary cases. And cases from families with 
an early onset of disease carried significantly more risk alleles as compared to cases from 
families with a late onset of disease. Overall, our results in chapter 4 suggest a clustering of 
low-risk variants exists in familial CRC which is likely to contribute to the observed excess risk 
in relatives of patients.
Chapter 5 describes our results of the genomic profiling of carcinomas from MUTYH-asso-
ciated polyposis patients. Although MUTYH deficiency triggers carcinogenesis by G:C>T:A 
transversions, the exact role of MUTYH deficiency in the tumor progression in MAP patients is 
still unknown. Therefore, we studied 26 MAP carcinomas for genome-wide copy number aber-
rations and loss of heterozygosity (LOH) using SNP arrays. Our results showed that these 
tumors mainly show copy-neutral LOH and less chromosomal losses, suggesting a relation 
between the base excision repair mechanism and mitotic recombination. The number of gains 
in the MAP carcinomas is similar to sporadic CRCs. Flow cytometry showed that most tumors 
had a near-diploid or near-triploid DNA content.
In Chapter 6 we applied the same approach to study the genomic tumor profile of patients with 
familial CRC. We studied 30 microsatellite stable carcinomas from 15 MMR proficient CRC fa-
milies. Our aim was to generate a familial colorectal cancer profile of genomic aberrations. In 
addition, we studied the tumor profiles from family members to identify candidate regions that 
might harbor high or moderate penetrance risk factors. We observed an increased frequency 
of 20q gain and an increased frequency of genome-wide cnLOH in MMR proficient familial 
CRC, while the overall pattern of aberrations resembles sporadic CRC.
The detection of copy number aberrations and LOH in tumor samples is generally impaired by 
tumor heterogeneity, low tumor cell percentage and lack of knowledge of the ploidy status of 
the tumor. In chapter 7, we set up a novel approach to study chromosomal copy number aber-
rations and allelic imbalance in tumors. In our study, we combined flow sorting with SNP array 
analysis, which significantly improved the detection of chromosomal aberrations. Additionally, 
we developed a new algorithm, the lesser allele intensity ratio (LAIR), to accurately determine 
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the allelic (im)balances. Further incorporation of the ploidy status of the tumor enabled the 
identification of the allelic state of all chromosomal aberrations, including LOH, copy-neutral 
LOH, balanced amplifications, and allelic imbalances.
In chapter 8, concluding remarks and perspectives for future research are given. Collectively, 
the results presented in this thesis suggest that the increased risk in the remaining familial 
CRC is not explained by a single dominant high penetrance factor. Solitary young patients 
without a family history of CRC might be explained by a recessive origin of disease. In MMR 









Ieder jaar wordt er in Nederland bij ongeveer 11.000 patiënten dikke darmkanker gediag-
nosticeerd. Het is samen met borstkanker en longkanker een van de meest voorkomende 
kankersoorten in de Westerse wereld. Het gemiddelde risico om in de loop van het leven 
darmkanker te ontwikkelen bedraagt in Nederland ongeveer 6%. En ongeveer 45% van de 
patiënten overlijdt binnen 5 jaar na het stellen van de diagnose aan de ziekte.
Het risico op het ontwikkelen van kanker van de dikke darm wordt beïnvloed door erfelijke 
(genetische) factoren en omgevingsfactoren, zoals voeding. In studies met eeneiige en twee-
eiige tweelingen is bepaald dat genetische factoren een rol spelen in 10%-30% van alle darm-
kanker patiënten. Er zijn verschillende syndromen bekend die darmkanker veroorzaken, maar 
deze syndromen kunnen samen slechts ongeveer 6% van het totaal aantal darmkankergeval-
len verklaren. Voor de overige patiënten met erfelijke darmkanker is onduidelijk welke gene-
tische factor of factoren bij hen een verhoogd risico op darmkanker veroorzaakt. Deze groep 
patiënten wordt vaak aangeduid als familiaire darmkankerpatiënten.
Het onderzoek dat is beschreven in dit proefschrift had als doel nieuwe genetische factoren 
te identificeren die het verhoogde kankerrisico in familiare darmkankerpatiënten verklaren. 
Zeldzame genetische varianten die een sterk verhoogd risico op darmkanker veroorzaken 
zouden een rol kunnen spelen in families waarin veel familieleden zijn gediagnosticeerd met 
dikke darmkanker. In andere patiënten zou een combinatie van minder zeldzame genetische 
factoren die een klein verhoogd risico veroorzaken een verklaring kunnen bieden.
In dit proefschrift zijn verschillende methodes toegepast om zulke genetische risicofactoren te 
identificeren. Alle methodes hebben gemeen dat ze het erfelijk materiaal - het DNA - onder-
zoeken. Het DNA is te vergelijken met een bouwtekening voor het menselijk lichaam. Het DNA 
is verspreid over 23 verschillende chromosomen en elke cel bevat twee sets van 23 chromo-
somen (een set van vader en een set van moeder). In totaal bevat elke cel dus 46 chromoso-
men. Alle eigenschappen die een mens heeft, bijvoorbeeld de kleur van de ogen, maar ook 
het risico op bepaalde ziekten, staan “beschreven” in het DNA. Het DNA is een hele lange 
keten opgebouwd uit vier verschillende moleculen, die worden aangeduid met de letters A, C, 
G en T. De volgorde van de “letters“ van het DNA is voor alle mensen bijna identiek, maar er 
bestaan kleine – veelal onschadelijke – variaties (‘single nucleotide polymorfismen’, SNPs). 
Van deze polymorfismen is gebruik gemaakt bij het onderzoek. In hoofdstuk 3 werden circa 
10.000 polymorfismen geanalyseerd, met behulp van SNP arrays, in zeven grote families die 
belast zijn met dikke darmkanker. In deze families werd de SNPs van de gezonde familie-
leden vergeleken met die van de aangedane familieleden met behulp van een zogenaamd 
koppelings-onderzoek of linkage analysis. Aangezien de analyse van 10.000 polymorfismen 
in grote families statistisch zeer complex is en veel computer capaciteit vergt, werd eerst een 
methode opgezet om deze analyses uit te voeren. Dit is beschreven in hoofdstuk 2. Een pro-
cedure werd opgezet om zulke analyses met gebruik van bestaande programmatuur die vrij 
te verkrijgen is uit te voeren. De ontwikkelde procedure werd gevalideerd in een familie met 
een bekende afwijking in het gen MLH1 gelegen op chromosoom 3. Deze afwijking veroor-








hebben. De ontwikkelde procedure was in staat dit gen te identificeren als risicofactor in deze 
darmkanker familie. Toepassing van de procedure op zeven grote darmkanker families met 
onbekende onderliggende erfelijkheid leverde echter geen nieuw kandidaatgebied in het DNA 
op, dat een risicofactor voor dikke darmkanker zou kunnen herbergen. Het onderzoek leverde 
wel een bevestiging op van een eerder beschreven kandidaatgebied voor darmkankergevoe-
ligheid op chromosoom 3q (hoofdstuk 3). 
Om het verhoogde darmkankerrisico in deze families verder te verklaren, werd de mogelijke 
rol van zes laagrisicofactoren onderzocht. Deze zes risicofactoren zijn recent geïdentificeerd 
in grote genoombrede associatie studies (GWAS). Het zijn factoren die veel voorkomen in 
de algemene populatie en die slechts een klein verhoogd risico met zich meebrengen. Twee 
van deze factoren (op chromosoom 8q23.3 en chromosoom 18q21.1) waren significant geas-
socieerd met darmkanker in de families. Wanneer het aantal risicofactoren dat in de families 
voorkomt wordt vergeleken met controles, werd geen verrijking voor laagrisicofactoren gevon-
den in deze families. Tot slot werden de tumoren van de patiënten onderzocht op genetische 
afwijkingen. De genetische afwijkingen die in de tumoren werden waargenomen, komen sterk 
overeen met de afwijkingen die in sporadische tumoren ontstaan. Er werden echter ook an-
dere afwijkingen geïdentificeerd. 
Samenvattend, werd er geen bewijs gevonden dat één genetische hoogrisicofactor het ver-
hoogde darmkankerrisico in deze families verklaard. De resultaten suggereren dat andere 
factoren, zoals risicofactoren die een laag tot matig risico met zich mee brengen, het ver-
hoogde kankerrisico in deze families verklaren.
In hoofdstuk 4 werd de rol van zes laagrisicofactoren, gelegen op chromosoom 8q24.21, 
18q21.1, 15q13.3, 11q23.3, 8q23.3 en 10p14, in een groep van 995 familiaire darmkanker-
patiënten en 1340 gezonde controles bestudeerd. Al deze factoren, met uitzondering van 
de risicofactor gelegen op 10p14, waren significant geassocieerd met een verhoogd darm-
kankerrisico in de bestudeerde groep van familiaire darmkankerpatiënten. Er werd ook on-
derzocht of deze risicofactoren geassocieerd waren met klinische parameters als geslacht, 
leeftijd bij diagnose, locatie van de tumor in de darm en de familieanamnese. De risicofactor 
op chromosoom 18q21.1 was significant geassocieerd met tumoren aan de linkerzijde van 
de darm. Bovendien werd er een associatie gevonden tussen deze factor en patiënten met 
ten minste twee eerstegraads familieleden met darmkanker, afgezet tegen patiënten zonder 
eerstegraads familieleden met darmkanker (solitaire patiënten).
Ook werd vastgesteld dat het totaal aantal risicofactoren (allelen) dat familiaire darmkanker-
patiënten hebben hoger is vergeleken met gezonde controles. Bovendien hadden patiënten 
met twee aangedane eerstegraads familieleden meer risico-allelen dan solitaire patiënten. Tot 
slot, hadden families waarin darmkanker werd gediagnosticeerd onder de leeftijd van 50 jaar 
meer risico-allelen dan families waarin de diagnose boven de 50 jaar werd gesteld. Al deze 
resultaten duiden erop dat een cluster van laagrisicofactoren een deel van het verhoogde 
darmkankerrisico in families kan verklaren, hoewel dit effect in zeven grote darmkankerfami-
lies (hoofdstuk 3) niet werd waargenomen.
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Naast analyse van DNA uit de kiembaan, werd ook het DNA van darmtumoren onderzocht in 
dit proefschrift. Tumoren ontstaan door een opeenstapeling van foutjes in het DNA. Enerzijds 
ontstaan er kleine veranderingen van één “letter” op plaatsten in het DNA die de belangrijk 
zijn voor celgroei en celdeling. Anderzijds ontstaan er veranderingen waarbij grote stukken 
DNA, vaak zelfs hele chromosomen, verloren gaan of waarbij grote stukken DNA verdub-
beld worden. Dit proces wordt chromosomale instabiliteit genoemd. Met behulp van de ana-
lyse van 10.000 SNPs (polymorfismen) werden in dit proefschrift het DNA van verschillende 
darmtumoren onderzocht. In hoofdstuk 5 werd het DNA van carcinomen van patiënten met 
MUTYH-geassocieerde polyposis (MAP) onderzocht. MUTYH is een eiwit dat een rol speelt 
bij het herstellen van fouten die ontstaan in het DNA bij celdeling. Bij MAP patiënten werkt dit 
eiwit niet meer naar behoren. Uit ons onderzoek is gebleken dat de tumoren van MAP pati-
enten een uniek patroon van chromosomale instabiliteit hebben. De chromosomen in MAP 
carcinomen worden met name getroffen door verlies van heterozygotie (LOH) zonder dat 
er een verschil ontstaat in het aantal kopieën van dat chromosoom (kopie-neutrale LOH of 
cnLOH). Van het totaal aantal gevonden chromosomale afwijkingen betrof 71% cnLOH. Het 
aantal chromosomen waarvan een kopie verloren gaat was daarentegen laag. Dit profiel van 
afwijkingen is anders dan het profiel van sporadische darmtumoren, waarin juist veel verlies 
van chromosomen wordt waargenomen, echter maar weinig kopie-neutrale LOH. Het per-
centage afwijkingen waarbij een extra kopie van een chromosoom aanwezig is in de tumoren 
is ongeveer gelijk voor de MAP carcinomen en de sporadische carcinomen. Kopie-neutrale 
LOH werd in de MAP carcinomen voornamelijk waargenomen op chromosoom 17p (57%), 
18q (52%) en 15q (52%). In sporadische tumoren gaat vaak een kopie van chromosoom 17p 
en 18q verloren.
Naast de analyse van chromosomale instabiliteit, werd ook de totale DNA inhoud van de tu-
mor cellen geanalyseerd met behulp van ‘flow cytometrie’. Gezonde cellen bevatten van elk 
chromosoom twee kopieën en zijn daarmee diploïd. Van de MAP tumoren had circa de helft 
(52%) een diploïde DNA index, hetgeen betekent dat in elke cel van elk chromosoom gemid-
deld twee kopieën aanwezig zijn. Bovendien werd er in acht MAP tumoren (35%) een bijna tri-
ploïde DNA index gemeten, dus van elk chromosoom gemiddeld drie kopieën. In sporadische 
darmtumoren is een triploïde DNA index ongebruikelijk.
Naar analogie van het unieke chromosomale patroon van MAP carcinomen en Lynch syn-
droom carcinomen (die eerder werden onderzocht in de context van het proefschrift van M. 
van Puijenbroek) werden de chromosomale profielen van familiaire darmkankerpatiënten met 
onbekende oorzaak onderzocht (hoofdstuk 6). Dertig tumoren afkomstig uit vijftien darmkan-
ker families werden onderzocht. Het profiel van afwijkingen toonde veel overeenkomsten met 
de afwijkingen die in sporadische tumoren worden waargenomen, zoals een extra kopie van 
chromosoom 13 en verlies van chromosoom 17p en chromosoom 18p en 18q. Echter, een 
zeer hoog percentage (77%) familiaire tumoren had een extra kopie van chromosoom 20q, 
hetgeen ze onderscheid van sporadische tumoren waarin dit percentage lager is (30-50%). 








afwijking belangrijk is voor de progressie van familiaire darmtumoren. Daarnaast betrof in de 
familiare tumoren een verhoogd aantal afwijkingen kopie-neutrale LOH en daarmee minder 
verlies van chromosomen vergeleken met sporadische darmtumoren.
Naast chromosomale instabiliteit werden ook drie gebieden in het DNA (genen) die coderen 
voor eiwitten die belangrijk zijn voor celgroei en celdeling, KRAS, BRAF en PIK3CA, on-
derzocht op mutaties. De frequenties van de mutaties in KRAS (26%), BRAF (12%) waren 
vergelijkbaar met eerdere studies in familiaire tumoren. Er werden geen mutaties gevonden 
in PIK3CA. Samenvattend, wijzen de resultaten van de analyse van familiaire darmtumoren 
er op dat de chromosomale afwijkingen lijken of die van sporadische darmtumoren, maar 
met een verhoogde frequentie van een extra kopie van chromosoom 20q en een verhoogde 
frequentie van kopie-neutrale LOH. 
Tot slot werd in hoofdstuk 7 de methode om chromosomale instabiliteit in tumoren te analyse-
ren verfijnd. In tumorweefsel bevinden zich tussen de tumorcellen ook gezonde cellen, zoals 
cellen van het immuunsysteem. Wanneer er DNA wordt geïsoleerd uit tumorweefsel, wordt 
er dus ook vaak wat DNA uit gezonde cellen geïsoleerd. Bovendien bevinden er zich in een 
tumor soms twee groepen tumorcellen die ieder een andere genetische samenstelling heb-
ben. Deze twee factoren vertroebelen het beeld, wanneer de chromosomale afwijkingen van 
tumoren worden geanalyseerd. In hoofdstuk 7 werd een methode opgezet om dit probleem 
te omzeilen. Met behulp van een ‘flow cytometrie’ is het mogelijk om de tumorcellen van de 
gezonde cellen te scheiden. Bovendien kan deze techniek verschillende groepen tumorcellen 
met een verschil in DNA index (DNA inhoud van een cel) van elkaar scheiden. Wanneer deze 
groepen tumorcellen vervolgens afzonderlijk worden geanalyseerd ontstaat een zuiver beeld 
van de chromosomale afwijkingen. Een additioneel voordeel van de zuivering van de cellen 
met behulp van ‘flow cytometrie’, is dat het de gemiddelde DNA inhoud van de cellen (DNA 
index) wordt gemeten met deze techniek. De DNA index maakt het mogelijk om het aantal 
kopieën van elk chromosoom nauwkeurig te schatten, terwijl zonder het betrekken van de 
DNA index in de analyse alleen relatieve winst en verlies van chromosomen is waar te nemen. 
Deze verfijning van de methode om chromosomale instabiliteit in tumoren te analyseren leidt 
dus tot een verbeterde analyse van chromosomale afwijkingen en maakt het mogelijk geneti-
sche mechanismen in de klonale evolutie van subpopulaties te bestuderen.
In hoofdstuk 8 worden een aantal concluderende opmerkingen gemaakt aangaande het on-
derzoek dat werd beschreven in dit proefschrift. Bovendien worden een aantal implicaties 
voor toekomstig onderzoek gegeven. Over het geheel genomen wijzen de resultaten van het 
onderzoek beschreven in dit proefschrift er op dat er niet één enkele hoogrisicofactor is die het 
verhoogde darmkankerrisico in familiaire darmkanker veroorzaakt. Een combinatie van een 
aantal laagrisicofactoren kan een deel van het verhoogde risico verklaren. Het overige deel 
van het verhoogde kankerrisico in familiaire darmkankerpatiënten is misschien te verklaren 
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